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I, Eric Hermann Decloedt, do hereby declare that this thesis is based on 5 journal 
manuscripts, 4 of which have been published (chapters 2, 3, 5 and 6) and 1 is under 
review for publication in an international journal (chapter 4). The contents of each of 
these manuscripts remains unchanged from that which has been published or submitted 
for publication. The manuscripts are listed below with a description of my contribution to 
each. 
I confirm that I have been granted permission by the University of Cape Town’s Doctoral 
Degrees Board to include the following publication(s) in my PhD thesis, and where co-
authorships are involved, my co-authors have agreed that I may include the 
publication(s). 
Chapter 2 
Decloedt EH, Rosenkranz B, Maartens G, Joska J. Central nervous system penetration 
of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic 
considerations. Clin Pharmacokinet. 2015 Jun;54(6):581-98.  
I wrote this invited review as background to the study in Chapter 4. We conducted a 
systematic review with the assistance of Cochrane South Africa who developed the 
search strategy to identify the 505 studies reviewed. I summarised the data and wrote 
the manuscript. John Joska and Gary Maartens provided input on the study selection as 
outlined in the chapter. My co-authors reviewed the final draft. 
Chapter 3 
Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert 
Opin Drug Saf. 2013 Nov;12(6):841-6.  
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the data and wrote the manuscript. Gary Maartens reviewed the final draft. 
Chapter 4 
Pharmacogenetic and pharmacokinetic study of central nervous system 
penetration of efavirenz and its metabolites, tenofovir disoproxil fumarate and 
emtricitabine in South African patients. Decloedt EH, Sinxadi PZ, Van Zyl GU, 
Wiesner L, Khoo S, Joska JA, Haas DW, Maartens G. Submitted for publication. 
I was the lead investigator on this clinical study and initiated the study. I lead the study 
design, the funding application, clinical data collection, statistical and pharmacokinetic 
analysis. I wrote the manuscript.  
Phumla Sinxadi lead the pharmacogenetic data analysis. I worked closely with her during 
the analysis. She reviewed the final draft of the manuscript. 
John Joska was involved in the study design, assisted with day-to-day clinical trial 
managment and supervised the neurocognitive assessments. He reviewed the final draft 
of the manuscript. 
Gary Maartens and David Haas were the co-principal investigators on the study.They 
were involved in the study design and facilitated the pharmacokinetic and 
pharmacogenetic analysis. David Haas supervised the pharmacogenetic data analysis. 
Both reviewed the final draft of the manuscript. 
Lubbe Wiesner and Saye Khoo’s laboratories analysed the antiretroviral concentrations 
in plasma and cerebrospinal fluid as outlined in the manuscript. Both reviewed the final 
draft of the manuscript. 
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Gert van Zyl’s laboratory performed the viral analysis in plasma and cerebrospinal fluid. 
He reviewed the final draft of the manuscript. 
The following study team members in alphabetical order were also involved in the study: 
Laura Comrie (clinical support), Carla Freeman (clinical support), Shahieda Isaacs (viral 
sequencing), Pam Jordan (data capturer), Teboho Linda (neuropsychology technician). 
Nozipho Mawisa (study nurse), Queen Maswana (recruiter), Rasmita Ori (clinical support), 
Kareema Poggenpoel (administration support) and Shireen Surtie (study coordinator). 
Chapter 5 
Decloedt EH, Freeman C, Howells F, Casson-Crook M, Lesosky M, Koutsilieri E, 
Lovestone S, Maartens G, Joska JA. Moderate to severe HIV-associated 
neurocognitive impairment: A randomized placebo-controlled trial of lithium. Medicine 
(Baltimore). 2016 Nov;95(46):e5401.  
I was the lead investigator on this clinical study and initiated the study. I lead the study 
design, the funding application, clinical data collection and statistical analysis. I wrote the 
manuscript.  
Carla Freeman assisted me with the clinical conduct of the study. She reviewed the final 
manuscript. 
Maia Lesosky was responsible for the randomisation and assisted with the data analysis. 
I worked closely with her during the analysis. She reviewed the final draft of the 
manuscript. 
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John Joska was the principal investigator and was involved in the study design, assisted 
with day-to-day clinical trial managment and supervised the neurocognitive assessments. 
He reviewed the final draft of the manuscript. 
Gary Maartens was involved in the study design. He reviewed the final draft of the 
manuscript. 
Martine Casson-Crook was responsible for the neurocognitve assessments. She 
reviewed the final draft of the manuscript. 
Simon Lovestone and Eleni Koutsilieri were our European co-investigators. They reviewed 
the final draft of the manuscript. 
Fleur Howells was responsible for the proton magnetic resonance spectroscopy imaging and 
data analysis. 
The following study team members in alphabetical order were also involved in the study: 
Laura Comrie (clinical support), Pam Jordan (data capturer), Nicky Kramer (study 
pharmacist), Teboho Linda (neuropsychology technician), Queen Maswana (recruiter), 
Nozipho Mawisa (study nurse), Rasmita Ori (clinical support), Kareema Poggenpoel 
(administration support), Wynand Smythe (study pharmacist) and Shireen Surtie (study 
coordinator). 
Chapter 6 
Decloedt EH, Lesosky M, Maartens G, Joska JA. Renal safety of lithium in HIV-infected 
patients established on tenofovir disoproxil fumarate containing antiretroviral 
therapy: analysis from a randomized placebo-controlled trial. AIDS Res Ther. 2017 
Feb 4;14(1):6.  
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the study design and statistical analysis. I wrote the manuscript.  
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John Joska and Gary Maartens were involved in the study design. They reviewed the 
final draft of the manuscript. 
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ABSTRACT 
Title: Treatment of HIV associated neurocognitive disorders 
Background 
Human immunodeficiency virus (HIV) invades the central nervous system (CNS) as early as 
8 days after HIV infection, causing a wide spectrum of neuropathological changes including 
HIV associated neurocognitive disorders (HAND). HAND is a spectrum of cognitive 
impairment, which in its most severe form cause marked interference with day-to-day 
functioning (HIV-associated dementia). Antiretroviral therapy (ART) has substantially 
reduced the incidence of HIV-associated dementia, but has not had an impact on the overall 
prevalence of HAND. The prevalence of milder stages of HAND in ART experienced 
individuals varies from 15 - 50%. Transporters expressed in the blood brain barrier and 
blood cerebrospinal fluid (CSF) barrier affect influx and efflux of drugs including 
antiretrovirals. Antiretrovirals that have better penetration into the CNS may result in 
improved cognitive function in patients with HAND, however this has not yet been 
conclusively shown. On the other hand, prolonged CNS exposure to high antiretroviral 
concentrations has been proposed as a cause of secondary decline in cognitive function as 
several antiretrovirals are neurotoxic. Efavirenz in particular, but also tenofovir and 
emtricitabine, have been shown to have direct neurotoxicity in preclinical models. 
Polymorphisms in genes that encode these enzymes or transporters may therefore affect 
antiretroviral CSF concentrations. Africans are the most genetically diverse population 
worldwide and South Africa has the world’s largest ART programme, with most of patients 
currently receiving efavirenz-tenofovir-emtricitabine. The impact of pharmacogenetic 
polymorphisms on the pharmacokinetics of efavirenz-tenofovir-emtricitabine CNS 
penetration are lacking. A number of adjunctive pharmacotherapies for HAND have been 
studied, including lithium. Multiple mechanisms have been suggested for the potential 
beneficial cognitive effect of lithium, including the inhibition of glycogen synthase kinase-3-
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beta, which mediates inflammation signaling pathways and neuronal apoptosis. Lithium has 
been used in mood disorders and other neuropsychiatric conditions for more than 40 years. 
In addition, lithium is a low-cost drug and widely available in public service settings in low 
and middle-income countries. There is a need for controlled data to evaluate the efficacy of 
lithium as adjunctive therapy for HAND. Finally, it is unknown whether lithium causes 
additive nephrotoxicity in combination with tenofovir. 
Methods 
We conducted a 24-week randomised placebo-controlled trial of lithium as adjunctive 
pharmacotherapy in participants with moderate to severe HAND established on ART for at 
least 6 months, with suppressed viral loads. We randomised 66 participants to lithium (n=32) 
or placebo (n= 34). Our primary efficacy endpoint was the change in Global Deficit Score 
(GDS) from baseline to 24 weeks, while our secondary endpoint was the change in proton 
magnetic resonance spectroscopy (1H-MRS) brain metabolite concentrations. We collected 
paired plasma-CSF samples in 47 adult participants with and without HAND treated with 
efavirenz-tenofovir-emtricitabine. We considered 2049 single-nucleotide polymorphisms 
(SNPs), including SNPs known to affect plasma efavirenz exposure, from potentially relevant 
genes (ABCC5, ABCG2, ABCB1, SLCO2B1, SCLO1A2, ABCC4, CYP2B6 and CYP2A6) 
and 880 met a linkage disequilibrium pruning threshold.  We investigated genetic 
polymorphisms associated with CSF exposure of efavirenz and its metabolites, tenofovir and 
emtricitabine. The secondary objective was to explore the pharmacokinetic-
pharmacodynamic relationships with neurocognitive performance. Finally, we investigated 
the change in estimated glomerular filtration rate (eGFR) in participants who received 
concomitant tenofovir and lithium. 
Results 
The median change in GDS between baseline and week 24 for the lithium and placebo arms 
were -0.57 (95% confidence interval [CI] -0.77, -0.32) and -0.56 (-0.69, -0.34) respectively, 
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with a mean difference of -0.054 (95% CI -0.26, 0.15); p = 0.716. The improvement 
remained similar when analysed according to age, severity of impairment, CD4+ count, time 
on ART and ART regimen. Standard 1H-MRS metabolite concentrations were similar 
between the treatment arms. The study drug was well tolerated in both study arms. There 
was no statistically significant difference in the reduction in eGFR or in potassium between 
the two arms during the 24 weeks. We identified 9 efavirenz slow, 21 intermediate, and 17 
extensive metabolizers based on composite CYP2B6 15582/516/983 genotype. A model that 
included composite CYP2B6 15582/516/983 genotype in univariate analyses best predicted 
log10-transformed concentrations of plasma efavirenz (β=0.34, P=1.7 x10-05), plasma 7-
hydroxy-efavirenz (β=0.45, P=5.8 x10-05), plasma 8-hydroxy-efavirenz-to-efavirenz ratio (β=-
0.29, P=3.7 x10-08) and CSF efavirenz (β=0.33, P=1.7 x10-05). Individual polymorphisms 
CYP2B6 516G→T and 983T→C also predicted these concentrations. Lower plasma 7-
hydroxy-efavirenz concentrations were independently associated with CYP2A6 rs10853742 
(β=-0.55, P=3.5 x10-05), ABCB1 rs115780656 (β=-0.65, P=4.1 x10-05) and CYP2A6 -48A→C 
(β=-0.59, P=1.0 x10-02). CYP2A6 -48A→C was also independently associated with higher 
CSF 8-hydroxy-efavirenz-to-efavirenz ratio (β=0.55, P=4.8 x10-02). The CYP2B6 rs2279345 
polymorphism was associated with lower plasma 7-hydroxy-efavirenz-to-efavirenz ratio in 
univariate and multivariate analyses adjusting for CYP2B6 516G→T and 983T→C (P<0.05). 
No polymorphisms were associated with CSF-to-plasma ratios for each of the 3 drugs, 
plasma or CSF concentrations of 8-hydroxy-efavirenz, tenofovir or emtricitabine, or 
neurocognitive performance.  
Conclusion 
Adjunctive lithium pharmacotherapy in patients on ART with HAND was well tolerated but 
had no additional benefit on neurocognitive impairment. We found that 24-week treatment of 
HIV-infected patients with lithium and tenofovir did not result in increased nephrotoxicity. We 
identified novel genetic associations with plasma efavirenz, plasma 7-hydroxy-efavirenz, 
plasma 7-hydroxy-efavirenz-to-efavirenz ratio, plasma 8-hydroxy-efavirenz-to-efavirenz ratio, 
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CSF efavirenz and CSF 8-hydroxy-efavirenz-to-efavirenz ratio concentrations. No 
polymorphisms were associated with CSF-to-plasma ratios of efavirenz, tenofovir or 
emtricitabine; plasma or CSF 8-hydroxy-efavirenz, tenofovir or emtricitabine concentrations; 
or neurocognitive performance. 
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Human immunodeficiency virus (HIV) central nervous system (CNS) invasion occurs as 
early as 8 days after HIV infection.1 Neuropathological changes occur and macroscopic 
brain changes were detected in 62% of HIV-infected patients during post-mortem 
examinations.2 HIV associated neurocognitive disorders (HAND) is a spectrum of cognitive 
impairment, which may not interfere with everyday functioning (HIV-associated 
asymptomatic neurocognitive impairment) or in its most severe form cause marked 
interference with day-to-day functioning (HIV-associated dementia).3,4 Patients with HAND 
perform below the mean for norms on neuropsychological tests by at least 1 standard 
deviation in at least 2 cognitive domains.3,4 Antiretroviral therapy (ART) has substantially 
reduced the incidence of HIV-associated dementia, but has not had an impact on the overall 
prevalence of HAND.5 The milder stages of HAND remain prevalent in ART experienced 
individuals with prevalence rates varying from 15 - 50% in different settings.6–12 The social 
and economic burden of HAND is enormous.  HAND is associated with a range of 
impairments of daily activities, including employment, driving and medication adherence 
related to a combination of neurocognitive and neurological impairment.7 HAND will continue 
to place an increasing burden on health resources, especially as those living with HIV age 
and require residential care.13 
CNS cell damage due to HIV sustained prior to ART (legacy effect), ongoing HIV replication 
in the CNS, chronic neuroinflammation caused by persistent CNS immune and glial cell 
activation, neurodegeneration due to aging, cerebrovascular disease and antiretroviral 
toxicity are some of the pathological mechanisms proposed to drive ongoing cognitive 
impairment.14,15 Antiretroviral CNS penetration-effectiveness (CPE) ranking have been 
proposed based on the chemical properties, CSF pharmacology and effectiveness in the 
CNS (Table 1).16 Antiretrovirals with a high CNS penetration-effectiveness (CPE) rank have 
been proposed to penetrate the CNS better and treat ongoing residual CNS viral replication, 
however it has not been conclusively shown that ART regimens with high CPE result in 
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improved cognitive function in patients with HIV-associated neurocognitive disorder 
(HAND).16,17 A South African observational study found similar cognitive outcomes 
irrespective of ART regimen.18   
Table 1 CNS penetration-effectiveness (CPE) ranking 
CPE score 
Antiretroviral class 4 3 2 1 







NNRTI Nevirapine Delavirdine 
Efavirenz 
Etravirine 
















Table taken unchanged from a published transcript of a lecture presented by Prof Scott Letendre.19 NRTI = nucleoside 
reverse transcriptase inhibitors; NNRTI = non-nucleoside reverse transcriptase inhibitors; PI = protease inhibitors; /r = 
/ritonavir 
Preclinical data suggest that high CNS penetrating antiretrovirals may be neurotoxic.20 A 
therapeutic range for antiretrovirals in the CNS has been proposed with concentrations 
exceeding the therapeutic range causing ongoing cognitive impairment.19 Higher CPE 
regimens have paradoxically been associated with an increased risk of HIV dementia, which 
could be due to antiretroviral neurotoxicity.21 Prolonged ART exposure has been proposed 
as a cause of secondary decline in cognitive function when antiretroviral neurotoxicity 
exceeds CNS viral suppression efficacy.22 Efavirenz in particular, but also tenofovir and 
emtricitabine, have been linked to direct neurotoxicity in preclinical models individually and in 
combination (see Chapter 3 of thesis).20 Interrupting ART after a median of 4.5 years was 
associated with improved cognitive function, especially among efavirenz recipients in one 
study.23 In a randomised controlled trial (RCT), patients starting efavirenz, tenofovir and 
emtricitabine rather than protease inhibitors or all-nucleoside reverse transcriptase inhibitor 
regimens had less improvement in neurocognitive function scores after 48 weeks and 
patients from the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) cohort who 
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received efavirenz performed worse in several cognitive domains compared with protease 
inhibitor users after more than a year of ART.24,25 Efavirenz and emtricitabine both have 
above average CPE ranking and tenofovir below average.19 However, recently it has been 
shown that efavirenz protein-free concentrations are similar in plasma and cerebrospinal 
fluid (CSF) indicating excellent CNS penetration.26 Human genetic variants have been 
associated with antiretroviral pharmacokinetics and pharmacodynamics, but ART CNS-
targeted strategies have not incorporated pharmacogenetic findings (see Chapter 2 of 
thesis).27 Transporters expressed in the blood brain barrier (BBB) and blood CSF barrier 
(BCSFB) affect influx and efflux of drugs including antiretrovirals.28,29 Polymorphisms in 
genes that encode these enzymes or transporters may therefore affect efavirenz-tenofovir-
emtricitabine CSF penetration. Africans comprise the most genetic diversity worldwide and 
South Africa has the world’s largest ART programme with most patients currently receiving 
efavirenz-tenofovir-emtricitabine.30,31 The impact of pharmacogenetic polymorphisms on the 
pharmacokinetics of efavirenz-tenofovir-emtricitabine CNS penetration are lacking (see 
Chapter 4 of thesis). 
ART is the most effective treatment for HAND, as prevention or to slow down progression. 
However a subset of patients continue to develop HAND or have HAND progression despite 
ART.32 Local data from Cape Town found that while patients with severe cognitive 
impairment prior to ART initiation show the most cognitive improvement, 23% - 45% of 
patients remained cognitively impaired after 1 year on ART.11 The pathogenic cellular 
mechanisms of how HIV causes ongoing neuronal injuries have been identified but 
adjunctive therapy to target these pathogenic pathways have not been identified.33–35 A 
number of adjunctive pharmacotherapies for HAND have been studied, including lithium.36 
There is a strong rationale to further investigate lithium as adjunctive treatment for HAND 
(see Chapter 5 of thesis). Lithium is well known psychotropic agent that has been used in 
mood disorders and other neuropsychiatric conditions for more than 40 years. In addition, 
lithium is a low-cost drug and widely available in public service settings in low and middle-
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income countries. Two pilot studies investigating lithium in HAND have been published. 
Lithium improved neurocognitive impairment in one study and neuronal integrity in both 
studies after 10–12 weeks of use in patients established on ART.37,38 In the first study, 6 of 
the 8 individuals improved sufficiently to reduce their global deficit score (GDS) from 
impaired to the normal range.37 While in the second study, cognitive performance did not 
improve significantly after the 10-week lithium treatment, but several changes on 
neuroimaging suggested neurocognitive improvement.38 However, both studies were limited 
by small sample sizes (n=8 and n=15 respectively), no comparator arm and short duration of 
lithium treatment.  
Multiple mechanisms have been suggested for the beneficial cognitive effect of lithium but 
the best understood mechanism is the inhibition glycogen synthase kinase-3-beta (GSK-3-
β), a serine-threonine protein kinase, that mediates inflammation signaling pathways and 
neuronal apoptosis.39–41 HIV-infected brain macrophages, microglia and astrocytes release 
neurotoxic viral proteins (Tat and gp120) and proinflammatory molecules (cytokines and free 
radicals) which alter the integrity of synaptic architecture and neuronal function and 
eventually leads to neuronal apoptosis.35,42 The HIV protein Tat in particular has been 
implicated in the neuropathogenesis of HIV.34 The addition of Tat to rat neurons increased 
GSK-3-β activity but the addition of lithium inhibited GSK-3-β and Tat-mediated 
neurotoxicity.43 In HIV encephalitis murine models lithium reduced GSK-3-β activity and 
restored loss of synaptic density.44 Lithium pre-treatment in mice exposed to gp120 was 
neuroprotective, suggesting that prophylactic treatment with lithium may prevent the 
progression of HAND.45 Lithium might also have direct anti-inflammatory effects.46  
Key research questions 
This thesis identified and addressed the following key research questions: 
1) Which genetic polymorphisms are associated with CSF exposure of efavirenz, 8-
hydroxy-efavirenz, tenofovir and emtricitabine in black South Africans?
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2)  Are there pharmacokinetic-pharmacodynamic relationships between CSF efavirenz, 
8-hydroxy-efavirenz, tenofovir and emtricitabine exposure and neurocognitive 
performance? 
3) Is lithium efficacious as adjunctive treatment for patients on ART with moderate to 
severe HAND? 
4) Does lithium cause additive nephrotoxicity in combination with tenofovir? 
 
Description of the project 
We screened participants at referral sites and involved as many sites as possible in the 
Cape Town metropole for referral to our study site at Groote Schuur Hospital. Our most 
productive referral site was Nolungile Site C clinic in Khayelitsha outside of Cape Town. 
Participants who were screened but did not meet the cognitive impairment inclusion criteria 
of the RCT were invited to participate in the pharmacokinetic-pharmacogenetic sub-study. 
Figure 1 outlines the chronological order of the study.
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Figure 1 Outline of the chronological order of the study and the manuscript preparation and publication 
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Coherence of the thesis 
Three key points link the coherence of this thesis. First, I am the first author and lead 
investigator on all the studies and manuscripts included. I initiated and lead all the projects 
from conception to execution to publication. Second, the work stems from a single project 
with the same cohort of patients. Third, the unifying theme is the pharmacological treatment 
of patients with HAND. 
 
Outline of the thesis 
Chapters 2 and 3 are reviews as background and literature to the thesis. Chapter 2 is a 
systematic review on CNS penetration of ART with a critical focus on pharmacokinetic, 
pharmacodynamics and pharmacogenomics considerations. In chapter 3 I review the data to 
support the neurotoxicity of efavirenz. Both reviews set the scene for chapter 4.  
Chapter 4 reports on the pharmacogenetic sub-study with 47 HIV-infected participants 
established on ART with various degrees of HAND. We conducted a cross-sectional study 
and measured efavirenz-tenofovir-emtricitabine exposure in the CSF and plasma and 
assessed neurocognitive function.  We investigated potential genetic polymorphisms 
associated with CSF exposure of efavirenz, 8-hydroxy-efavirenz, tenofovir and emtricitabine 
in black South Africans. The secondary objective was to explore the pharmacokinetic-
pharmacodynamic relationships of CSF antiretroviral exposure with neurocognitive 
performance. 
In chapter 5 I describe a 24-week RCT trial of 66 participants randomised to lithium (n=32) 
or placebo (n=34) to assess the efficacy and safety of lithium as adjunctive 
pharmacotherapy in patients with moderate to severe HAND. There is no effective adjunctive 
therapy and lithium was an adjunctive intervention with some evidence of efficacy from pilot 
studies. Our primary efficacy endpoint was the change GDS from baseline to 24 week in the 
placebo arm compared to the lithium arm. Our secondary endpoint was the change between 
20
baseline (-4 to 0 weeks) and week 23 in proton magnetic resonance spectroscopy brain 
metabolite concentrations in three brain areas.  
 
Renal safety was a major concern when studying lithium in combination with tenofovir. Both 
tenofovir and lithium are associated with renal tubular toxicity, which could be additive. 
Chapter 6 describes, to my knowledge, the first safety data of co-administered lithium with 
tenofovir. I framed the relevance of this study in the context the more common indication of 
lithium as an effective mood stabiliser. The prevalence of bipolar disorder in HIV-infected 
patients is 4 to 5 times higher than the general population and tenofovir is frequently used as 
part of ART. 
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Abstract The prevalence of HIV-associated neurocog-
nitive disorder (HAND) is increasing despite the wide-
spread use of combination antiretroviral therapy (ART).
Initial reports suggest that the use of antiretrovirals with
good central nervous system (CNS) penetration leads to
better neurocognitive outcomes, but this has not yet been
confirmed in a large cohort study or randomised controlled
trial. There is emerging evidence that high CNS concen-
trations of some antiretrovirals are potentially neurotoxic
and may be associated with the development of HAND.
Antiretroviral CNS exposure is ideally determined by de-
termining the ratio of cerebrospinal fluid (CSF):plasma
area under the curve of unbound drug, but usually only
total drug concentrations are measured and the ratio of
CSF:plasma drug concentration is done at a single time
point, which can result in misclassifying CNS penetration
ability. Efavirenz was previously thought to have poor
CNS penetration, measured by the CSF:plasma ratio
(0.87 %), but when unbound concentrations were measured
it was found to have good CNS penetration (85 %). Indi-
navir and efavirenz are the only antiretroviral drugs for
which CNS area under the concentration–time curves using
unbound plasma and CSF concentrations has been calcu-
lated. Patient data to support the contribution of blood–
brain barrier transporter polymorphisms to CNS antiretro-
viral concentrations are currently limited and lack power to
detect true associations. Correlations between CNS an-
tiretroviral exposure and effect is multifaceted, and to ac-
curately predict CNS effects there is a need to develop a
sophisticated intra-brain pharmacokinetic–pharmacody-
namic–pharmacogenetic model that includes transporters
as well as the influence of HIV.
Key Points
There are limited antiretroviral pharmacokinetic
studies that adequately estimate CNS exposure
calculating area under the concentration–time curve
using total and unbound cerebrospinal fluid
antiretroviral concentrations.
Data on the clinical relevance and extent of the
contribution of polymorphisms in genes encoding for
blood–brain transporters to CNS antiretroviral
exposure are limited due to the small number of
studies and lack of power.
Current understanding and categorizing of
antiretroviral CNS penetration has not translated into
better clinical outcomes and there is a need to
develop a sophisticated intra-brain pharmacokinetic–
pharmacodynamic–pharmacogenetic model that
includes transporters as well as the influence of HIV.
E. H. Decloedt (&)  B. Rosenkranz
Division of Clinical Pharmacology, Department of Medicine,
Faculty of Medicine and Health Sciences, Tygerberg Hospital,




Division of Clinical Pharmacology, Department of Medicine,
Groote Schuur Hospital, University of Cape Town, Observatory
7925, South Africa
J. Joska
Division of Neuropsychiatry, Department of Psychiatry and
Mental Health, Groote Schuur Hospital, University of Cape
Town, Observatory 7925, South Africa





The overall prevalence of all forms of HIV-associated
neurocognitive disorders (HANDs) is increasing despite
the widespread use of combination antiretroviral therapy
(ART) [1]. While the incidence of severe disorders, such as
HIV-dementia (HIV-D), has significantly reduced, milder
forms of HAND are on the rise. This disease burden is, in
large part, being driven by the longer life expectancy of
treated individuals and the associated neurocognitive im-
pairment due to cardiovascular disease and related degen-
erative diseases of aging [2]. HAND is associated with a
range of functional impairments that can affect employ-
ment, driving and medication adherence [1, 3]. Proposed
mechanisms of the development or progression of HAND
in people receiving ART include persistent neurodegen-
eration and neurotoxicity from antiretroviral drugs [4].
In vitro data suggest that antiretroviral drugs cause neu-
rotoxicity at therapeutic doses [5, 6]. Better central nervous
system (CNS)-penetrating antiretroviral drugs were ini-
tially associated with better neurocognitive outcomes, but
large cohort data suggest an associated increased risk of
developing dementia [7, 8].
The association between viral replication and cere-
brospinal fluid (CSF) antiretroviral concentrations has been
the subject of intensive investigation. Physiochemical
properties of the drug (size, lipophilicity, plasma protein
binding, active transport into the CNS and metabolism in
the CNS) can predict CNS drug exposure to some extent
but pharmacokinetic studies are required for confirmation
[9]. Pharmacokinetic studies of CNS penetration of drugs
are usually done by sampling CSF, which is in close con-
tact with brain extracellular fluid [10]. There are caveats
when making inferences about CNS drug exposure using
CSF drug concentrations [11, 12]. First, CSF acts as a
slowly equilibrating compartment relative to plasma with
reduced and delayed concentration peaks and an overall
flatter profile shape of the area under the concentration–
time curves (AUCs) [13]. CSF:plasma drug ratios, which
are often used as a measure of CNS exposure, will there-
fore vary depending on the time of sampling. Estimation of
CSF and plasma AUCs followed by calculating the ratio of
exposure is a more robust method of estimating CNS drug
penetration [11]; however, CSF AUC estimation is ham-
pered by the difficulty in obtaining multiple CSF samples.
Second, measuring total drug concentrations rather than
unbound concentrations gives misleading information
about CNS exposure as only unbound drug is able to act at
the receptor site [14]. Efavirenz CSF penetration was
thought to be limited based on total efavirenz concentra-
tions, but efavirenz CSF penetration is excellent, with
similar plasma and CSF unbound concentrations [14].
Third, the non-nucleoside reverse transcriptase inhibitors
(NNRTIs) and protease inhibitors (PIs) are both highly
protein bound, with NNRTIs predominantly binding to a1-
acid glycoprotein, while PIs bind to albumin [14, 15].
Antiretroviral entry into the CNS is therefore governed
largely by multiple influx and efflux drug transporters at
the blood–brain barrier and the blood–CSF barrier [16–19].
Drug exchange between blood, CSF and brain extracellular
fluid does not occur freely, and drug concentration mea-
surements made in any one of these compartments may not
accurately reflect events in the other compartments [10,
20]. Fourth, genetic polymorphisms in relevant me-
tabolizing enzymes and transporters at the different blood–
brain interfaces may influence drug disposition and re-
sponse [21, 22]. Last, HIV disease compromises the blood–
brain barrier integrity which will influence drug exposure
[23]. Healthy volunteer data may therefore not reflect drug
exposure seen in HIV-infected patients.
A recent review in Clinical Pharmacokinetics discussed
the pharmacokinetics and pharmacodynamics of antiretro-
virals in the CNS [24]. We critically reviewed the phar-
macokinetic data of antiretroviral drug exposure in the
CNS with the focus on the quality of the CSF pharma-
cokinetic studies according to the different antiretroviral
drug classes, which included a focus on total and unbound
concentration analysis. We identified variables that influ-
ence CNS exposure, including the potential role of genetic
polymorphisms on drug transporters and their influence on
CNS antiretroviral exposure. Finally, we explored links
between antiretroviral CNS pharmacokinetics and clinical
outcomes.
1.1 Study Selection
We conducted a systematic search in the PubMed database
from inception until 1 January 2015. Two reviewers (ED
and JJ) independently identified studies that reported on the
measurement of CSF antiretroviral concentrations in HIV-
infected patients. Discrepancies between the two reviewers
were mediated by a third reviewer (GM). We evaluated the
quality of the data using the following criteria: a priori
sample size calculation, CSF and plasma antiretroviral
bound and unbound drug analysis, and estimation of CSF
and plasma antiretroviral exposure using AUC. We
evaluated pharmacodynamic or clinical outcomes if any
were reported, and excluded studies that evaluated an-
tiretroviral drug exposure in animal models.
1.2 Search Strategy
We conducted multiple searches on human antiretroviral
pharmacokinetic studies in HIV-infected patients which
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measured drug concentrations in the CSF. For search 1 we
used the following Medical Subject Heading (MeSH)
terms: Search (HIV Infections[MeSH] OR HIV[MeSH] OR
hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab]
OR hiv2[tiab] OR hiv infect*[tiab] OR human immun-
odeficiency virus[tiab] OR human immunedeficiency
virus[tiab] OR human immuno-deficiency virus[tiab] OR
human immune-deficiency virus[tiab] OR ((human im-
mun*[tiab]) AND (deficiency virus[tiab])) OR acquired
immunodeficiency syndrome[tiab] OR acquired im-
munedeficiency syndrome[tiab] OR acquired immuno-
deficiency syndrome[tiab] OR acquired immune-deficiency
syndrome[tiab] OR ((acquired immun*[tiab]) AND (defi-
ciency syndrome[tiab])) OR ‘‘sexually transmitted dis-
eases, Viral’’[MeSH:NoExp]). For search 2 we used the
following MeSH terms: Search (antiretroviral therapy,
highly active[MeSH] OR anti-retroviral agents[MeSH] OR
antiviral agents[MeSH:NoExp] OR ((anti[tiab]) AND
(hiv[tiab])) OR antiretroviral*[tiab] OR ((anti[tiab]) AND
(retroviral*[tiab])) OR HAART[tiab] OR ((anti[tiab])
AND (acquired immunodeficiency[tiab])) OR ((anti[tiab])
AND (acquired immuno-deficiency[tiab])) OR ((anti[-
tiab]) AND (acquired immune-deficiency[tiab])) OR ((an-
ti[tiab]) AND (acquired immun*[tiab]) AND (deficiency
[tiab])). For search 3 we used the following MeSH terms:
Search (central nervous system[mh] OR central nervous
system*[tiab] OR cerebrospinal fluid[mh] OR cere-
brospinal fluid*[tiab]). For search 4 we used the following
MeSH terms: Search (pharmacokinetics[mh] OR pharma-
cokinetics[tiab] OR transport*[tiab] OR penetra*[tiab] OR
blood-brain barrier[mh] OR blood-brain barrier*[tiab]).
We combined searches 1 and 2 and further refined the
search by performing searches 3 and 4. The search strategy
identified 505 articles that studied the CSF exposure of 18
different antiretroviral drugs. A meta-analysis was not
possible due to study methodology heterogeneity. We
opted to discuss each antiretroviral drug class critically,
and conducted an additional search focused on human
genetic polymorphisms and the association with CSF an-
tiretroviral exposure.
2 Pharmacokinetics and Pharmacodynamics
Various pharmacodynamic markers for HIV CNS are used
[25]. CSF inhibitory concentrations are frequently used in
antiretroviral pharmacokinetic studies. Recently, CSF
95 % inhibitory quotients (IQ95) were proposed as an im-
proved marker, with high CSF IQ95 being associated with
better CSF viral suppression and a lower prevalence of
CSF escape [26]. IQ95 is the ratio between the CSF con-
centration and the 95 % inhibitory concentration (IC95),
and a ratio of more than 1 is considered adequate exposure.
The relationship between IQ95 and the potential for neu-
rotoxicity has not been investigated. Clinical neurocogni-
tive endpoints and the relationship with antiretroviral
pharmacokinetics has been best described by the CNS
penetration-effectiveness (CPE) score hypothesis studies.
The updated CPE score places antiretroviral drugs into four
categories according to physiochemical drug properties,
measured CSF drug concentrations, and efficacy as deter-
mined by CSF viral suppression and neurocognitive im-
provement [27]. Antiretrovirals with lower CPE scores are
associated with higher CSF viral loads [8]. Antiretrovirals
with higher CPE scores penetrate the CNS better and are
thought to be more appropriate for patients with HIV-as-
sociated neurocognitive symptoms. In uncontrolled obser-
vational studies, higher CNS-penetrating antiretrovirals
were associated with better CSF viral load suppression,
while others also showed an association with improved
neurocognitive outcomes compared with lower penetrating
antiretrovirals [8, 28–30]. In a large cohort of nearly 62,000
patients followed-up for a median of 37 months, patients
receiving drugs with a high CPE score were found to be at
increased risk of developing dementia, with a hazard ratio
of 1.74 (95 % confidence interval 1.15–2.65), compared
with patients receiving ART with a lower CPE score [7].
Antiretroviral-mediated increase in the deposition of b-
amyloid, as well as neurotoxicity, were cited as some of the
reasons for the findings [6, 31]; however, this finding
should be further studied as the association may have been
confounded by the majority of patients switching from
their original ART regimen, and initiation with a high CPE
regimen may have been informed by patients presenting
with neurocognitive symptoms. The association between
higher CPE scores and better neurocognitive outcomes was
not demonstrated in a recent randomised controlled trial,
but the trial was underpowered and stopped early due to
low accrual [32]. Current understanding and categorizing
of antiretroviral CNS penetration has not translated into
better clinical outcomes. In the following sections, we will
review the pharmacokinetic data on which CNS penetra-
tion inferences are based on, and highlight the gaps in our
knowledge.
2.1 Nucleoside and Nucleotide Reverse Transcriptase
Inhibitors
The nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) have good CNS penetration, with the exception of
tenofovir (see Table 1). Exposure of NRTIs in the CSF
exceeds the in vitro inhibitory concentration to suppress
50 % viral replication (IC50), but no unbound data are
available (see Table 2). However, CSF sampling measures
extracellular drug concentrations and NRTIs require in-
tracellular phosphorylation to be pharmacologically active,
PK, PD, and PG of Antiretrovirals in the CNS 583
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Table 1 Nucleoside and nucleotide reverse transcriptase inhibitors’ central nervous system pharmacokinetic data
Reported CSF penetration in relation to
plasma exposure
CSF exposure Plasma exposure Methodology sample (CSF–plasma) References
Abacavir
Range of 150–600 mg 12-hourly
Total concentration CSF/plasma AUC
ratio: 36 ± 5 %b (95 % CI 28–46)
Total concentration: 128
(37–384) ng/mla
Total concentration: 139 ng/ml (\40 to
1130) ng/mla
POPPK estimates of paired CSF–plasma total
concentrations of 70 CSF and 64 plasma
samples taken at various time points during
the dosing interval
[83]
Range of 600–1800 mg daily
Total concentration CSF/plasma AUC
ratio: 35 (31–44) %a
Total AUC?: 5.14
(2.01–13.13) lgh/mlc
Total AUC?: 12.81 (8.66–18.96) lgh/mlc Analysis of seven paired CSF–plasma total
concentrations taken during the first 6 h of
dosing from three patients who received a
single dose
[36]




Total AUC?: 0.74 (0.66–0.84) lgh/mlc to
0.92 (0.83–1.02) lgh/ml, depending on
the dose
Analysis of nine mid-dose paired CSF–




Range of 8–20 mg/kg daily




Not stated Analysis of six paired CSF–plasma total
concentrations taken at 2 h post-dosing
from six patients
[84]
Range of 0.5–10 mg/kg/daily
Total concentration CSF/plasma ratio:
12 (0–46) %a
Total concentration: 0.07
(undetectable–0.12) lMa to 0.99
(0.32–2.23) lMa
Total AUCoral: 2.84 (1.04) lMhc to 61.8
(35.8) lMhc, depending on the dose
Analysis of 68 paired CSF–plasma total




Total concentration CSF/plasma ratio:




Total concentration: median range
400–960 ng/ml (interpreted from a graph)
Analysis of 22 paired CSF–plasma total
concentrations taken at 2–8 h post-dosing
from 22 patients
[86]
Total concentration CSF/plasma ratio:
15.1 (1.3)c (range 12.4–17.5) %
Total AUC12: 3346 (219) nMhc
(range 2768–3740) nMh
Total AUC12: 22,216 (580)
c (range
21,307–23,787) nMh
Analysis of ultra-intensive paired CSF–
plasma total concentrations taken twice
over 48 h from four patients
[81]
Total concentration CSF/plasma ratio:
22.9 (0–49) %e




Total concentration CSF/plasma ratio:
38.9 (3.9)c (range 34.1–50.4) %
Total AUC12: 1814 (414) nMhc
(range 1034–2938) nMh
Total AUC12: 4524 (622)
c (range
3035–5825) nMh
Analysis of ultra-intensive paired CSF–
plasma total concentrations taken twice
over 48 h from four patients
[81]
Total concentration CSF/plasma ratio:




Total concentration: median range
100–280 ng/ml
(interpreted from a graph)
Analysis of 17 paired CSF–plasma total



















Reported CSF penetration in relation to
plasma exposure
CSF exposure Plasma exposure Methodology sample (CSF–plasma) References




TotalAUC?: 2116 (346.52) ngh/mlc Analysis of four paired CSF–plasma total
concentrations taken at 4–5 h post-dosing
from four patients
[87]
Total concentration CSF/plasma ratio:
20.4 (0.0–20.4)a




Total concentration CSF/plasma ratio:
5.7 (3.0–10.0)c (range 0.4–84) %
Total concentration: 5.5 (2.7–11.3)b
(range\0.9–38.5) ng/ml
Total concentration: 95.5 (46.9–153.2)b
(range\0.9–859.7) ng/ml
Analysis of 77 paired CSF-plasma total





Total concentration CSF/plasma ratio:




Total concentration: median range
40–340 ng/ml
(interpreted from a graph)
Analysis of 11 paired CSF–plasma total
concentrations taken at 2–8 h post-dosing
from 11 patients
[86]
Total concentration CSF/plasma ratio:
78 (6–320) %a
Total concentration 3-amino-3-





Total concentration: 118 (13–740) ng/mla
Total concentration 3-amino-3-
deoxythymidine: 2.5 (0.77–6.6) ng/mla
Analysis of 23 paired CSF–plasma total
concentrations taken at 2–8 h post-dosing
from 23 patients
[88]
Single dose of 2.5 mg/kg intravenously
Total concentration CSF/plasma ratio:
75 ± 26 %c
Total AUC?:
358 ± 200 lmolmin/l
Total AUC6: 448 ± 213 lmolmin/l Analysis of six paired CSF–plasma total
concentrations taken up to 6 h post-dosing
from six patients
[34]
AUC area under the concentration–time curve, AUCoral AUC for the oral dose, AUC6 AUC from time zero to 6 h, AUC12 AUC from time zero to 12 h, AUC? AUC from time zero to infinity, CI
confidence interval, CSF cerebrospinal fluid, POPPK population pharmacokinetic
a Median (range)
b Median (interquartile range)
c Mean (standard deviation)






























limiting efficacy conclusions from total or unbound NRTI
concentrations [33]. Zidovudine penetrates the CNS well,
with total intravenous CNS exposure of 75 % of that in
plasma [34, 35]. Approximately 35 % of total abacavir
plasma concentrations penetrate the CSF [36, 37]. Lami-
vudine, stavudine and tenofovir CSF AUCs have not been
described (see Table 1). Only 5 % of tenofovir penetrates
the CSF, most likely via active transport, therefore CSF
concentrations are well below the in vitro IC50 to suppress
viral replication for most patients [38].
2.2 Non-Nucleoside Reverse Transcriptase Inhibitors
Efavirenz is more than 99.5 % protein bound, with low
total efavirenz cerebrospinal exposure of less than 1 % of
that of plasma; however, unbound efavirenz concentrations
reach equilibrium between the two compartments (see
Table 3) [14, 39]. The equilibrium between unbound con-
centrations in CSF and plasma is in contrast to the PIs and
suggests that unbound efavirenz easily penetrates the CNS
and is not actively cleared from the CNS. Efavirenz is
predominantly metabolized by cytochrome P450 (CYP)
2B6 into several metabolites, of which 8-hydroxy efavirenz
is the main metabolite [40, 41]. Other metabolites include
7-hydroxy efavirenz and 8,14 hydroxy efavirenz [40].
Efavirenz metabolites do not seem to inhibit viral repli-
cation but may play a role in its adverse event profile,
which predominantly involves the CNS [5, 14, 40, 42].
8-hydroxy efavirenz has been hypothesized to be impli-
cated in neurotoxicity [5]. Extensive metabolisers may
generate more 8-hydroxy efavirenz and be predisposed to
develop more neurotoxicity [43]. CSF 8-hydroxy efavirenz
has in fact been associated with an increase in patient
neurocognitive symptoms [44]; however, no association
was found between 8-hydroxy efavirenz and CYP2B6
genotype or efavirenz plasma concentration in a small
study of patients of mostly Asian origin [44]. The
investigators postulated that 8-hydroxy efavirenz gets
trapped in the CNS. Plasma 8-hydroxy efavirenz or CNS-
metabolised 8-hydroxy efavirenz may undergo glucoro-
nidation and be unable to cross the blood–brain barrier
[44]. Total and unbound efavirenz exposure in the CSF is
significantly higher than the IC50 required to suppress viral
replication (see Table 4) [14, 39, 40, 45, 46]. Efavirenz has
the highest IQ95 of the NNRTIs [26].
Limited CSF penetration data exist for nevirapine but its
drug properties may allow for good CSF penetration [47–
49]. Nevirapine is the least protein bound NNRTI (60 %
protein binding) and has a low molecular weight of
266.6 g/mol. The effect of CSF penetration on viral sup-
pression has not been studied.
Etravirine is extensively protein bound (96–99.9 %) in
CSF and in plasma [50]. Total etravirine concentrations in
the CSF are 1–4 % of total plasma etravirine concentra-
tions, but less than 2 % of CSF total etravirine concen-
tration is unbound [50, 51]. The unbound etravirine
concentration is well below the in vitro IC50 to suppress
viral replication but does not seem to affect its in vivo CSF
viral activity (see Table 4) [50, 51]. Nguyen et al. [50]
postulated that adequate intracellular etravirine rather than
unbound extracellular etravirine is required for viral
suppression.
2.3 Protease Inhibitors
The PIs have a molecular weight above 500 Da and are
more than 90 % plasma protein bound, with the exception
of indinavir, which is less than 60 % protein bound in
plasma [13, 52]. The low protein binding of indinavir
translates into higher total drug concentrations in the CSF
than with other PIs. Only 6 % of indinavir in the CSF is
bound to proteins [13, 52]. Unbound PI concentrations in
the CSF do not reach equilibrium, even at steady-state [13,
52, 53]. The lack of equilibrium is likely explained by
Table 2 Nucleoside and nucleotide reverse transcriptase inhibitors’ central nervous system pharmacodynamic data
Drug In vitro efficacy in CSF Efficacy data References
Abacavir IC50 0.07 lg/ml POPPK model predicted that CSF troughs would exceed the IC50 for 85 % of
the dose interval
[83]
CSF Cmax exceeded the IC50 by 8–20 times [36, 37]
Lamivudine IC50 (not specified) Total CSF concentrations exceed the IC50 [86]
Stavudine IC50 0.009–4.1 lmol/l Total CSF concentrations exceed the IC50 [86]
IC50 52 ng/ml Total CSF concentrations exceed the IC50 [87]
Tenofovir IC50 11.5 ng/ml Total CSF concentrations did not exceed the IC50 in 77 % (59/77) of patients [38]
Zidovudine IC50 0.002–2.400 lmol/l Total CSF concentrations exceed the IC50 [86]
IC50 (not specified) Total CSF trough concentrations exceed the IC50 by twofold [34]
Cmax maximum concentration, CSF cerebrospinal fluid, IC50 50 % inhibitory concentration, POPPK population pharmacokinetic
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Table 3 Non-nucleoside reverse transcriptase inhibitors’ central nervous system pharmacokinetic data
Reported CSF penetration in relation to plasma
exposure
CSF exposure Plasma exposure Methodology sample (CSF–plasma) References
Efavirenz
Total concentration plasma/CSF ratio:
134 (116–198) %
Unbound concentration plasma/CSF ratio:










Analysis of 13 mid-dose paired CSF–
plasma unbound and total
concentrations
[14]
Total concentration CSF/plasma ratio:
0.5 (0.26–0.76)b or 0.5 %
POPPK estimate total concentration CSF
penetration: 0.48 (0.47–0.49) % with AUCCSF





POPPK estimates of 80 mid-dose paired
CSF–plasma total concentrations
[45]
Total concentration efavirenz CSF/plasma
ratio: 0.88 %
Total concentration 8-hydroxy efavirenz
CSF/plasma ratio: 1.07 % (not reported, but
calculated by authors)
Total concentration efavirenz: 19
(7–24) ng/mlb
Total concentration 8-hydroxy




efavirenz: detectable in n = 2/13:
0.375 ng/ml and 0.444 ng/ml





Total concentration 8-hydroxy efavirenz:
314.5 (206–362.3) ng/mlb
Total concentration 7-hydroxy efavirenz:
8.84 (6.21–12.48) ng/mlb
Total concentration 8,14-hydroxy
efavirenz: 5.63 (4.58–6.16) ng/mlb
Unbound concentration 8-, 7- and 8,14-
hydroxy efavirenz: Undetectable
Analysis of 13 mid-dose paired CSF–
plasma unbound and total
concentrations
[5, 40]
Total concentration CSF/plasma AUC24 ratio:
0.44 (0.03–0.9) %a
Unbound concentration CSF/plasma ratio
(estimated): 88 %
Total AUC24: 0.38 mgh/l









POPPK estimates of paired CSF–plasma
total concentrations over 24 h dosing
interval in one patient
[39]
Total concentration efavirenz CSF/plasma
ratio: 1.07 %
Total concentration efavirenz: 10
(7.0–14.0) ng/mla
Total concentration efavirenz: 936
(382–1116) ng/mla




Total concentration CSF/plasma ratio:
ABCB1-3435 C/T or T/T genotype: 62 %
ABCB1-3435 C/C genotype: 43 %
Reported per CYP2B6 genotype Reported per CYP2B6 genotype Analysis of 14 paired CSF–plasma total
concentrations taken around tmax in 11
paediatric patients
[48]
Total concentration CSF/plasma ratio:
62.6 (41–77) %a
Not reported Not reported Analysis of 16 paired CSF-plasma total
concentrations.
[49]




Analysis of plasma and CSF total































active removal of the PIs from the CSF by efflux pumps
such as p-glycoprotein [13, 52].
Indinavir CSF exposure has been very well character-
ized, although it is no longer routinely used [54]. Table 5
summarizes the pharmacokinetic data of indinavir expo-
sure at different dosing regimens. In vitro data suggest that
unboosted indinavir reaches sufficient concentrations to
inhibit wild-type virus in the majority of patients (see
Table 6) [13, 55–57]. Ritonavir boosting to increase CSF
concentrations specifically has been studied using indinavir
[52]. Ritonavir increased plasma but not CSF unbound
indinavir exposure [52]. Ritonavir has a minimal effect on
p-glycoprotein at the blood–brain barrier level as low un-
bound concentrations reach the CNS in comparison to the
gut and liver [52, 58]
Atazanavir, which has 86 % protein binding, is the PI
that has the second highest proportion of unbound drug in
the CSF [59]. Ritonavir added to atazanavir increases
plasma total atazanavir concentrations by more than dou-
ble, while CSF concentrations only increase slightly (see
Table 5) [59]. The modelled estimate of total atazanavir
penetration boosted with ritonavir in the CSF is 0.74 % of
plasma concentrations [59]. CSF atazanavir failed to
achieve concentrations above the in vitro IC50 in many
patients (see Table 6). Unboosted atazanavir has the lowest
IQ95 of the PIs [26]. Additional ritonavir increases the IQ95
of atazanavir similar to that of boosted lopinavir [26].
Nelfinavir manufacturing has been discontinued and no
longer available as a treatment option. It is highly protein
bound (99.7 ± 0.10 %) and reaches undetectable CSF
concentrations, mostly when measured [57, 60–63]. Total
nelfinavir CSF exposure in relation to plasma has not been
adequately quantified despite sensitive methodology and
instrumentation (see Table 5) [63, 64]. CSF nelfinavir
concentrations are in the range of in vitro inhibitory con-
centrations of wild-type virus (see Table 6) [63, 64].
When boosted with ritonavir, lopinavir reaches
therapeutic concentrations in plasma. Lopinavir is
97–99 % protein bound, with less than 0.5 % of total
lopinavir concentrations reaching the CSF (see Table 5)
[46, 60, 61, 65, 66]. Lopinavir total CSF concentrations
exceed in vitro concentrations required to inhibit wild-type
virus [46, 65, 66]. Data on lopinavir AUC exposure and
CSF unbound concentrations are lacking.
Darunavir is only 6.5 % unbound in plasma and 97.2 %
in CSF [53]. At the darunavir/ritonavir dose of
600/100 mg, total darunavir CSF concentrations are ap-
proximately 1 % of total plasma concentrations (see
Table 5) [53, 67, 68]. Unbound darunavir CSF concentra-
tions are significantly higher at 8.5 % of unbound plasma
concentrations [53]. Darunavir has adequate CSF exposure
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The unbound plasma fraction of saquinavir is less than
1 % [69, 70]. CSF unbound concentrations are mostly
unmeasurable, and when measured the unbound saquinavir
CSF:plasma ratio is less than 1 % [69]. CSF concentrations
are below the in vitro concentrations required to inhibit
wild-type virus (see Table 6) [63, 69, 71].
2.4 Other Antiretroviral Drugs
The CSF concentrations of the fusion inhibitor enfuvirtide
are not quantifiable due to negligible CSF penetration
[72]. Although no unbound AUC penetration data are
available, total CSF and plasma paired samples indicate
that the entry inhibitor maraviroc and the integrase in-
hibitor raltegravir enter the CSF. Maraviroc achieves total
CSF concentrations in excess of threefold the effective
concentration to inhibit viral replication of 0.57 ng/ml
[73]. In seven paired total CSF and plasma concentrations
the median and range of plasma and CSF concentrations
were 94.9 (21.4–478) and 3.63 (1.83–12.2) ng/ml, re-
spectively, giving a median CSF/plasma ratio of 3 %
(1–10) [73]. Raltegravir total CSF concentrations are ap-
proximately 6.0 % that of plasma, and exceed the con-
centration required to inhibit 50 % of viral replication in
all patients but fail to exceed the IC95 in at least half of the
patients (see Tables 7, 8) [74, 75].
3 Pharmacogenetic Data
A spectrum of transporters, classified into ATP-binding
cassette (ABC) or solute-carrier (SLC) transporters, exist
to facilitate or prevent the movement of molecules across
the blood–CNS interface. Transport of ART out of the
CNS is mediated by p-glycoprotein (also known as MDR-
1 or ABCB1), the multidrug resistance-associated proteins
(or MRPs, also known as ABCC) and breast cancer re-
sistance protein (BCRP, also known as ABCG2) [17, 76,
77]. Limited data are available on the SLC superfamily at
the blood–brain barrier, but they also seem to play an
important role in the efflux of molecules [78]. Although
CYP1B1 has been detected at the human blood–brain
barrier, CYP3A4, CYP2C9 and CYP2D6 have not, and the
impact of the enzymatic barrier on cerebral disposition of
ART is probably negligible [18]. Genetic polymorphisms
in ART blood–brain barrier transporters may therefore
contribute to the difference in CNS ART exposure [19,
79]. Patient data to support the contribution of blood–brain
barrier transporter polymorphisms to CNS antiretroviral
concentrations are currently limited (see Table 9) and
plagued by the lack of power to detect true associations
[80].
4 Discussion and Conclusion
We reviewed the CNS pharmacokinetic, pharmacodynamic
and pharmacogenetic data of ART. The movement of drug
molecules into the CNS is complex, and extrapolation of
CNS drug exposure from CSF drug concentrations over-
simplifies the pharmacokinetics of CNS ART; however,
CSF is the most accessible CNS matrix [10]. The majority
of published ART CNS penetration studies measured
CNS penetration by using single paired CSF–plasma
Table 4 Non-nucleoside reverse transcriptase inhibitors’ central nervous system pharmacodynamic data
Drug In vitro efficacy in CSF Efficacy data References
Efavirenz IC50 0.51 ng/ml CSF unbound above the wild-type in vitro IC50 in lymphocytes of
0.51 ng/ml, and CSF total concentrations exceeded the wild-type IC50
in lymphocytes of 0.51 ng/ml by a ratio of 26 (8–41)a
[14, 45]
CSF total concentrations exceeded the IC50 in 14/18 (78 %) patients [46]
IC50 0.36 ng/ml CSF total concentration above the IC50. Metabolites (8-, 7- and 8,14-OH)
considered to be minimally effective at inhibiting viral replication. CSF
concentrations below the IC50 for 8-OH efavirenz (42.25 ng/ml), 7-OH
efavirenz (44.68 ng/ml) and 8,14-OH efavirenz (2238.4 ng/ml)
[40]
IC50 1.3 ng/ml CSF total concentration exceeded the wild-type IC50 in lymphocytes in a
protein-free medium of 1.3 ng/ml by 12-fold
[39]
Etravirine IC50 range of 0.39–2.4 ng/ml CSF total concentrations exceeded the IC50 range [51]
IC50 of 0.9 ng/ml CSF total concentrations exceeded the vitro unbound IC50 for wild-type HIV-
1 of 0.9 ng/ml, but unbound CSF concentrations were all below the IC50
[50]
CSF cerebrospinal fluid, IC50 50 % inhibitory concentration
a Interquartile range
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Table 5 Protease inhibitors’ central nervous system pharmacokinetic data
Reported CSF penetration in relation to
plasma exposure
CSF exposure Plasma exposure Methodology sample (CSF–plasma) References
Indinavir
800 mg 8-hourly without ritonavir
Not stated Total concentration: 223 (200)c (range
80–660) nmol/l
Total concentration: 2086 (3400)c
(range 70–10,300) nmol/l
Analysis of 32 paired CSF–plasma total
concentrations at various time points during the
dosing interval from 25 patients
[89]
Total concentration CSF/plasma




AUC8 ratio: 14.7 (2.6)
c (range
10.3–17.7) %
Total AUC8: 1720 (538)
c (range
886–2256) nmolh/l
Unbound AUC8: 1616 (493)
c (range
861–2172) nmolh/l
Total AUC8: 26,939 (8908)
c
(range 11,845–38,930) nmolh/l
Unbound AUC8: 11,218 (3780)
c
(range 5165–16,974) nmolh/l
Analysis of 80 paired CSF–plasma unbound and




ratio: 6 (95 % CI 5–9) %
Total concentration: 145 (43–480) nMa Total concentration: 1491
(40–11,670) nMa
POPPK analysis of 22 paired CSF–plasma total
concentrations at various time points during the
dosing interval from 22 patients
[56]
Total concentration CSF/plasma





Analysis of 19 paired CSF–plasma total
concentrations at various time points during the
dosing interval from 19 patients
[90]
Total concentration CSF/plasma
ratio: median 14 %
Total concentration: 86 (13)c;
median 81 ng/ml
Total concentration: 485 (137)c;
median 283 ng/ml
Analysis of 16 paired CSF–plasma total
concentrations at various time points during the
dosing interval from 16 patients
[60]
Total concentration CSF/plasma
ratio: 17 (10–49) %b
Total concentration: 73 (52–92) ng/mlb Total concentration: 357
(155–914) ng/mlb
Analysis of 28 paired CSF–plasma total
concentrations at various time points during the
dosing interval from 14 patients
[61]
800 mg 8-hourly with 100 mg ritonavir 12-hourly
Not stated Total concentration: 104 (68–207) ng/mlb
with ritonavir:
100 mg ritonavir dosed with 800 mg





Analysis of four paired CSF–plasma total
concentrations taken 1 h after dosing from four
patients
[55]
800 mg 12-hourly with 100 mg ritonavir 12-hourly
Not stated Total concentration: 104 (68–207) ng/mlb
with ritonavir:
100 mg ritonavir dosed with 800 mg





Analysis of four paired CSF–plasma total
concentrations taken 1 h after dosing from four
patients
[55]
Total concentration CSF/plasma ratio:
9.9 (3.3)c (range 7.4–16.6) %
Unbound concentration CSF/plasma ratio:
17.5 (6.4)c (range 12.8–31.4) %
Total AUC12: 6606 (2481)
c (range
3903–11,385) nmolh/l
Unbound AUC12: 6502 (2397)
c
(range 3903–11,043) nmolh/l
Total AUC12: 68,913 (23,302)
c
(range 50,404–117,049) nmolh/l
Unbound AUC12: 38,829 (15,124)
c
(range (26,614–71,283) nmolh/l
Analysis of 63 paired CSF–plasma unbound and
total concentrations over 8 h dosing interval
taken from seven patients
[52]

















Reported CSF penetration in relation to
plasma exposure
CSF exposure Plasma exposure Methodology sample (CSF–plasma) References
Not stated Total concentration: 39 (27–54) ng/mlb
without ritonavir
Total concentration: 104 (68–207) ng/mlb
with ritonavir:
100 mg ritonavir dosed with 800 mg





Analysis of 11 paired CSF–plasma total
concentrations taken 1 h after dosing taken
from 11 patients
[55]
Not stated Total concentration: median 71 ng/ml Not stated Analysis of 17 paired CSF–plasma total
concentrations at various time points during the





ratio: 1.12 (0.5–13.9) %a
Total concentration: 7.9 (\5 to 40) ng/mla Total concentration: 523 (\128 to
6200) ng/mla
Analysis of nine paired CSF–plasma total
concentrations at various time points during the
dosing interval
[59]
300 mg daily with ritonavir
Total concentration CSF/plasma
ratio: 0.74 %
Total concentration: 10.3 (\5 to 38) ng/mla Total concentration: 1278 (\128 to
5295) ng/mla
POPPK analysis of 62 paired CSF–plasma total
concentrations at various time points during the
dosing interval
[59]
400 mg daily and 300 mg daily with ritonavir
Not stated Total concentration: 14.5 (1.9–17.5) ng/mlb






Analysis of 12 paired CSF–plasma total
concentrations at a median post-dose sampling
interval of 15.5 h
[46]
Total concentration CSF/plasma
ratio: 0.9 (0.8)c (range 0.1–2.7) %
Total concentration: 8.3 (0.6–40) ng/mla Total concentration: 1250
(205–3555) ng/mla
Analysis of 22 paired CSF–plasma total
concentrations at various time points during the
dosing interval from 22 patients
[91]
Nelfinavir
Not stated Total concentration:\2.0 (\2.0 to 23.0) nMa
(detectable in 9 of 15 samples)
Total concentration: 4.1 (\0.13 to
10.6) lMa
Unbound concentration: 10.0
(\2.0 to 31.0) nMa
Analysis of 15 paired CSF–plasma unbound and
total concentrations at different intervals from
eight patients
[63]
Not stated Total concentration: 9 (6–29) nMa
(detectable in 16 of 18 samples and
quantifiable in 8 of 18 samples)
Not stated Analysis of 18 paired CSF–plasma unbound and
total concentrations at various time points









Analysis of ten paired CSF–plasma total trough































Reported CSF penetration in relation to
plasma exposure
CSF exposure Plasma exposure Methodology sample (CSF–plasma) References
Total concentration CSF/plasma
ratio: 0.23 (0.12–0.75) %b
Total concentration: 17.0 (12.1–22.7) lg/lb Total concentration: 5889
(4805–9620) lg/lb
Analysis of 31 paired CSF–plasma total
concentrations at a median post-dose sampling
interval of 4.3 h from 26 patients
[65]
Not calculable Undetectable Total concentration: 5463
(720) ng/mlc
Analysis of 16 paired CSF–plasma total trough
concentrations from 16 patients
[60]







Analysis of 42 paired CSF–plasma total
concentrations at a median post-dose sampling
interval of 6 h
[46]
Not calculable Undetectable Total concentration Cmin: 5863
(3505–7453) ng/mlb
Analysis of 12 paired CSF–plasma total trough
concentrations from 12 patients
[61]
Darunavir
800 mg and 100 mg ritonavir daily
Total concentration CSF/plasma
ratio: 0.32 (0.25–0.44) %b
Total concentration: 10.7 (6.7–23) ng/mlb Not separately reported Analysis of nine paired CSF–plasma total trough
concentrations
[68]
600 mg and 100 mg ritonavir 12-hourly
Total concentration CSF/plasma
ratio: 0.9 (0.60–1.53) %b




ratio: 1.4 (0.9–1.8)b (range
0.3–2.6) %
Unbound concentration CSF/plasma
ratio: 8.5 (6.2–12.7)b (range
2.9–412.4) %
Total concentration: 55.8 (39.5–79.1)b (range
19.4–159.6) ng/ml






(369–968)b (range 1–2206) ng/
ml
Analysis of 29 paired CSF–plasma unbound and
total concentrations at various time points
during the dosing interval from 16 patients
[53]
Total concentration CSF/plasma
ratio: 0.9 (0.3–1.8) %b
Total concentration: 34.2 (15.9–212) ng/mlb Total concentration: 3930
(1800–12,900) ng/mla
Analysis of 14 paired CSF–plasma total
concentrations at various time points during the
dosing interval from eight patients
[67]
Saquinavir
Dosing regimen not stated
Total concentration CSF/plasma
ratio: 0.1 and 0.2 %, respectively
Total concentration: measured in 2/11
participants: 0.3 and 1.6 ng/ml, respectively
Not stated Analysis of 11 paired CSF-plasma total
concentrations at 6–8 h post-dosing from 11
patients
[71]
Not stated Total concentration:\2.5 (\2.5 to 9.0) nMa
(detectable in 7 of 15 samples)
Total concentration: 300 (\80 to
6600) nMa
Unbound concentration:\2.5
(\2.5 to 96.0) nMa
Analysis of 15 paired CSF–plasma unbound and
total concentrations at different intervals from
eight patients
[63]
400 mg with 400 mg ritonavir 12-hourly
Unbound concentration CSF/plasma ratio:
0.16 ± 0.09 %c
Unbound concentration: 0.40 ± 0.30 ng/mlc
(detectable in 5 of 12 samples)
Unbound concentration:
6.8 ± 9.5 ng/mlc
Analysis of 12 mid-dose paired CSF–plasma

















concentration points to determine exposure. AUC accu-
rately estimates exposure, which can only be determined by
using multiple paired CSF–plasma concentrations in a pa-
tient or by combining samples from multiple patients using
a population pharmacokinetic approach. Indinavir and
efavirenz CNS penetration was characterized by measuring
unbound plasma and CSF concentrations to calculate
AUCs. The importance of measuring total and unbound
drug concentrations is illustrated by efavirenz, where the
CSF total concentration is a tiny fraction of plasma total
concentration, while unbound concentrations in the two
compartments are similar [14]. The unbound concentration
of indinavir in the CSF is double that of the total concen-
tration in the CSF [81]. Accurate inferences of ART CNS
penetration without unbound AUC data in plasma and CSF
compartments are limited.
Future studies should measure total and unbound an-
tiretroviral concentrations and aim to calculate AUCs as a
measure of exposure. High CPE score ART CNS exposure
is a risk factor for HIV-D, suggesting that a therapeutic
window does indeed exist for ART in the CNS where
concentrations at the higher and lower spectrum lead to
ART toxicity or viral replication, respectively [7, 27].
Laboratory evidence suggests that antiretrovirals are di-
rectly neurotoxic [5, 6]. Neurons challenged for a week
with different concentrations of antiretrovirals, including
therapeutic concentrations, underwent structural loss, as
quantified using microtubule-associated protein-2 [6].
Neurotoxicity was most pronounced with abacavir, ataza-
navir, efavirenz, etravirine and nevirapine. Of particular
interest is the inactive metabolite of efavirenz (8-hydroxy
efavirenz), which was tenfold more toxic than efavirenz in
rat neuronal cultures and has been associated with more
CNS symptoms in patients [5, 44]. Future studies should
quantify ART CNS therapeutic ranges not only to deter-
mine which antiretroviral drugs penetrate the CNS
adequately to suppress viral replication but also which
antiretroviral drugs penetrate the CNS to such an extent
that they contribute to neurotoxicity. The impact of genetic
polymorphisms in drug transport across membranes (in-
cluding the blood–brain barrier) is well established for
many drugs, including ART [21, 22, 82]. However, data on
the clinical relevance and extent of the contribution of
polymorphisms in genes encoding for blood–brain trans-
porters to CNS antiretroviral exposure are limited due to
the small number of studies and the lack of power. The
invasiveness of lumbar punctures limits the sample size of
CSF exposure studies. Correlations between CNS an-
tiretrovira lexposure and effect is multifaceted. To accu-
rately predict CNS effects there is a need to develop a
sophisticated intra-brain pharmacokinetic–pharmacody-
namic–pharmacogenetic model that includes transporters
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Table 6 Protease inhibitors’ central nervous system pharmacodynamic data
Drug In vitro efficacy in CSF Efficacy data References
Indinavir IC95 30–60 ng/ml
MEC 40 ng/ml
Total CSF concentrations exceeded IC95 and MEC when indinavir is dosed with
ritonavir. Without ritonavir, patients may have CSF total concentrations below IC95
and MEC
[55]
IC95 25–100 nmol/l Unbound CSF concentrations exceeded the IC95 for 85 % of the dosing interval in
seven of eight participants with a Cmin 122 (51)
a (range 49–204 nmol/l)
[13]
Median total CSF concentration exceeded the IC95 [89]
Unbound CSF concentrations exceeded the IC95 for 100 % of the dosing interval in all
participants with a Cmin 280 (131)
a (range 149–527 nmol/l)
[52]
All total CSF concentrations exceeded 25 nmol/l, while only 54 % (12/22) of patients
exceeded 100 nM
[56]
IC95 18–70 ng/ml Median total CSF concentration exceeded IC95 [57]
Atazanavir IC50 1 ng/ml Total CSF concentrations were near the IC50 in 16 % (11/67) of samples [59]
Total CSF concentrations were below the IC50 in 17 % (2/12) of samples [46]
Total CSF concentrations were considered to be above the IC50 in general [91]
Nelfinavir IC50 (not specified) Detectable CSF concentrations were in the range of IC50 for wild-type virus [63]
IC95 0.35–10 nM Unbound nelfinavir in CSF in the concentration range of the IC95 in some of the CSF
samples (8/18)
[64]
Lopinavir IC50 1.9 lg/l (3.0 nmol/) Total CSF concentrations exceeded IC50 for wild-type replication by a median (IQR)
5.9-fold (3.9–8.6)
[66]
Total CSF concentrations exceeded IC50 for wild-type replication by a median (IQR)
5.3-fold (3.8–7.2)
[65]
Extrapolated trough concentrations above IC50 for 98 % (41/42) of CSF samples [46]
CSF HIV-1 RNA levels HIV-1 RNA levels detectable in 3 of 10 patients (median 350 copies/ml) [60]
HIV-1 RNA levels detectable in 3 of 12 patients (median 350 copies/ml) [61]
Darunavir IC50 2.75 ng/ml None of the patients receiving darunavir/ritonavir 600/100 mg 12-hourly compared




All unbound CSF concentrations exceeded the IC50 and IC90 wild-type HIV-1 by a
median of 28.1-fold and 20.6-fold, respectively
[53]
IC50 12–55 ng/ml Total CSF concentrations were in the range of, or exceeded, the IC50 [67]
Saquinavir IC50 42–55 ng/ml Detectable CSF concentrations were below the IC50 for wild-type virus [63, 69, 71]
Cmin minimum concentration during dosing interval, CSF cerebrospinal fluid, IC95 95 % inhibitory concentration, IC50 50 % inhibitory con-
centration, IC90 90 % inhibitory concentration, IQR interquartile range, MEC minimal effective concentration,
a Mean (standard deviation)
Table 7 Integrase inhibitors’ central nervous system pharmacokinetic data
Reported CSF penetration in
relation to plasma exposure











Analysis of 25 paired CSF–plasma total
concentrations taken at 1.2–14 h














Analysis of 22 paired CSF–plasma total
concentrations taken at 6.1 ± 4.2 hb










Analysis of 40 paired CSF–plasma total
concentrations taken at 4 h post-dosing
from 40 participants
[80]
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Table 8 Integrase inhibitors’ central nervous system pharmacodynamic data
Drug In vitro efficacy in CSF Efficacy data References
Raltegravir IC95 9–15 ng/ml Total CSF concentrations exceed the IC95 in half of the patients (13/25) [74]
IC50 3.2 ng/ml
IC95 9–15 ng/ml
Total CSF concentrations exceed the IC50 by a median of 4.5-fold,
and little less than half of the patients (10/21) exceeded the IC95
[92]
Total CSF concentrations exceeded the IC50 in all patients,
and 28.6 % (10/35) exceeded the IC95
[25]
CSF cerebrospinal fluid, IC50 50 % inhibitory concentration, IC95 95 % inhibitory concentration,




Nevirapine ABCB1 3435 C[T
CYP2B6-G516T
ABCB1-C3435T C/T or T/T genotypes (n = 9) associated with higher nevirapine
CSF/plasma ratios compared with ABCB1-C3435T C/C genotype (n = 5);
p = 0.01. No significant difference was observed when the ratios were compared
with the CYP2B6-G516T genotype (p = 1.00)
[48]






AA compared with AG genotype-carrying patients showed a trend towards higher
CSF concentrations and plasma/CSF ratios: 32 (22–72) ng/mla vs. 29.8
(139–36.4) ng/mla (p = 0.13) and 0.78 (0.78–1.88) %a vs. 0.56 (0.35–0.96) %a
(p = 0.13), respectively
[68]
Nelfinavir ABCB1 3435 C[T
ABCB1 2677 G[A/T
CC 3435 genotype occurred more frequently in patients with undetectable CSF viral
loads (6/7 compared with 6/12), but the finding was not statistically significant
[64]











No significance between selected SNPs and CSF/plasma ratios [25]
Bolded text denotes an association
AUC area under the concentration–time curve, CSF cerebrospinal fluid, CYP cytochrome P450, SNPs single nucleotide polymorphisms
a Median (interquartile range)
Table 7 continued
Reported CSF penetration in
relation to plasma exposure









Analysis of 41 paired CSF–plasma total
concentrations taken at 2–15 h
post-dosing from 41 participants
[25]
AUC area under the concentration–time curve, AUC12 AUC from time zero to 12 h, CSF cerebrospinal fluid, CSF4h cerebrospinal fluid
concentration at 4 hours
a Median (range)
b Mean (standard deviation)
c Median (interquartile range)
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Introduction: Efavirenz commonly causes early neuropsychiatric side effects, but
tolerance develops in most patients. There is emerging evidence that efavirenz
use may damage neurons, which could result in impaired neurocognitive
performance.
Areas covered: The authors conducted a systematic review using the PubMed
database, references cited by other articles and conference web sites to
determine if there is evidence that efavirenz may contribute to cognitive
impairment by damaging nerve cells.
Expert opinion: There is weak clinical evidence suggesting that efavirenz use
may worsen neurocognitive impairment or be associated with less improve-
ment in neurocognitive impairment than other antiretrovirals. Efavirenz,
especially its major metabolite 8-hydroxy-efavirenz, is toxic in neuron cultures
at concentrations found in the cerebrospinal fluid. Extensive metabolizers of
efavirenz may therefore be more likely to develop efavirenz toxicity by form-
ing more 8-hydroxy-efavirenz. Several potential mechanisms exist to explain
the observed efavirenz neurotoxicity, including altered calcium hemostasis,
decreases in brain creatine kinase, mitochondrial damage, increases in brain
proinflammatory cytokines and involvement of the cannabinoid system.
There is a need for large randomized controlled trials to determine if the
neuronal toxicity induced by efavirenz results in clinically significant
neurological impairment.
Keywords: efavirenz, neurocognitive impairment, neurotoxicity
Expert Opin. Drug Saf. (2013) 12(6):841-846
1. Introduction
Efavirenz is a widely used non-nucleoside reverse transcriptase inhibitor in combi-
nation with other antiretroviral agents for the treatment of human immunodefi-
ciency virus type 1 (HIV-1) infection. Efavirenz use is commonly complicated by
early neuropsychiatric adverse events in up to 68% of patients [1-5]. Most patients
report mild symptoms of headache, dizziness, impaired concentration, sleep distur-
bance, abnormal dreams, anxiety or depression [2]. Clinical symptoms commonly
start within days, but even after a single dose of efavirenz, the neuropsychiatric test-
ing domains are affected [1,6,7]. Symptoms peak at 1 week after treatment initiation
and usually resolve within the first month despite ongoing ingestion of efavirenz.
One study reported that mild neuropsychiatric symptoms persisted for up to 3 years
in many patients [8]. Early severe neuropsychiatric symptoms usually resolve on dis-
continuation of efavirenz [9-14]. A recent case report of vacuolar axonopathy leading
to a depressed level of consciousness, aspiration pneumonia and death was thought
to be efavirenz induced, suggesting that efavirenz neurotoxicity may on occasion be
more severe than transient neuropsychiatric effects [15].
There is emerging evidence that efavirenz use may damage neurons, which could
result in impaired neurocognitive performance. We conducted a systematic review
using the electronic journal database PubMed, Cochrane Database of Systematic
10.1517/14740338.2013.823396 © 2013 Informa UK, Ltd. ISSN 1474-0338, e-ISSN 1744-764X841







































































Reviews and Google Scholar. We conducted our search from
1997 onward to capture all studies from 1998 when efavirenz
was approved by the US Food and Drug Agency (FDA). We
also searched the electronic conference databases of the Inter-
national Workshop on Clinical Pharmacology of HIV Ther-
apy, Conferences on Retroviruses and Opportunistic
Infections and International AIDS Conference. Our search
strategy included but was not limited to the following medical
subject heading (MeSH) terms: efavirenz, toxicity, AIDS
dementia complex, neurons, neuropsychiatric disorders and
neurocognitive impairment. We included all fields in our
search but limited our search to the English literature. We
also scrutinized the citations of reviewed articles for any refer-
ences not identified in our search.
Several studies have shown a correlation between higher
plasma efavirenz concentrations and an increased risk of early
neuropsychiatric side effects [8,16-21]. Efavirenz concentrations
are characterized by marked interpatient variability, some of
which is explained by polymorphisms in CYP2B6, the major
cytochrome P450 metabolizing enzyme [22]. Efavirenz is
metabolized into three metabolites: two hydroxylated metab-
olites 8-hydroxy-efavirenz and 7-hydroxy-efavirenz and a
third metabolite that undergoes glucuronidation. More than
90% of efavirenz is metabolized by CYP2B6 into the major
metabolite 8-hydroxy-efavirenz. CYP2A6 metabolizes < 8%
of efavirenz into 7-hydroxy-efavirenz [23]. UGT2B7 is respon-
sible for conjugation to efavirenz-glucuronide [24]. Three
polymorphisms in CYP2B6 are associated with higher efavir-
enz concentrations [22]. The CYP2B6 516 G!T polymor-
phism has the strongest effect on efavirenz concentrations,
followed by the 983 T!C polymorphism [22]. An in vitro--in
vivo extrapolation model estimated that a dose reduction from
600 to 400 mg in patients with the 516 GT genotype and to
200 mg in those with the 516 TT genotype could reduce the
risk of developing early neuropsychiatric side effects without
affecting the probability of viral suppression [21].
Efavirenz plasma drug concentrations correlate with central
nervous system (CNS) drug concentrations. The brain is
protected from transient changes in the composition of the
blood by the blood--brain barrier (BBB) and the blood--cere-
brospinal fluid (CSF) barrier (BCSFB). The BBB and BCSFB
are not passive anatomical barriers but dynamic interfaces that
express a variety of influx and efflux transporters. Drug influx
and efflux transporters in the BBB play an important role in
the disposition of drugs in the CNS and may impede access
of antiretroviral drugs to the CNS [25,26]. Transporters at the
BBB and the BCSFB that have been implicated in the pene-
tration of antiretrovirals into the CNS includes p-glycoprotein
(MDR-1 or ABCB1), organic cation transporters (OCTs),
organic anion transporters (OATs), organic anion-transport-
ing polypeptide (OATP), breast cancer resistance protein
(BRCP) and multidrug resistance-associated proteins (MRP
or ABCC) [25,27,28]. There is weak evidence that efavirenz is
a substrate of p-glycoprotein, which is an important BBB
efflux pump [29-31]. However, unbound efavirenz concentra-
tions in the plasma and CSF have recently been shown to be
similar in humans despite large differences in the total CSF
and plasma efavirenz concentrations, suggesting that simple
diffusion rather than transporter-mediated efflux or influx
determines efavirenz CSF concentrations [32].
There is emerging clinical evidence indicating that efavirenz
use may worsen neurocognitive impairment or be associated
with less improvement in neurocognitive impairment than
other antiretrovirals. A small open-label study randomly
assigned HIV-infected patients commencing antiretroviral
therapy (ART) of tenofovir plus emtricitabine combined with
either efavirenz (n = 9), atazanavir plus ritonavir (n = 8) or zido-
vudine plus abacavir (n = 11) [33]. Changes in neurocognitive
function were assessed at baseline, week 24 and week 48 using
a validated battery of tests. Patients receiving the efavirenz-
based regimen had less overall neurocognitive improvement
and performed statistically significantly worse compared
with the other two arms on the speed domains on follow-
up neuropsychiatric testing. The potential neurotoxicity of
ART was explored in a cohort of asymptomatic HIV-infected
patients on ART [34]. Twenty-five out of the 129 (19%)
patients on ART received efavirenz-based ART. In multivariate
analysis, efavirenz use independently predicted worse perfor-
mance in tests of higher attention and executive load domains.
The association remained significant when the analysis was
restricted to patients on their current ART regimen for 1 year
or longer. ART improves HIV-associated neurocognitive disor-
der, but residual impairment is common [35,36]. Therefore, one
would expect that neurocognition would worsen when ART
is discontinued. However, a cohort study of patients who
had been on ART for a median of 4.5 years with CD4
counts > 350 cells/mm3 who elected to interrupt ART found
that scores of neuropsychological tests actually improved after
discontinuing ART [37]. Interruption of efavirenz-based ART
was associated with greater neurocognitive improvement
compared with other regimens.
There is evidence to suggest that efavirenz is directly toxic
to neurons in laboratory studies. Two recent studies evaluated
Article highlights.
. Efavirenz commonly causes early neuropsychiatric side
effects, but tolerance develops in most patients.
. There is emerging clinical evidence indicating that
efavirenz use may worsen neurocognitive impairment or
be associated with less improvement in neurocognitive
impairment than other antiretrovirals.
. Efavirenz and especially the major metabolite
8-hydroxy-efavirenz are toxic in neuron cultures at
concentrations found in the CSF.
. There is a need for large randomized controlled trials to
determine if the neuronal toxicity induced by efavirenz
results in clinically significant neurological impairment
before any conclusions can be made about ongoing use
of this widely used antiretroviral drug.
This box summarizes key points contained in the article.
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the direct effect of efavirenz on cultures of rat neurons [38,39].
In the first study, direct neurotoxicity of 15 antiretroviral
drugs, including efavirenz was evaluated [38]. The neuron cul-
tures were challenged for 1 week with each of the antiretrovi-
ral drugs at a range of concentrations. The antiretroviral drug
concentrations ranged from at least 1 order of magnitude
above and below the therapeutic plasma concentrations. Neu-
ronal damage was quantified using microtubule-associated
protein-2 (MAP-2) immunostaining, measuring the loss of
area occupied by MAP-2-stained neurons. A toxicity index
was calculated using toxicity data derived from the
dose--response curves for neuronal damage as well as the
therapeutic antiretroviral drug plasma concentrations and
the estimated CSF concentrations. Highest neurotoxicities
were seen with abacavir, atazanavir, efavirenz, etravirine and
nevirapine at drug concentrations similar to plasma concen-
trations. However, estimated neurotoxicity risk of efavirenz
toxicity was low with predicted CSF concentrations. In the
second study, the effect of efavirenz and its metabolites on cal-
cium homeostasis, dendritic spine morphology and survival of
rat neuronal cultures was studied [39]. 8-Hydroxy-efavirenz,
but not efavirenz or 7-hydroxy-efavirenz, caused a loss of
membrane integrity and release of calcium. Although both
efavirenz and its metabolites induced neuronal damage in a
dose-dependent manner, 8-hydroxy-efavirenz was 10-fold
more toxic. The investigators measured CSF efavirenz and
8-hydroxy-efavirenz concentrations from 13 patients established
on efavirenz-based ART enrolled on a neurocognitive
impairment study. CSF concentrations of both efavirenz
and 8-hydroxy-efavirenz were found to be similar to the
concentrations to elicited neuronal damage in the rat neurons.
Several potential mechanisms exist to explain efavirenz
neurotoxicity. First, efavirenz and its metabolites may cause
direct neuronal damage by disrupting calcium homeosta-
sis [39]. Second, creatine kinase (CK) concentrations were
significantly reduced in the cortex and cerebellum in mice
treated with efavirenz [40]. A decrease in CK has been associ-
ated with neurodegenerative diseases [41]. Third, efavirenz
causes a concentration-dependent mitochondriopathy in human
hepatic cells by inhibiting complex 1 of the respirator
chain [42]. Mitochondria play a crucial role and cell survival
and a decline in mitochondrial function has been associated
with aging and dementia [43]. Efavirenz reduces mitochondrial
respiratory chain complex IV activity in the brains of mice [44].
However, neurotoxicity was unrelated to mitochondrial damage
or cell death in rat neurons [38,44]. Fourth, efavirenz-treated rats
displayed memory deficits and stress, which were associated
with increased proinflammatory cytokines interleukin-1 beta
and tumor necrosis factor-alpha [45]. Cytokines and their
signaling pathways affect the metabolism of multiple neuro-
transmitters such as serotonin, dopamine and glutamate by alter-
ing their synthesis, release and reuptake [46]. Finally, efavirenz is
selective cytotoxic against cancer cells. The antineoplastic effect
of efavirenz is possibly mediated via cannabinoid signaling
pathways [47].
The weak evidence that efavirenz may worsen HIV-associ-
ated neurocognitive impairment should be viewed in context
of the high risk of severe AIDS dementia with untreated
HIV infection. Efavirenz is widely recommended as a first-
line ART in both resource-rich and resource-poor settings
because it is well tolerated and effective [48,49]. In low- and
middle-income countries, HIV-associated tuberculosis is
very common; therefore, the fact that efavirenz-based ART
is less prone to interactions with antituberculosis therapy
compared with other ART is an important advantage [50].
2. Conclusion
Efavirenz commonly causes transient early neuropsychiatric
side effects. There is emerging clinical evidence, indicating
that efavirenz use may worsen neurocognitive impairment
or be associated with less improvement in neurocognitive
impairment than other antiretrovirals. Animal data indicate
that efavirenz, especially its major metabolite 8-hydroxy-
efavirenz, is directly toxic to neurons at concentrations
achieved in the CSF of HIV-infected patients. Several poten-
tial mechanisms exist to explain efavirenz neurotoxicity,
including altered calcium haemostasis, decreases in brain
CK, mitochondrial damage, increases in proinflammatory
cytokines and involvement of the cannabinoid system. There
is a need for randomized controlled trials to determine if the
neuronal toxicity induced by efavirenz results in a clinically
significant neurological impairment. Until these trials are
conducted, it is premature to recommend against the use
of efavirenz.
3. Expert opinion
Efavirenz commonly causes mild neuropsychiatric effects of
therapy, but tolerance develops over a few weeks, even in
patients with CYP2B6 polymorphisms resulting in higher efa-
virenz concentrations [51]. These transient early neuropsychi-
atric side effects do not appear to cause permanent damage
and seldom result in discontinuation. However, if efavirenz
use is associated with an increased risk of neurocognitive
impairment, this could result in significant disability.
The clinical evidence that efavirenz use may worsen neuro-
cognitive impairment or be associated with less improvement
in neurocognitive impairment than other antiretrovirals is
weak. Animal data indicate that efavirenz is neurotoxic,
together with a number of other antiretrovirals. A key finding
in our understanding of efavirenz neurotoxicity is that the
8-hydroxy-efavirenz is 10 times more toxic in neuron cultures
compared with the parent drug. The implication for this
finding is that extensive metabolizers, who generate more
8-hydroxy-efavirenz, may develop more neurotoxicity. A
number of mechanisms could account for the observed neuro-
toxicity, either acting singly or in combination. One of the
plausible mechanisms is that efavirenz acts indirectly on the
cannabinoid system or its downstream signaling mechanisms.
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The action of efavirenz on the cannabinoid system may
explain the resemblance with the side-effect profile of
orally administered tetrahydrocannabinol such as dizziness,
somnolence and abnormal dreams [47]. There is limited
evidence currently to suggest that efavirenz directly influences
neurotransmitter pathways.
Inferences about efavirenz neurotoxicity are usually made
using plasma concentrations. A therapeutic window for ART
effectiveness in the CNS probably exists, but the therapeutic
range is poorly defined [39,52]. In the majority of studies, a
simultaneous single CSF and plasma concentration is mea-
sured and expressed as a ratio. Single-point CSF:plasma ratios
are less accurate approximations of drug exposure as plasma
concentrations vary more widely over time compared with
CSF concentrations [53]. The ratio of the average steady-
state unbound plasma:CSF concentrations is the gold
standard and is approximated by the area under the concen-
tration--time curves (AUC) for CSF and plasma [53,54]. How-
ever, frequent CSF sampling to determine AUC is generally
not feasible. Future approaches could use population pharma-
cokinetic modeling to estimate pharmacokinetic parameters
from a single sample collected at different times from multiple
patients to estimate the plasma:CSF exposure [55-57].
The next step would be to conduct an adequately powered
clinical trial to determine if the neurotoxicity of efavirenz results
in inferior neurologic outcomes that are clinically significant.
Determining the genotypic metabolizer status and plasma con-
centrations of efavirenz and the 8-hydroxy metabolite would
be important variables to measure in the clinical trial, which
would further our understanding of neurotoxicity. It is impor-
tant that unbound efavirenz CSF drug concentrations are mea-
sured since only the unbound drug fraction crosses the BBB.
CSF analysis should include the 8-hydroxy metabolite in addi-
tion to efavirenz concentrations. Plasma and CSF efavirenz
and metabolite concentrations as well as genotypic metabolizer
status should be used as variables to develop an algorithm that
permits safer use of this widely used antiretroviral drug.
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There is limited data on pharmacogenetics and pharmacokinetics of central nervous system penetration of 
efavirenz, tenofovir and emtricitabine. 
Objectives 
We investigated genetic polymorphisms associated with cerebrospinal fluid (CSF) exposure of efavirenz 
and its metabolites, tenofovir and emtricitabine. The secondary objective was to explore the 
pharmacokinetic-pharmacodynamic relationships with neurocognitive performance. 
Methods 
We included 47 HIV-infected South African Black adults with and without HIV-associated neurocognitive 
disorder on antiretroviral therapy with efavirenz-tenofovir-emtricitabine for at least 6 months with 
suppressed viral loads. We collected paired plasma-CSF samples. We considered 2049 single-nucleotide 
polymorphisms (SNPs), including SNPs known to affect plasma efavirenz exposure, from potentially 
relevant genes (ABCC5, ABCG2, ABCB1, SLCO2B1, SCLO1A2, ABCC4, CYP2B6 and CYP2A6) and 880 
met a linkage disequilibrium (LD)-pruning threshold. We assessed neurocognitive impairment using Global 
Deficit Score. 
Results 
We identified 9 efavirenz slow, 21 intermediate and 17 extensive metabolizers based on composite 
CYP2B6 15582/516/983 genotype. A model that included composite CYP2B6 15582/516/983 genotype in 
univariate analyses best predicted log10-transformed concentrations of plasma efavirenz [β=0.34, 95% CI 
(0.20 to 0.48), P=1.7 x10-05], plasma 7-hydroxy-efavirenz [β=0.45, 95% CI (0.10 to 0.66), P=5.8 x10-05], 
plasma 8-hydroxy-efavirenz-to-efavirenz ratio [β=-0.29, 95% CI (-0.38 to -0.21), P=3.7 x10-08] and CSF 
efavirenz [β=0.33, 95% CI (0.17 to 0.48), P=1.7 x10-05]. Individual polymorphisms CYP2B6 516G→T and 
983T→C also predicted these concentrations. Lower plasma 7-hydroxy-efavirenz concentrations were 
independently associated with CYP2A6 rs10853742 [β=-0.55, 95% CI (-0.78 to -0.32), P=3.5 x10-05], 
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ABCB1 rs115780656 [β=-0.65, 95% CI (-0.92 to -0.37), P=4.1 x10-05] and CYP2A6 -48A→C [β=-0.59, 95% 
CI (-1.01 to -0.16), P=1.0 x10-02]. CYP2A6 -48A→C was also independently associated with higher CSF 8-
hydroxy-efavirenz-to-efavirenz ratio [β=0.55, 95% CI (0.05 to 1.03), P=4.8 x10-02]. The CYP2B6 rs2279345 
polymorphism was associated with lower plasma 7-hydroxy-efavirenz-to-efavirenz ratio in univariate and 
multivariate analyses adjusting for CYP2B6 516G→T and 983T→C (P<0.05). No polymorphisms were 
associated with CSF-to-plasma ratios for each of the 3 drugs, plasma or CSF concentrations of 8-hydroxy-
efavirenz, tenofovir or emtricitabine, or neurocognitive performance.  
 
Conclusion 
We identified novel genetic associations with plasma concentrations of efavirenz, 7-hydroxy-efavirenz, 
plasma 7-hydroxy-efavirenz-to-efavirenz ratio, plasma 8-hydroxy-efavirenz-to-efavirenz ratio, CSF 
efavirenz and CSF 8-hydroxy-efavirenz-to-efavirenz ratio concentrations. 
 
Keywords 




The fixed dose combination efavirenz (EFV), tenofovir (TFV) and emtricitabine (FTC) has been 
recommended by the World Health Organization (WHO) as first-line antiretroviral therapy (ART) for HIV-
infected adults and is extensively prescribed.1 However, prolonged ART exposure may cause a secondary 
decline in cognitive function when ART neurotoxicity exceeds central nervous system (CNS) viral 
suppression efficacy, a hypothesis supported by preclinical and limited clinical data.2 Efavirenz in particular, 
but also TFV and FTC have been linked to direct neurotoxicity in in vitro studies individually and in 
combination.3 Interrupting ART after a median of 4.5 years was associated with improved cognitive 
function, especially among EFV recipients.4 In a randomised controlled trial (RCT), patients starting EFV, 
TFV and FTC rather than protease inhibitors or all-nucleoside reverse transcriptase inhibitor regimens had 
less improvement in neurocognitive function scores after 48 weeks.5  
 
An antiretroviral CNS penetration-effectiveness (CPE) ranking has been developed, however it has not 
been conclusively shown that ART regimens with higher CPE result in improved cognitive function in 
patients with HIV-associated neurocognitive disorder (HAND).6,7 However, higher CPE regimens have been 
associated with increased risk of HIV dementia, which could be due to antiretroviral toxicity.8 Human 
genetic variants have been associated with antiretroviral pharmacokinetics and pharmacodynamics, but 
ART CNS-targeted strategies have not considered pharmacogenetics.9 The impact of pharmacogenetics on 
the pharmacokinetics of EFV-TFV-FTC CNS penetration are lacking. 
 
More than 90% of EFV is metabolized by cytochrome P450 (CYP) 2B6 into 8-hydroxy-EFV (8-OH-EFV) 
while CYP2A6 metabolism forms the 7-hydroxy-EFV (7-OH-EFV) metabolite.10 The AIDS Clinical Trials 
Group first showed that the non-synonymous polymorphism CYP2B6 516G→T (rs3745274) was strongly 
associated with increased plasma EFV exposure and many studies have since replicated this 
association.11–16 The CYP2B6 516 TT genotype is more common in Africans and African-Americans than in 
Caucasians, with a frequency of 11% to 23%.11,17,18 Additional polymorphisms that are less frequent than 
516G→T in Africans and African-Americans, 983T→C (rs28399499) and CYP2B6 15582C→T 
(rs4803419), also predict increased plasma EFV exposure.10,18 The CYP2B6 983 C allele is found almost 
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exclusively with African ancestry with an allele frequency of only 4-9% but is associated with a 46% 
increase in plasma EFV concentrations.18,19 Polymorphisms in genes beyond CYP2B6 have been 
infrequently reported to be associated with EFV concentrations including polymorphisms in CYP2A6.15,20 
Polymorphisms in CYP2B6 are associated with higher EFV plasma concentrations and predispose patients 
to EFV-mediated neurotoxicity.11,21 Patients with CYP2B6 slow metabolizer genotypes not only have higher 
plasma concentrations, but also higher cerebrospinal fluid (CSF) EFV exposure.22 In vitro studies have 
implicated EFV and especially its metabolite 8-OH-EFV in causing direct neuronal toxicity.3,23,24 In a CSF 
sub-study of the ENCORE1 trial, 8-OH-EFV exposure correlated with adverse neuropsychiatric outcomes.22 
However, the CYP2B6 516 G→T allele only predicted EFV plasma and CSF concentrations and not 8-OH-
EFV plasma or CSF concentrations.22,25,26  
 
Transporters expressed in the blood-brain barrier (BBB) and blood-CSF barrier (BCSFB) affect influx and 
efflux of drugs including antiretrovirals.27,28 The superfamily of solute carriers (SLC) genes, including  
SLCO2B1, SLCO1A2 and SLCO1B1, influence the expression of  influx transporters in the BBB and 
BCSFB.29,30 The efflux transporters in the BBB and BCSFB are influenced by adenosine triphosphate 
(ATP)-binding cassette (ABC) genes and include ABCB1 (which encodes P-glycoprotein, P-gp), ABCG2, 
ABCC4 and ABCC5.30,31 Reported pharmacogenetic associations with EFV pharmacokinetics beyond 
CYP2B6 and CYP2A6 have not been well replicated. There is conflicting data regarding whether EFV is a 
P-gp substrate and whether ABCB1 polymorphisms predict EFV concentrations.13,32,33  ABCC4 
polymorphisms (rs1751034 and rs2274407) have been associated with lower and higher steady-state 
plasma EFV maximum concentrations respectively and in patients receiving EFV, ABCG2 rs2231142 has 
been associated with an increased risk of abnormal dreams.34,35 ABCC5 transporters are ubiquitous and 
known are to mediate efflux of antiviral nucleotide analogs such as TFV and FTC.36 In vitro assays have 
demonstrated that TFV is a substrate of ABCG2, ABCC4 and P-gp, and that FTC is a substrate of 
SLC47A1.37–39 TFV exposure in the CSF is approximately 6% of plasma concentrations and CSF 
penetration requires active transport.40 ABCG2 rs2231142 has been associated with a 1.5-fold increase in 
plasma TFV exposure.41 Loss-of function polymorphisms in ABCC4 may lead to reduced clearance of 
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TFV.39  Antiretrovirals, mainly protease inhibitors, are also substrates of SLC transporters SLCO2B1, 
SLCO1A2 and SLCO1B1.42  
 
Africans are the most genetically diverse population worldwide.43 South Africa has the world’s largest ART 
programme, with most patients currently receiving EFV-TFV-FTC.44 Polymorphisms in genes that encode 
these enzymes or transporters may therefore affect EFV, TFV or FTC CSF penetration. We investigated 
associations between genetic polymorphisms and CSF exposure of EFV, 8-OH-EFV, TFV and FTC in 
Black South Africans. The secondary objective was to explore pharmacokinetic-pharmacodynamic 
relationships of CSF EFV, 8-OH-EFV, TFV and FTC with neurocognitive performance. 
 
Patients and methods 
Participants: Adults (≥ 18 and ≤ 70 years) who had participated in an RCT (PACTR201310000635418) 
investigating the safety and efficacy of lithium in patients with HIV-associated neurocognitive impairment 
(Global Deficit Score [GDS] of ≥ 0.5) were invited to participate in this study. Inclusion and exclusion criteria 
of the RCT have been published elsewhere.45 We also invited participants who were screened for the RCT 
but were excluded based on cognitive impairment criteria, to join this study. We included participants 
established on EFV-based ART for at least 6 months and had suppressed plasma HIV-1 RNA. All 
participants provided written informed consent. The study was approved by the University of Cape Town 
Human Research Ethics Committee. 
Pharmacokinetic sampling: We collected paired plasma and CSF samples for EFV and metabolites, TFV 
and FTC assays. Participants recorded dosing time the night before, and were admitted in the morning for 
pharmacokinetic sampling. Mid-dosing lumbar punctures were performed to collect the CSF. Whole blood 
samples were collected within 45 minutes of CSF sampling, were centrifuged within 1 hour of collection, 
aliquoted and stored at -80°C until analysis. CSF samples were aliquoted and stored at -80°C until 
analysis. 
EFV and metabolites, TFV and FTC measurement: Drug assays were performed at 2 laboratories. The 
analytical laboratory in the Division of Clinical Pharmacology at the University of Cape Town measured total 
EFV, TFV and FTC concentrations in plasma and CSF using validated liquid chromatography tandem mass 
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spectrometry (LC/MS-MS) assays. The laboratory subscribes to the National Institute of Allergies and 
Infectious Diseases Division of AIDS Clinical Pharmacology Quality Assurance Antiretroviral Proficiency 
Testing Program. Lower limit of quantification (LLOQ) for plasma EFV, TFV and FTC were 19.5 ng/ml, 10.0 
ng/ml and 37.5 ng/ml, respectively.  For CSF measurements, the LLOQ for total EFV, TFV and FTC were 
0.5 ng/ml. The Bioanalytical Facility, Department of Molecular and Clinical Pharmacology at the University 
of Liverpool measured total CSF 8-OH-EFV, plasma 8-OH-EFV and 7-OH-EFV concentrations in plasma 
and CSF samples using validated LC/MS-MS assays.25 We were not able to measure CSF 7-OH-EFV 
concentrations. The LLOQ for CSF 8-OH-EFV, plasma 8-OH-EFV and plasma 7-OH-EFV was 3.125 ng/ml, 
5.0 ng/ml and 5.0 ng/ml, respectively. Concentrations below the limit of quantification (BLQ) were analyzed 
as missing data.  
Characterization of genetic polymorphisms: We extracted human DNA from buffy coats using 
Qiasymphony®. Genotyping was done using Illumina MEGAEX (Illumina, San Diego, CA). Single nucleotide 
polymorphisms (SNPs) that were not genotyped were imputed. SNPs were extracted for the following 
seven genes ± 50KB in each direction: ABCB1 (301 SNPs), ABCC4 (630 SNPs), ABCC5 (225 SNPs), 
ABCG2 (164 SNPs), CYP2A6/B6 (202 SNPs), SLCO1A2 (406 SNPs) and SLCO2B1 (118 SNPs). SNPs 
were excluded for genotyping efficiency less than 99%, a 5% minor allele frequency cut-off, and Hardy-
Weinberg equilibrium (HWE) P-values less than 0.00001. We further performed targeted genotyping of 
CYP2B6 516G→T (rs3745274) and CYP2A6 -48A→C (rs28399433) by TaqManTM (Applied Biosystems, 
Foster City, California, USA), CYP2B6 983T→C (rs28399499) and 15582C→T (rs4803419) and 
SLCO1B1 521T→C (rs4149056) and SLCO1B1 (rs4149032) by MassARRAY® iPLEX Gold (Sequenom 
Inc., San Diego, California, USA). We confirmed genotypes by visual inspection of plots and all samples 
were genotyped in duplicate. The final data set included 2049 SNPs from 47 participants. All genotyping 
was done at the Vanderbilt Technologies for Advanced Genomics (VANTAGE). Laboratory personnel with 
no knowledge of clinical data performed the genotyping. Metabolizer genotype groups for CYP2B6 were 
assigned as follows: extensive metabolizer (CYP2B6 15882CC-516GG-983TT or CYP2B6 15882CT-
516GG-983TT), intermediate metabolizer (CYP2B6 15882TT-516GG-983TT or CYP2B6 15882CC-516GT-
983TT or CYP2B6 15882CC-516GG-983CT or CYP2B6 15882CT-516GT-983TT or CYP2B6 15882CT-
516GG-983CT) and slow metabolizer (CYP2B6 15882CC-516TT-983TT or CYP2B6 15882CC-516GT-
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983CT or CYP2B6 15882CC-516GG-983CC). Furthermore, among participants with slow metabolizer 
genotype, additional assessment of CYP2A6 -48A→C (rs28399433) was assessed to categorize the 
metabolizer status into an ordinal 12-level metabolizer status as described elsewhere. 10,46 
Neurocognitive performance: We assessed neurocognitive impairment by summarizing the 
neuropsychological test results of selected cognitive domains, adjusting for age, education, gender and 
ethnicity using appropriate norms, to provide a GDS.47 We previously reported the domains and tests 
included.45 Neurocognitive impairment was defined as a GDS ≥ 0.5. We screened for symptoms of 
depression using the Center for Epidemiologic Studies Depression (CES-D) scale.48  
 
EFV and metabolite neurotoxicity: We compared CSF EFV and 8-OH-EFV concentrations with 
concentrations reported to be associated with neuronal damage in vitro (31.6 ng/ml and 3.3 ng/ml 
respectively).23  
 
Viral load assessment: We determined HIV-1 RNA concentrations in plasma and CSF using the Abbott 
RealTime HIV-1 assay (Abbott Park, Illinois, U.S.A.). We considered participants to be virologically 
suppressed if the viral load was < 400 copies/ml. In plasma and CSF, the lower limit of detection was 40 
copies per ml. In CSF, we performed a previously described nested polymerase chain reaction (PCR) and 
automated DNA sequencing method to detect HIV-1 transactivator viral protein Tat mutations, which have 
been associated with HIV-1 associated neurocognitive impairment.49,50 
 
Blood-brain-barrier integrity: We calculated the CSF-to-blood albumin ratio (CSF albumin [mg/l]/serum  
albumin [g/l)] to determine blood-brain-barrier (BBB) integrity. The blood-brain-barrier was considered intact 
if this ratio was less than 6.8 in participants younger than 45 years of age, and less than 10.2 in participants 
older than 45 years of age.51  
 
Pharmacokinetic statistical analysis: We assessed the normality of data visually and using the Shapiro-
Wilk test. Normally-distributed data were described using the means and standard deviations while median 
and interquartile ranges (IQR) were used for skewed data. Pharmacokinetic data were not normally 
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distributed and were additionally expressed as geometric means (95% confidence interval). We corrected 
for plasma protein-binding and estimated protein-free plasma concentrations in our pharmacokinetic 
analysis by multiplying total plasma concentrations by the protein-free concentrations reported in the 
literature (EFV 0.22%, TFV 1% and FTC 4%).52–54 Total CSF concentrations were considered to be similar 
to CSF protein-free concentrations.52 Pearson’s r correlation was used to assess correlations between 
plasma and CSF concentrations. We performed statistical analysis using STATA version 15.0 (StataCorp, 
College Station, Texas, USA). Graphs were created using GraphPad Prism version 7.03 for Windows 
(GraphPad Software, La Jolla, California, USA). 
 
Genetic association analysis: Genetic associations with pharmacokinetic parameters were analyzed by 
univariate and multivariate linear or logistic regression. Pharmacokinetic data were log-transformed (log10) 
for genetic analysis. We used ratios of measured concentrations (total in CSF and plasma) without 
correcting for protein binding. CSF-to-plasma ratios were calculated using raw concentrations then log10-
transformed. For EFV analyses, we subsequently adjusted for CYP2B6 516G→T, 983T→C and 
15582C→T. We performed genetic associations analyses in PLINK version 1.9 
(http://zzz.bwh.harvard.edu/plink/). For the primary analyses, we employed LD pruning with a LD r2 
threshold of 0.95 within a 50kb window at 5kb increments. The final analysis dataset included 880 SNPs 
which met the LD pruning threshold. We used Bonferroni correction to adjust for multiple testing (P-value = 
0.05 divided by 880 SNPs). We generated a LD plot using Haploview 
(https://www.broadinstitute.org/haploview/haploview).   
 
Results 
Study participant characteristics. We sampled 47 participants (Table 1), 33 (70%) of whom had mild to 
moderate neurocognitive impairment. All participants self-identified as Black Xhosa, and all were 
virologically suppressed in plasma. Four participants had detectable viral loads, with the highest being 128 
copies per ml. CSF viral loads were < 40 copies per ml in all participants. Five participants had detectable 
HIV-1 Tat DNA, all of whom had the C30C31S substitution. We were able to determine the CSF-to-blood 
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albumin ratio in 31 (66%) of 47 of participants, with a median value of 2.6 (range 1.1 to 5.2), indicating an 
intact BBB.  
 
EFV, TFV and FTC pharmacokinetics. Concentrations of EFV (plasma and CSF), 8-OH-EFV (plasma and 
CSF), 7-OH-EFV (plasma), TFV (plasma and CSF) and FTC (plasma and CSF) are described in Table 2. 
Plasma 8-OH-EFV and 7-OH-EFV concentrations correlated with plasma EFV concentrations (p < 0.0001 
for each) (Figure 1, Panels A and B). Concentrations of EFV, FTC and TFV in CSF correlated with 
concentrations of these drugs in plasma (P < 0.0001 for each) (Figure 1, Panels C, D and E). There was 
no correlation between CSF 8-OH-EFV and plasma EFV, CSF 8-OH-EFV and plasma 8-OH-EFV or 
plasma 7-OH-EFV and plasma 8-OH-EFV (Figure 1, Panels F, G and H). There was no statistically 
significant association of CSF-to-plasma ratios versus time after dosing, which ranged from approximately 
13 hours to 18 hours, for EFV, 8-OH-EFV, TFV or FTC (Figure 2). CSF EFV concentrations were above 
the 50% inhibitory concentration (IC50) 1.3 ng/ml in all participants.52,55–57 CSF TFV concentrations were 
below the IC50 for TFV (11.5 ng/ml) in all participants and CSF FTC concentrations were below the IC50 
(70.0 ng/ml) in 21 (49%) of 43 of participants.54,58 CSF EFV concentrations and CSF 8-OH-EFV 
concentrations were above the in vitro toxic concentration (CSF EFV 31.6 ng/ml; CSF 8-OH-EFV 3.3 ng/ml) 
in 7 (15.2%) of 46 participants and 14 (29.8%) of 47) participants, respectively.23 
 
Genetic associations for EFV  
Genotyping of 4 polymorphisms with known effects on EFV (CYP2B6 516G→T, 983T→C and 15582C→T 
and CYP2A6 -48 A→C) and 2 polymorphisms in SLCO1B1 (rs4149056 and rs4149032) was successful in 
all 47 participants. SLCO1B1 rs4149056 was monomorphic. In 43 (91%) of 47 participants, additional 2043 
polymorphisms from ABCB1, ABCC4, ABCC5, ABCG2, CYP2A6, CYP2B6, SLCO1A2 and SLCO2B1 were 
successfully genotyped. All 2048 polymorphisms were in HWE based on a Bonferroni adjusted P-value 
threshold of 0.00002; 18 had unadjusted P-values <0.05 (data not shown). The 880 polymorphisms 
included in the final dataset based on LD pruning were in HWE based on a Bonferroni adjusted P-value 
threshold of 5.7 x10-05. Ten polymorphisms had unadjusted P-values <0.05.  
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CSF-to-plasma EFV concentration ratios: The linear regression analyses results for associations 
between genetic polymorphisms and CSF-to-plasma ratios for EFV are displayed in Table 3. In univariate 
linear regression models, of the 880 polymorphisms, rs9584273 in ABCC4 had the lowest P-value for 
association with log10-transformed CSF-to-plasma EFV concentration ratio [β=0.14, 95% CI (0.05 to 0.22), 
P=2.3 x10-03]. This was not statistically significant [Bonferroni corrected P<5.7x10-05].  There was a trend 
between 11 additional polymorphisms (6 in ABCC4, 2 in ABCC5, 1 in ABCB1, CYP2B6, and CYP2G1P) 
and CSF-to-plasma EFV concentration ratios (P<0.01). There were no significant associations between 
individuals SNPs CYP2B6 516G→T, 983T→C, 15582C→T and CYP2A6 -48A→C and CSF-to-plasma EFV 
concentration ratios (P>0.05) (Table 3). No polymorphisms were significant after correcting for multiple 
testing in multivariate analyses adjusting for CYP2B6 516G→T,  516G→T 983T→C,  516G→T 983T→C 
and 15582C→T. 
 
CSF-to-plasma 8-OH-EFV concentration ratios: The linear regression analyses results for associations 
between genetic polymorphisms and CSF-to-plasma ratios for 8-OH-EFV concentration ratios in 16 
participants are displayed in Table 4. In univariate linear regression models, of the 880 polymorphisms, 
ABCC5 rs6762938 had the lowest P-value for a trend between log10-transformed CSF-to-plasma 8-OH-
EFV concentration ratio [β=0.23, 95% CI (0.14 to 0.32), P=2.6 x10-04]. There was a trend between 17 
additional polymorphisms (7 in ABCC4, 7 in ABCC5, 1 in ABCB1, ABCG2 and SLCO1B1) and CSF-to-
plasma 8-OH-EFV concentration ratios (P <0.01). There were no significant associations between 
individual SNPs CYP2B6 516G→T, 983T→C, 15582C→T and CYP2A6 -48A→C and CSF-to-plasma 8-
OH-EFV concentration ratios (P>0.05) (Table 4). No polymorphisms were significant after correcting for 
multiple testing in multivariate analyses adjusting for CYP2B6 516G→T, 983T→C and 15582C→T. 
 
Plasma EFV concentrations: Relationships between CYP2B6 slow metabolizer genotypes and EFV 
concentrations in all individuals are described in Table 5. Plasma EFV concentrations were significantly 
higher in CYP2B6 slow metabolizers compared with intermediate and extensive metabolizers. Figure 3 
shows concentrations of log10-transformed EFV and metabolites in the plasma and CSF by CYP2B6/A6 
metabolizer status. In univariate linear regression models, composite CYP2B6 15582/516/983 genotype 
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was most strongly associated with plasma EFV concentrations [β=0.34, 95% CI (0.20 to 0.48), P = 1.7 x10-
05] (Supplemental Table S1). Of the 880 polymorphisms, CYP2B6 rs60618302 had the lowest P value and 
showed a negative association with log10-transformed plasma EFV concentrations [β=-0.43, 95% CI (-0.62 
to 0.25), P = 5.3 x10-05]. Seven additional polymorphisms showed an association with log10-transformed 
plasma EFV concentrations at P< 0.01 and included CYP2B6 516G→T [β=0.30, 95% CI (0.12 to 0.49), P = 
2.0 x10-03] and another CYP2B6 polymorphism (rs59243457) in LD with 516G→T at r2>0.6 [β=0.31, 95% 
CI (0.12 to 0.49), P = 2.7 x10-03]. There was an association between CYP2B6 983T→C and log10-
transformed plasma EFV concentrations [β=0.35, 95% CI (0.08 to 0.62), P = 1.4 x10-02]. There was no 
association with CYP2B6 15582C→T [β=-0.23, 95% CI (-0.54 to 0.08), P = 0.15]. To identify independent 
predictors of EFV concentrations we performed multivariable linear regression analysis adjusted for 
CYP2B6 516G→T. By this analysis, the polymorphism associated at P< 0.05 was CYP2B6 983T→C 
[β=0.38, 95%CI (0.14 to 0.61), P=2.7 x10-3)]. In an analysis that adjusted for both CYP2B6 516G→T and 
983T→C, no additional polymorphism was associated with EFV concentrations at the Bonferroni corrected 
P value of 5.7 x10-5, the lowest P-value being for ABCB1 rs115780656 [β=-0.37, 95%CI (-0.58 to -0.17), 
P=9.7 x10-4)]. There was no apparent association with CYP2B6 15582C→T [β=-0.00, 95%CI (-0.29 to -
0.28), P=0.98)] or CYP2A6 -48A→C [β=-0.31, 95%CI (-0.62 to 0.00), P=0.05)]. 
 
Plasma 8-OH-EFV concentrations: Plasma 8-OH-EFV concentrations were not associated with CYP2B6 
metabolizer status. (Table 5). The linear regression analyses for associations between genetic 
polymorphisms and plasma 8-OH-EFV concentrations are displayed in Supplemental Table S1. In 
univariate linear regression models, of the 880 polymorphisms, ABCB1 rs115780656 had the lowest P-
value for association with log10-transformed plasma 8-OH-EFV concentrations [β=-0.36, 95% CI (-0.55 to -
0.18), P=4.3 x10-04]. There was a trend between 11 additional polymorphisms (3 in ABCG2, 2 in ABCB1, 2 
in ABCC4, 1 in CYP2G1P, 1 in CYP2A6 and 1 in CYP2A7) and plasma 8-OH-EFV concentrations (P 
<0.01). There were no significant associations between individuals SNPs CYP2B6 516G→T, 983T→C, 
15582C→T or CYP2A6 -48A→C and plasma 8-OH-EFV concentrations (P>0.05) (Supplemental Table 
S1). No polymorphisms were significant after correcting for multiple testing in multivariate analyses 
adjusting for CYP2B6 516G→T, or CYP2B6 516G→T and 983T→C. 
69
Plasma 7-OH-EFV concentrations: Plasma 7-OH-EFV concentrations were significantly higher in 
CYP2B6 slow metabolizers compared with intermediate and extensive metabolizers (Table 5). In univariate 
linear regression models, composite CYP2B6 genotype best described the association between log10-
transformed plasma 7-OH-EFV concentrations [β=0.45, 95% CI (0.10 to 0.66), P=5.9 x10-05] 
(Supplemental Table S1). Among the individual polymorphisms, CYP2B6 516G→T [β=0.39, 95% CI (0.14 
to 0.70), P=5.5 x10-03] and CYP2B6 983T→C [β=0.50, 95% CI (0.12 to 0.86), P=1.5 x10-02] were 
significantly associated with log10-transformed plasma 7-OH-EFV concentrations. There was a trend 
between 11 additional polymorphisms (4 in CYP2B6, 4 in CYP2A6, 2 in ABCB1 and 1 in ABCC4) and 
log10-transformed plasma 7-OH-EFV concentrations (P <0.01), with the CYP2A6 rs56164728 having the 
lowest P value [β=-1.02, 95% CI (-1.47 to -0.57), P=6.4 x10-05]. Furthermore, there were no significant 
associations between individuals SNPs CYP2B6 15582C→T and CYP2A6 -48A→C and log10-transformed 
plasma 7-OH-EFV concentrations (P>0.3) (Supplemental Table S1). After adjusting for CYP2B6 516G→T, 
CYP2B6 983T→C remained significant [β=0.59, 95% CI (0.22 to 0.96), P=3.7 x10-03] and ABCB1 
rs11578656 became significant [β=-0.71, 95% CI (-1.01 to -0.42), P=2.9 x10-05]. The association between 
ABCB1 rs11578656 and log10-transformed plasma 7-OH-EFV concentrations remained significant after 
correcting for multiple testing in multivariate analyses adjusting for CYP2B6 516G→T and CYP2B6 
983T→C [β=-0.65, 95% CI (-0.92 to -0.37), P=4.1 x10-05]. Two additional polymorphisms in CYP2A6 
became significant in multivariate analyses adjusting for CYP2B6 516G→T and CYP2B6 983T→C; 
CYP2A6 rs10853742 [β=-0.55, 95% CI (-0.78 to -0.32), P=3.5 x10-05] and known polymorphism CYP2A6 -
48A→C [β=-0.59, 95% CI (-1.01 to -0.16), P=0.01]. There was no association with between CYP2B6 
15582C→T and log10-transformed plasma 7-OH-EFV concentrations in univariate (P=0.61) or multivariate 
analyses (P>0.60).  
 
CSF EFV concentrations: CSF EFV concentrations were significantly higher in CYP2B6 slow 
metabolizers compared with intermediate and extensive metabolizers (Table 5). In univariate linear 
regression models, composite CYP2B6 genotype best described the association between log10-
transformed CSF EFV concentrations [β=0.33, 95% CI (0.17 to 0.48), P=1.7 x10-04] (Supplemental Table 
S2). Among the individual polymorphisms, CYP2B6 516G→T [β=0.29, 95% CI (0.09 to 0.49), P=6.2 x10-03] 
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and CYP2B6 983T→C [β=0.33, 95% CI (0.04 to 0.61), P=3.0 x10-02] were significantly associated with 
log10-transformed CSF EFV concentrations. There was a trend between 8 additional polymorphisms (3 in 
CYP2B6, 3 in ABCB1, 1 in ABCC4 and 1 in ABBC5) and log10-transformed CSF EFV concentrations (P 
<0.01). ABCB1 rs115780656 had the lowest P-value for a trend towards a negative association with log10-
transformed CSF EFV concentrations [β=-0.51, 95% CI (-0.77 to -0.26), P=3.4 x10-04]. There were no 
significant associations between 15582C→T and CYP2A6 -48A→C and log10-transformed CSF EFV 
concentrations (P>0.05) (Supplemental Table S2). After adjusting for CYP2B6 516G→T, the association 
between CYP2B6 983T→C and log10-transformed CSF EFV concentrations remained significant [β=0.36, 
95% CI (0.10 to 0.62), P=1.0 x10-02]. No polymorphisms were significant after correcting for multiple testing 
in multivariate analyses adjusting for CYP2B6 516G→T, or CYP2B6 516G→T and CYP2B6 983T→C.  
 
CSF 8-OH-EFV concentrations:  There was no relationship between log10-transformed CSF 8-OH-EFV 
concentrations and CYP2B6 metabolizer status (Table 5). CSF 8-OH-EFV concentrations were only 
detectable in 16 participants. Linear regression analysis results for associations between polymorphisms 
and CSF 8-OH-EFV concentrations are displayed in Supplemental Table S2. In univariate linear 
regression models, of the 880 polymorphisms, ABCC5 rs6762938 had the lowest P-value for association 
with log10-transformed CSF 8-OH-EFV concentrations [β=0.18, 95% CI (0.11 to 0.24), P=7.8 x10-05] when 
the analysis was restricted to the 16 participants with detectable CSF 8-OH-EFV. Ten additional 
polymorphisms (3 in ABCC5, 3 in ABCC4, 2 in ABCB1, 1 in SLCO2B1 and 1 in CYP2B6) showed a trend 
towards an association with log10-transformed CSF 8-OH-EFV concentrations, including CYP2B6 983T→C 
[β=-0.17, 95% CI (-0.34 to 0.00), P=0.08]. There were also no significant associations between composite 
CYP2B6 15582/516/983 genotype or individual polymorphisms CYP2B6 516G→T, CYP2B6 15582C→T or 
CYP2A6 -48A→C and log10-transformed CSF 8-OH-EFV concentrations (P>0.05) (Supplemental Table 
S2). CYP2B6 983T→C remained not significant after adjusting for CYP2B6 516G→T (P=0.07). No 
polymorphisms were significant after correcting for multiple testing in multivariate analyses adjusting for 
CYP2B6 516G→T, or CYP2B6 516G→T and CYP2B6 983T→C. In univariate logistic regression analyses 
in all 47 participants comparing those with detectable CSF 8-OH-EFV concentrations versus those with 
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undetectable concentrations, there were no significant associations between polymorphisms and 
detectable CSF 8-hydroxy-efavirenz (Supplemental Table S2).   
 
Plasma 8-OH-EFV/EFV ratios: Regression analysis results for genetic associations with plasma 8-OH-
EFV/EFV are displayed in Supplemental Table S3. In univariate linear regression models, composite 
CYP2B6 15582/516/983 genotype was most strongly associated with log10-transformed 8-OH-EFV/EFV 
ratios [β=-0.29, 95% CI (-0.38 to -0.21), P=3.7 x10-08]. There were also significant associations between 
log10-transformed 8-OH-EFV/EFV ratio and individual polymorphisms, CYP2B6 516G→T [β=-0.27, 95% CI 
(-0.39 to -0.15), P=6.5 x10-05] and CYP2B6 983T→C [β=-0.28, 95% CI (-0.46 to -0.09), P=5.5 x10-03]. There 
were no significant associations between CYP2B6 15582C→T or CYP2A6 -48A→C and log10-transformed 
8-OH-EFV/EFV ratios (P>0.05) (Supplemental Table S3). There were 19 additional polymorphisms (7 in 
ABCC4, 5 in SLCO2B1, 4 in CYP2B6 and 1 in ABCG2, EGLN2, PKD2 and CYP2B6 respectively) that 
showed a trend with log10-transformed 8-OH-EFV/EFV ratios (P<0.01). After adjusting for CYP2B6 
516G→T, the association between CYP2B6 983T→C and log10-transformed 8-OH-EFV/EFV ratios 
remained significant [β=-0.31, 95% CI (-0.45 to -0.16), P=1.8 x10-04]. No polymorphisms were significant 
after correcting for multiple testing in multivariate analyses adjusting for CYP2B6 516G→T and CYP2B6 
983T→C.  
 
Plasma 7-OH-EFV/EFV ratios: In univariate linear regression models, a previously described CYP2B6 
polymorphism (rs2279345) was significantly associated with lower 7-OH-EFV/EFV ratios [β=-0.28, 95% CI 
(-0.42 to -0.15), P=1.8 x10-04] at P<0.05 (Supplemental Table S3). Of the 880 polymorphisms, rs56164728 
in CYP2A6 had the lowest P-value for a trend between log10-transformed 7-OH-EFV/EFV ratios [β=-0.50, 
95% CI (-0.72 to -0.27), P=1.1 x10-04]. Seven additional polymorphisms (3 in CYP2A6, 3 in ABBC4 and 1 in 
ABCB1) showed a trend at P<0.01. There were no significant associations between composite CYP2B6 
15582/516/983 genotype or individual polymorphisms, CYP2B6 516G→T, CYP2B6 983T→C, CYP2B6 
15582C→T or CYP2A6 -48A→C and log10-transformed plasma 7-OH-EFV/EFV ratios (P>0.05) 
(Supplemental Table S3). After adjusting for CYP2B6 516G→T, CYP2B6 516G→T and CYP2B6 
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983T→C, the association between CYP2B6 polymorphism (rs2279345) and lower 7-OH-EFV/EFV ratios 
remained significant at P<0.05. 
 
CSF 8-OH-EFV/EFV ratios: Linear regression analysis results for genetic associations with log10-
transformed CSF 8-OH-EFV/EFV ratios were available only in 16 participants and are displayed in 
Supplemental Table S3. In univariate linear regression models, 2 polymorphisms in ABCC5 showed a 
trend towards an association with higher log10-transformed CSF 8-OH-EFV/EFV ratios at P<0.01. In 
addition, rs76268776 downstream from CYP2A6 (P<0.01) and the composite CYP2B6 518/983 genotype 
(P<0.1) showed trends towards an association with lower CSF 8-OH-EFV/EFV ratios. After adjusting for 
CYP2B6 516G→T and CYP2B6 983T→C, the association between CYP2A6 -48A→C and higher log10-
transformed CSF 8-OH-EFV/EFV ratios became significant [β=0.55, 95% CI (0.05 to 1.03), P=4.8 x10-02]. 
 
Genetic polymorphisms and TFV concentrations  
Plasma TFV concentrations:  In univariate linear regression models, and correcting for multiple testing, 
there were no significant associations between any of the 880 polymorphisms and plasma TFV 
concentrations (Supplemental Table S4). Ten polymorphisms (3 in ABCG2, 3 in ABCC5, 3 in SLCO1A2 
and 1 in ABCC4) were associated with lower plasma TFV concentrations at P<0.01, with ABCG2 
(rs2231159) having the lowest P value [β=-0.32, 95% CI (-0.48 to -0.17), P=2.2x10-04]. 
 
CSF TFV concentrations: In univariate linear regression models, and correcting for multiple testing, there 
were no significant associations between any of the 880 polymorphisms CSF concentrations 
(Supplemental Table S4). Six polymorphisms (2 in ABCB1, 1 in ABCG2, 1 in ABCC5, 1 in SLCO1A2 and 
1 in ABCC4) were associated with lower CSF TFV concentrations at P<0.01, with ABCC4 (rs7982526) 
having the lowest P value [β=-0.58, 95% CI (-0.85 to -0.30), P=1.7 x10-04]. In addition, SLCO1A2 
(rs140377659) was associated with higher CSF TFV concentrations at P<0.01. 
CSF-to-plasma TFV ratios:  In univariate linear regression models, and correcting for multiple testing, 
there were no significant associations between any of the 880 polymorphisms and CSF-to-plasma TFV 
ratios (Supplemental Table S4). Eleven polymorphisms (3 in ABCB1, 2 in ABCG2, 6 SLCO1A2) were 
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associated with CSF-to-plasma TFV ratios at P<0.01, with ABCG2 (rs1989830) having the lowest P value 
[β=-0.12, 95% CI (-0.19 to -0.05), P=2.2x10-04]. Polymorphisms in SLCO1A2 showed a trend towards 
higher ratios, whereas polymorphisms in ABCB1 and ABCG2 showed trends with lower ratios.  
 
Genetic polymorphisms associated with FTC concentrations  
Plasma FTC concentrations: Only 39 participants were included in the analyses. In univariate linear 
regression models, and correcting for multiple testing, there were no significant associations between any 
of the 880 polymorphisms and plasma FTC concentrations (Supplemental Table S5). Six polymorphisms 
(3 in ABCC5, 1 in SLCO1A2 and 1 in ABCC4 and 1 in SLCO2B1) were associated with plasma FTC 
concentrations at P<0.01, with ABCG5 rs56889675 having the lowest P value [β=-0.26, 95% CI (-0.40 to -
0.12), P=8.0 x10-04]. ABCC5 rs74763842 showed a trend towards an association with higher plasma FTC, 
while the remaining polymorphisms towards an association with lower FTC concentrations.  
 
CSF FTC concentrations: In univariate linear regression models, and correcting for multiple testing, there 
were no significant associations between any of the 880 polymorphisms CSF FTV concentrations 
(Supplemental Table S5). Twelve polymorphisms (2 in ABCB1, 1 in ABCG2, 1 in ABCC5, 1 in SLCO1A2 
and 1 in ABCC4) were associated with lower CSF FTC concentrations at P<0.01, with ABCC5 rs56889675 
having the lowest P value [β=-0.32, 95% CI (-0.50 to -0.15), P=7.2 x10-04].  
 
CSF-to-plasma FTC ratios:  In univariate linear regression models, and correcting for multiple testing, 
there were no significant associations between any of the 880 polymorphisms and CSF-to-plasma FTC 
ratios (Supplemental Table S5). Eight polymorphisms (3 in ABCC5, 3 in ABCC4, 1 in ABCG2, 1 in 
SLCO1A2) were associated with CSF-to-plasma FTV ratios at P<0.01, with ABCC5 rs11921035 having the 
lowest P value [β=-0.32, 95% CI (-0.50 to -0.14), P=1.4 x10-03]. Two polymorphisms in ABCC4 showed a 





Pharmacokinetic-pharmacodynamic associations with neurocognitive performance  
We found no significant correlation between GDS and CSF concentrations of EFV, 8-OH-EFV, TFV or FTC. 
Detectable CSF 8-OH-EFV concentration tended to be associated with impaired executive function on the 
Colour Trails Test (P = 0.043). Participants with detectable CSF 8-OH-EFV had a higher GDS compared to 
participants without detectable CSF 8-OH-EFV (1.0 compared to 0.82), but this was not statistically 
significant. The GDS in the 5 participants in whom HIV-1 Tat DNA were detected, were similar to those in 
whom Tat DNA were not detected. 
 
Discussion 
We investigated whether genetic polymorphisms are associated with CSF disposition of EFV, TFV and FTC 
in Black South African adults. A model that included composite CYP2B6 15582/516/983 genotype in 
univariate analyses best predicted log10-transformed concentrations of plasma EFV, plasma 7-OH-EFV, 
plasma 8-OH-EFV/EFV ratio and CSF EFV. The individual polymorphisms CYP2B6 516G→T and 983T→C 
also predicted these concentrations. Lower plasma 7-OH-EFV concentrations were independently 
associated with CYP2A6 rs10853742, ABCB1 rs115780656 and CYP2A6 -48A→C. The CYP2A6 -48A→C 
polymorphism was also independently associated with higher CSF 8-OH-EFV/EFV ratio. The CYP2B6 
rs2279345 polymorphism was associated with lower plasma 7-OH-EFV/EFV ratio in univariate and 
multivariate analyses adjusting for CYP2B6 516G→T and 983T→C (P<0.05). No polymorphisms were 
associated with CSF-to-plasma ratios of all 3 drugs, plasma or CSF 8-OH-EFV, TDF or FTC concentrations 
or neurocognitive performance.  
 
We expected CSF 8-OH-EFV concentrations to be higher in extensive metabolizers as it is formed via the 
CYP2B6 enzymatic pathway. However, similar to the findings of others, 8-OH-EFV concentrations in 
plasma and CSF remained constant irrespective of metabolizer status. 22,25,26 It is possible that the small 
number of participants (16 of 47) with detectable CSF 8-OH-EFV concentrations contributed to the lack of 
the association between the metabolizer status and CSF 8-OH-EFV concentrations. Winston and 
colleagues proposed that CSF 8-OH-EFV concentrations are independent of metabolizer status as it is 8-
OH-EFV spill over from the plasma, or that EFV is metabolized to 8-OH-EFV in the CNS, trapping 8-OH-
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EFV within the CNS compartment.22 We found that CYP2A6 -48A→C was independently associated with 
higher CSF 8-OH-EFV/EFV ratio, which may suggest that in CYP2B6 slow metabolizers, EFV may be 
metabolized to 8-OH-EFV in the CNS by the accessory pathway CYP2A6. CSF 8-OH-EFV further 
undergoes phase II glucuronidation and sulfation; both CSF 8-OH-EFV-glucuronide and CSF 8-OH-EFV-
sulfate concentrations exceed by several fold that of the parent CSF 8-OH-EFV.26 Phase II metabolism 
enhances the polarity of CSF 8-OH-EFV into a less lipid-soluble molecule.26 However we did not find a 
statistically significant association with CYP2A6 -48A→C and CSF 8-OH-EFV or plasma 8-OH-EFV. 
 
We explored pharmacokinetic-pharmacodynamic relationships of EFV-TFV-FTC and neurocognition. 
Although CSF EFV and 8-OH-EFV concentrations were above the in vitro CSF toxicity threshold, in 15.2% 
and 29.8% of participants respectively, we did not find a relationship between GDS performance and 
plasma or CSF EFV-TFV-FTC concentrations or CSF 8-OH-EFV concentrations. Participants with 
detectable CSF 8-OH-EFV scored worse on the Colour Trails Test (P-value = 0.04) and had a higher GDS 
(median 1.39 compared to median 1.0), but this was not statistically significant. It is possible that CYP2A6 -
48A→C predisposes CYP2B6 slow metabolizers to higher CSF 8-OH-EFV concentrations and worse 
neurocognitive performance.  Various cellular mechanisms for EFV toxicity have been proposed.59 Higher 
EFV concentrations, which are associated with CYP2B6 slow metabolizer status, are associated with 
neurological symptoms, which may include serious presentations such as encephalopathy.21,60 In a CSF 
sub-study of the ENCORE1 trial, 8-OH-EFV exposure correlated with adverse neuropsychology outcomes 
as measured by the Depression Anxiety Stress Scale and EFV Symptom Questionnaire at 4 and 48 weeks 
of EFV initiation.22 CSF concentrations of EFV, 8-OH-EFV and the phase II metabolites of 8-OH-EFV have 
not been associated with EFV treatment discontinuations.26 Previous animal studies showed an association 
between the C30C31S substitution and a possible neuroprotective effect. However studies in HIV-1 
infected humans, including ours, do not confirm this association. The neurocognition scores (GDS) of the 5 
participants with C30C31S substitution were similar to other participants’.50,61 
 
Our study has limitations. We only studied 47 participants.  We had limited power to detect genetic 
associations between infrequent genotypes with small effect sizes (increase in plasma or CSF 
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concentrations). For example, the CYP2A6 -48A→C polymorphism has been associated with increased 
plasma EFV concentrations in CYP2B6 slow metabolizers,46 but we found no association as there only 3 
participants with CYP2B6 slow metabolizer genotype that carried a single CYP2A6 -48A→C allele. This 
may have also limited our ability to detect associations between CYP2B6 15582C→T and plasma EFV 
concentrations, as 15582CT heterozygosity has been associated with small increases in plasma EFV 
exposure, and there were no 15582TT homozygotes in our study.10 We were also not able to detect 
pharmacokinetic-pharmacodynamic associations due to limited power to detect smaller differences in 
cognitive impairment. However, to our knowledge this is the largest sample size examining 
pharmacogenetic, pharmacokinetic and pharmacodynamic associations with CSF EFV-TFV-FTC. Our 
study was cross-sectional. Neurocognitive changes would have been better assessed longitudinally. We 
did not measure unbound concentrations of EFV-TFV-FTC. EFV is 99.8% protein bound, but protein-free 
EFV concentrations are equivalent in blood plasma and CSF.52 TFV and FTC are less than 7% and 4% 
protein bound, respectively.54 We assessed CSF-to-plasma ratios of total concentrations. Protein-free CSF-
to-plasma concentrations of EFV in particular may have more accurately reflected the 
pharmacodynamically active concentrations. We did not measure the phase II EFV metabolites in CSF, 
which exceed concentrations of CSF EFV and CSF 8-OH-EFV.26 The effect of phase II EFV metabolites on 
neurocognition are unknown. As our study only included adults, pharmacokinetic and pharmacodynamic 
findings may not apply to a paediatric population. There are concerns about the limited safety data 
regarding EFV and neurocognitive development of children.62 Our inability to demonstrate a neurocognitive 
association with EFV-TFV-FTC pharmacokinetics in adults cannot be extrapolated to children. 
 
In summary, we investigated polymorphisms associated with CSF exposure of EFV, 8-OH-EFV, TFV and 
FTC in black South Africans. We also explored the pharmacokinetic-pharmacodynamic relationships of 
CSF EFV-TFV-FTC with neurocognitive performance. To our knowledge this is the largest study to 
examine pharmacogenetic, pharmacokinetic and pharmacodynamic associations with CSF EFV-TFV-FTC. 
We identified novel genetic associations with plasma EFV, plasma 7-OH-EFV, plasma 7-OH-EFV/EFV 
ratio, plasma 8-OH-EFV/EFV ratio and CSF efavirenz. No polymorphisms were associated with CSF-to-
77




The study participants. 
The study team in alphabetical order: Laura Comrie (clinical support), Carla Freeman (clinical support), 
Shahieda Isaacs (viral sequencing), Pam Jordan (data capturer), Teboho Linda (neuropsychology 
technician). Nozipho Mawisa (study nurse), Queen Maswana (recruiter), Rasmita Ori (clinical support), 
Kareema Poggenpoel (administration support) and Shireen Surtie (study coordinator). We are grateful to 
Cara Sutcliffe and the VANTAGE team at Vanderbilt. 
 
Funding 
This work was supported by the South African Medical Research Council and the European and 
Developing Countries Clinical Trials Partnership (SP.2011.41304.065). The drug assays analysed at UCT 
were supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes 
of Health (UM1 AI068634, UM1 AI068636, UM1 AI106701, U01 AI068632), the Eunice Kennedy Shriver 
National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental 








1.  World Health Organisation (WHO). First-line ART for Adults. 
http://www.who.int/hiv/pub/guidelines/arv2013/art/artadults/en/. Accessed June 1, 2017. 
2.  Underwood J, Robertson KR, Winston A. Could antiretroviral neurotoxicity play a role in the 
pathogenesis of cognitive impairment in treated HIV disease?. AIDS. 2015;29(3):253-261. 
doi:10.1097/QAD.0000000000000538. 
3.  Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012;18(5):388-399. 
doi:10.1007/s13365-012-0120-3. 
4.  Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable 
HIV-positive patients in an observational cohort. Neurology. 2010;74(16):1260-1266. 
doi:10.1212/WNL.0b013e3181d9ed09. 
5.  Winston A, Duncombe C, Li PCK, et al. Does choice of combination antiretroviral therapy (cART) 
alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected 
individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010;50(6):920-929. 
doi:10.1086/650743. 
6.  Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank 
for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65-
70. doi:10.1001/archneurol.2007.31. 
7.  Ellis RJ, Letendre S, Vaida F, et al. Randomized trial of central nervous system-targeted 
antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis. 2014;58(7):1015-1022. 
doi:10.1093/cid/cit921. 
8.  Caniglia EC, Cain LE, Justice A, et al. Antiretroviral penetration into the CNS and incidence of AIDS-
defining neurologic conditions. Neurology. 2014;83(2):134-141. 
doi:10.1212/WNL.0000000000000564. 
9.  Haas DW, Tarr PE. Perspectives on pharmacogenomics of antiretroviral medications and HIV-
associated comorbidities. Curr Opin HIV AIDS. 2015;10(2):116-122. 
doi:10.1097/COH.0000000000000134. 
10.  Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz 
79
pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. 
Pharmacogenet Genomics. 2012;22(12):858-867. doi:10.1097/FPC.0b013e32835a450b. 
11.  Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system 
side effects: an Adult AIDS Clinical Trials Group study. Aids. 2004;18(18):2391-2400. doi:00002030-
200412030-00006 [pii]. 
12.  Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M. Influence of CYP2B6 
516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of 
efavirenz in HIV-infected South African children. Eur J Clin Pharmacol. 2012;68(4):339-347. 
doi:10.1007/s00228-011-1148-7. 
13.  Ngaimisi E, Habtewold A, Minzi O, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for 
efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in 
two sub-Saharan Africa populations. Emery S, ed. PLoS One. 2013;8(7):e67946. 
doi:10.1371/journal.pone.0067946. 
14.  Jamshidi Y, Moreton M, McKeown DA, et al. Tribal ethnicity and CYP2B6 genetics in Ugandan and 
Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J Antimicrob 
Chemother. 2010;65(12):2614-2619. doi:10.1093/jac/dkq369. 
15.  Kwara A, Lartey M, Sagoe KWCK, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic 
polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS. 
2009;23(16):2101-2106. doi:10.1097/QAD.0b013e3283319908.CYP2B6. 
16.  Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C. High predictive value of CYP2B6 SNPs 
for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet 
Genomics. 2013;23(8):415-427. doi:10.1097/FPC.0b013e328363176f. 
17.  Gounden V, van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516G> T 
polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in 
South African HIV-infected patients. AIDS Res Ther. 2010;7:32. doi:10.1186/1742-6405-7-32. 
18.  Sinxadi PZ, Leger PD, McIlleron HM, et al. Pharmacogenetics of plasma efavirenz exposure in HIV-
infected adults and children in South Africa. Br J Clin Pharmacol. 2015;80(1):146-156. 
doi:10.1111/bcp.12590. 
80
19.  Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB. PharmGKB summary: very important 
pharmacogene information for CYP2B6. Pharmacogenet Genomics. 2010;20(8):520-523. 
http://www.ncbi.nlm.nih.gov/pubmed/20648701. 
20.  di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals 
with impaired CYP2A6 function. Pharmacogenet Genomics. 2009;19(4):300-309. 
doi:10.1097/FPC.0b013e328328d577. 
21.  Variava E, Sigauke FR, Norman J, et al. Brief Report: Late Efavirenz-Induced Ataxia and 
Encephalopathy: A Case Series. J Acquir Immune Defic Syndr. 2017;75(5):577-579. 
doi:10.1097/QAI.0000000000001451. 
22.  Winston A, Amin J, Clarke A, et al. Cerebrospinal fluid exposure of efavirenz and its major 
metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. Clin Infect 
Dis. 2015;60(7):1026-1032. doi:10.1093/cid/ciu976. 
23.  Tovar-y-Romo LB, Bumpus NN, Pomerantz D, et al. Dendritic spine injury induced by the 8-hydroxy 
metabolite of efavirenz. J Pharmacol Exp Ther. 2012;343(3):696-703. doi:10.1124/jpet.112.195701. 
24.  Brandmann M, Nehls U, Dringen R. 8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral 
drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes. Neurochem Res. 
2013;38(12):2524-2534. doi:10.1007/s11064-013-1165-2. 
25.  Nightingale S, Chau TTH, Fisher M, et al. Efavirenz and Metabolites in Cerebrospinal Fluid: 
Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to 
Tuberculous Meningitis. Antimicrob Agents Chemother. 2016;60(8):4511-4518. 
doi:10.1128/AAC.00280-16. 
26.  Aouri M, Barcelo C, Ternon B, et al. In vivo profiling and distribution of known and novel phase i and 
phase II metabolites of efavirenz in plasma, urine, and cerebrospinal fluid. Drug Metab Dispos. 
2016;44(1):151-161. doi:10.1124/dmd.115.065839. 
27.  Suhy AM, Webb A, Papp AC, Geier EG, Sadee W. Expression and splicing of ABC and SLC 
transporters in the human blood-brain barrier measured with RNAseq. Eur J Pharm Sci. 
2017;103:47-51. doi:10.1016/j.ejps.2017.02.010. 
28.  Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary 
81
of current knowledge and recommendations for further research. Antiviral Res. 2009;82(2):A99-109. 
doi:10.1016/j.antiviral.2008.12.013. 
29.  Alfirevic A, Durocher J, Elati A, et al. Misoprostol-induced fever and genetic polymorphisms in drug 
transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. 
Pharmacogenomics. 2015;16(9):919-928. doi:10.2217/pgs.15.53. 
30.  Stieger B, Gao B. Drug transporters in the central nervous system. Clin Pharmacokinet. 
2015;54(3):225-242. doi:10.1007/s40262-015-0241-y. 
31.  Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol 
Ther. 2009;123(1):80-104. doi:10.1016/j.pharmthera.2009.03.017. 
32.  Störmer E, von Moltke LL, Perloff MD, Greenblatt DJ. Differential modulation of P-glycoprotein 
expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. 
Pharm Res. 2002;19(7):1038-1045. http://www.ncbi.nlm.nih.gov/pubmed/12180537. 
33.  Swart M, Ren Y, Smith P, Dandara C. ABCB1 4036A>G and 1236C>T Polymorphisms Affect 
Plasma Efavirenz Levels in South African HIV/AIDS Patients. Front Genet. 2012;3(NOV):1-10. 
doi:10.3389/fgene.2012.00236. 
34.  Sánchez Martín A, Cabrera Figueroa S, Cruz Guerrero R, Hurtado LP, Hurlé AD-G, Carracedo 
Álvarez A. Impact of pharmacogenetics on CNS side effects related to efavirenz. 
Pharmacogenomics. 2013;14(10):1167-1178. doi:10.2217/pgs.13.111. 
35.  Sánchez-Martín A, Cabrera Figueroa S, Cruz R, et al. Gene-gene interactions between DRD3, 
MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of 
efavirenz in HIV infected patients. Drug Metab Pharmacokinet. 2016;31(5):349-355. 
doi:10.1016/j.dmpk.2016.06.001. 
36.  Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by 
the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003;63(5):1094-1103. 
http://www.ncbi.nlm.nih.gov/pubmed/12695538. 
37.  Reznicek J, Ceckova M, Cerveny L, Müller F, Staud F. Emtricitabine is a substrate of MATE1 but not 
of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017;47(1):77-85. 
doi:10.3109/00498254.2016.1158886. 
82
38.  Neumanova Z, Cerveny L, Ceckova M, Staud F. Interactions of tenofovir and tenofovir disoproxil 
fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the 
placenta. AIDS. 2014;28(1):9-17. doi:10.1097/QAD.0000000000000112. 
39.  Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of 
multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral 
drugs adefovir and tenofovir. Mol Pharmacol. 2007;71(2):619-627. doi:10.1124/mol.106.028233. 
40.  Best BM, Letendre SL, Koopmans P, et al. Low cerebrospinal fluid concentrations of the nucleotide 
HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012;59(4):376-381. 
doi:10.1097/QAI.0b013e318247ec54. 
41.  Baxi SM, Greenblatt RM, Bacchetti P, et al. Evaluating the association of single-nucleotide 
polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV. 
Pharmacogenomics J. May 2017. doi:10.1038/tpj.2017.3. 
42.  Kis O, Robillard K, Chan GNY, Bendayan R. The complexities of antiretroviral drug-drug interactions: 
role of ABC and SLC transporters. Trends Pharmacol Sci. 2010;31(1):22-35. 
doi:10.1016/j.tips.2009.10.001. 
43.  Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, 
modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet. 
2008;9:403-433. doi:10.1146/annurev.genom.9.081307.164258. 
44.  World Health Organisation. Antiretroviral therapy coverage data and estimates by country. Global 
Health Observatory data repository. http://apps.who.int/gho/data/node.main.626?lang=en. Published 
2017. Accessed April 23, 2018. 
45.  Decloedt EH, Freeman C, Howells F, et al. Moderate to severe HIV-associated neurocognitive 
impairment: A randomized placebo-controlled trial of lithium. Medicine (Baltimore). 
2016;95(46):e5401. doi:10.1097/MD.0000000000005401. 
46.  Haas DW, Kwara A, Richardson DM, et al. Secondary metabolism pathway polymorphisms and 
plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J 
Antimicrob Chemother. 2014;69(8):2175-2182. doi:10.1093/jac/dku110. 
47.  Carey CL, Woods SP, Gonzalez R, et al. Predictive Validity of Global Deficit Scores in Detecting 
83
Neuropsychological Impairment in HIV Infection. J Clin Exp Neuropsychol. 2004;26(3):307-319. 
doi:10.1080/13803390490510031. 
48.  Myer L, Smit J, Roux L Le, Parker S, Stein DJ, Seedat S. Common mental disorders among HIV-
infected individuals in South Africa: prevalence, predictors, and validation of brief psychiatric rating 
scales. AIDS Patient Care STDS. 2008;22(2):147-158. doi:10.1089/apc.2007.0102. 
49.  Mishra M, Vetrivel S, Siddappa NB, Ranga U, Seth P. Clade-specific differences in neurotoxicity of 
human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 
motif. Ann Neurol. 2008;63(3):366-376. doi:10.1002/ana.21292. 
50.  Paul RH, Joska JA, Woods C, et al. Impact of the HIV Tat C30C31S dicysteine substitution on 
neuropsychological function in patients with clade C disease. J Neurovirol. 2014;20(6):627-635. 
doi:10.1007/s13365-014-0293-z. 
51.  Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid. II. Reference values 
derived from healthy individuals 18-88 years of age. Eur Neurol. 1993;33(2):129-133. 
http://www.ncbi.nlm.nih.gov/pubmed/8467819. 
52.  Avery LB, Sacktor N, McArthur JC, Hendrix CW. Protein-free efavirenz concentrations in 
cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict 
protein-free drug concentration. Antimicrob Agents Chemother. 2013;57(3):1409-1414. 
doi:10.1128/AAC.02329-12. 
53.  Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and 
pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595-612. doi:10.2165/00003088-200443090-
00003. 
54.  Yilmaz A, Price RW, Gisslén M. Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob 
Chemother. 2012;67(2):299-311. doi:10.1093/jac/dkr492. 
55.  Best BM, Koopmans PP, Letendre SL, et al. Efavirenz concentrations in CSF exceed IC50 for wild-
type HIV. J Antimicrob Chemother. 2011;66(2):354-357. doi:10.1093/jac/dkq434. 
56.  Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN. Compartmentalization and antiviral effect of 
efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid. Drug Metab Dispos. 
2013;41(2):422-429. doi:10.1124/dmd.112.049601. 
84
57.  Yilmaz A, Watson V, Dickinson L, Back D. Efavirenz pharmacokinetics in cerebrospinal fluid and 
plasma over a 24-hour dosing interval. Antimicrob Agents Chemother. 2012;56(9):4583-4585. 
doi:10.1128/AAC.06311-11. 
58.  Best BM, Letendre SL, Koopmans P, et al. Low CSF Concentrations of the Nucleotide HIV Reverse 
Transcriptase Inhibitor, Tenofovir. J Acquir Immune Defic Syndr. 2013;59(4):376-381. 
doi:10.1097/QAI.0b013e318247ec54.LOW. 
59.  Apostolova N, Blas-Garcia A, Galindo MJ, Esplugues J V. Efavirenz: What is known about the 
cellular mechanisms responsible for its adverse effects. Eur J Pharmacol. 2017;812(April):163-173. 
doi:10.1016/j.ejphar.2017.07.016. 
60.  Kenyon C, Mfolozi S, Croxford R, Colebunders R, Cohen K. Severe efavirenz-induced vacuolar 
axonopathy complicated by fatal aspiration pneumonia. Br J Clin Pharmacol. 2012;74(6):1070-1072. 
doi:10.1111/j.1365-2125.2012.04299.x. 
61.  Dara J, Dow A, Cromwell E, et al. Multivariable analysis to determine if HIV-1 Tat dicysteine motif is 
associated with neurodevelopmental delay in HIV-infected children in Malawi. Behav Brain Funct. 
2015;11:38. doi:10.1186/s12993-015-0083-7. 
62.  Van de Wijer L, Schellekens AFA, Burger DM, Homberg JR, de Mast Q, van der Ven AJAM. 




Table 1. Baseline characteristics of study participants (n=47) 
Characteristic 
Gender  
  Male, n (%)  




Age in years† 36 (32 – 43) 
CD4+ T-cell count† (cells/mm3) 470 (384 – 586)  
Months on ART† (months) 38 (18 – 54)  
Body mass index‡ (kg/m2) 26.3 ± 5.3  
ART regimen 
  EFV-TFV-FTC, n (%) 





  GDS overall†  
  GDS ≥ 1, n (%) 
  GDS > 0.5 < 1, n (%) 
  GDS < 0.5, n (%) 
 





  No disease, n (%) 
  Mild-moderate disease, n (%) 






  ≥ 10, n (%) 
  < 10, n (%) 






  Employed§, n (%) 





  CES-D† 
 
7 (2 – 11) 
†Median and interquartile range; ‡Mean and standard deviation §Full-time or part-time work; EFV-
TFV-FTC = efavirenz-tenofovir-emtricitabine; EFV-TFV-3TC = efavirenz-tenofovir-lamivudine; GDS = 
Global Deficit Score; CES-D = Center for Epidemiologic Studies Depression scale 
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Table 2. Concentrations of efavirenz and its metabolites, tenofovir and emtricitabine in plasma and cerebrospinal fluid. 
Plasma (ng/ml):  
Total concentration 
Plasma (ng/ml):  
Protein corrected 
CSF concentration (ng/ml) CSF/plasma ratio:  
Total concentration (%) 
CSF/plasma ratio: 
Protein corrected (%) 
Efavirenz pharmacokinetics (n=47) 









(1390 – 3200) 
4.31 
(3.06 - 7.04) 
17.25 
(10.7 – 19.9) 
0.71 
(0.61 - 0.78) 
324.34 
(278.29 – 356.44) 
Range 55 – 18100 0.12 - 39.82 1.73 – 119 0.31 - 1.12 142.82 – 508.66 
Geometric mean concentration 
(95% CI) 
2081.5  
(1557.8 – 2781.4) 
4.58 
(3.43 – 6.12) 
15.64 
(12.08 – 20.24) 
0.69 
(0.64 – 0.75) 
315.54 
(291.90 – 341.10) 
8-Hydroxy-efavirenz pharmacokinetics (n=47)








(1325.5 – 2498.7) 
4.17 
(3.80 – 5.79) 
0.20 
(0.14 – 0.24) 
Range 68.81 – 4887.5 (3.15 – 9.56) 0.10 – 0.72 
Geometric mean concentration 
(95% CI) 
1570.7 
(1255 – 1965.9) 
4.69 
(3.93 – 5.60) 
0.21 
(0.16 – 0.26) 
7-Hydroxy-efavirenz pharmacokinetics (n=47)




(122.91 – 375.43) 
Range 11.45 – 2181.73 
Geometric mean concentration 
(95% CI) 
229.17 
(166.51 – 315.41) 
Tenofovir pharmacokinetics (n=47) 














(50.75 - 81.2) 
0.63 
(0.51 – 0.81) 
1.4 
(1.07 - 2.05)  
2.32 
(1.76 – 2.98)  
232.42 
(175.99 – 298.40) 
Range   23 – 246  0.23 – 2.46 0.51 - 5.33  1.17 - 4.65  117.39 – 465.22 
Geometric mean concentration  
(95% CI) 
62.57 
(53.91 – 72.63) 
0.63 
(0.54 - 0.73) 
1.49 
(1.28 – 1.73) 
2.34 
(2.09 – 2.61) 
233.56 
(208.97 – 261.05 
Emtricitabine pharmacokinetics (n=43) 











(IQR)   
139 
(109 – 166) 
5.56 
(4.36 – 6.64) 
63.5 
(47.4 – 102) 
53.45 
(39.23 - 67.55) 
1336.21 
(980.77 – 1688.74) 
Range   39.3 – 560 1.57 – 22.4 1.45 – 167  20.75 - 200.72 518.67 – 5017.9 
Geometric mean concentration  
(95% CI) 
133.68 
(112.14 – 159.35) 
5.35 
(4.49 – 6.37) 
55.95 
(41.74 – 74.99) 
52.78 
(46.01 – 60.54) 
1319.46 
(1150.37 – 1513.41) 
CSF = cerebrospinal fluid; IQR = interquartile range; 95% CI = 95% confidence interval 
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Univariate analysis 516G→T adjusted 516G→T & 983T→C adjusted 516G→T & 983T→C &  
CYP2B6 15582C→T adjusted 
β(95%CI)  P-value β(95%CI)  P-value β(95%CI) P-value β(95%CI) P-value 
13 ABCC4 rs9584273 (T) 0.07 0.14 (0.05 to 0.22) 2.3 x 10-03 0.14 (0.06 to 0.22) 2.2 x 10-03 0.14 (0.05 to 0.22) 2.8 x 10-03 0.14 (0.06 to 0.22) 2.5 x 10-03 
13 ABCC4 rs9590160 (A) 0.09 -0.12 (-0.19 to -0.04) 2.9 x 10-03 -0.12 (-0.19 to -0.04) 3.2 x 10-03 -0.12 (-0.19 to -0.04) 3.5 x 10-03 -0.12 (-0.19 to -0.04) 4.3 x 10-03 
13 ABCC4 rs74107818 (G) 0.10 -0.11 (-0.18 to -0.04) 3.0 x10-03 -0.11 (-0.18 to -0.04) 3.2 x10-03 -0.11 (-0.19 to -0.04) 3.3 x10-03 -0.11 (-0.18 to -0.04) 4.0 x10-03 
13 ABCC4 rs74107809 (A) 0.07 -0.13 (-0.21 to -0.04) 5.3 x10-03 -0.13 (-0.21 to -0.04) 5.8 x10-03 -0.13 (-0.21 to -0.04) 4.8 x10-03 -0.13 (-0.21 to -0.04) 5.7 x10-03 
19 CYP2B6 rs8100458 (C) 0.19 0.07 (0.02 to 0.12) 6.8 x10-03 0.07 (0.02 to 0.12) 6.8 x10-03 0.08 (0.03 to 0.14) 6.4 x10-03 0.10 (0.03 to 0.16) 5.4 x10-03 
3 ABCC5 rs7610724 (G) 0.07 0.10 (0.03 to 0.17) 7.6 x10-03 0.10 (0.03 to 0.18) 7.7 x10-03 0.10 (0.03 to 0.17) 7.6 x10-03 0.11 (0.03 to 0.18) 9.8 x10-03 
7 ABCB1 rs2235023 (T) 0.42 -0.06 (-0.10 to -0.02) 8.1 x10-03 -0.06 (-0.11 to -0.02) 7.8 x10-03 -0.06 (-0.11 to -0.02) 7.6 x10-03 -0.06 (-0.11 to -0.02) 9.2 x10-03 
19 CYP2G1P rs142357867 (T) 0.03 -0.16 (-0.28 to -0.04) 8.1 x10-03 -0.16 (-0.28 to -0.05) 8.9 x10-03 -0.17 (-0.29 to -0.06) 5.5 x10-03 -0.18 (-0.30 to -0.06) 5.1 x10-03 
13 ABCC4 rs200689258 (AC) 0.09 0.11 (0.03 to 0.18) 8.2 x10-03 0.11 (0.03 to 0.19) 8.0 x10-03 0.11 (0.03 to 0.18) 1.1 x10-02 0.11 (0.03 to 0.19) 1.2 x10-02 
3 ABCC5 rs7427051(A) 0.24 -0.07 (-0.11 to -0.02) 8.6 x10-03 -0.07 (-0.11 to -0.02) 8.6 x10-03 -0.07 (-0.12 to -0.02) 1.1 x10-02 -0.07 (-0.12 to -0.02) 1.2 x10-02 
13 ABCC4 rs73548889 (C) 0.06 0.13 (0.05 to 0.22) 9.5 x10-03 0.13 (0.04 to 0.22) 9.9 x10-03 0.13 (0.03 to 0.22) 1.1 x10-02 0.14 (0.05 to 0.24) 6.9 x10-03 
13 ABCC4 rs9524925 (G) 0.17 -0.07 (-0.12 to -0.02) 1.0 x10-02 -0.07 (-0.12 to -0.02) 7.6 x10-03 -0.07 (-0.13 to -0.02) 1.1 x10-02 -0.07 (-0.12 to -0.02) 1.0 x10-02 
19 CYP2B6 Composite CYP2B6 516/983 
(C) 
0.41 -0.02 (-0.06 to 0.03) 0.47 NA NA NA NA NA NA 
19 CYP2B6 CYP2B6 516G→T§ 0.29 -0.01 (-0.07 to 0.04) 0.62 NA NA NA NA NA NA 
19 CYP2B6 CYP2B6 983T→C* 0.13 0.02 (-0.10 to 0.06) 0.62 -0.03 (-0.10 to 0.06) 0.60 NA NA NA NA 
19 CYP2B6 CYP2B6 15582C→T* 0.10 -0.02 (-0.10 to 0.07) 0.72 -0.03 (-0.10 to 0.07) 0.68 -0.03 (-0.12 to 0.07) 0.57 NA NA 
19 CYP2A6 CYP2A6 -48A→C* 0.09 -0.00 (-0.09 to 0.09) 0.96 -0.00 (-0.09 to 0.09) 0.97 0.01 (-0.09 to 0.12) 0.78 0.01 (-0.09 to 0.12) 0.80 
†The targeted SNPs (CYP2B6 516G→T, CYP2A6 -48A→C, CYP2B6 983T→C, CYP2B6 15582C→T, SLCO1B1 521T→ C and SLCO1B1) included 47 patients and the rest 43 patients; CSF = cerebrospinal fluid; EFV 
= efavirenz; MAF = minor alele frequency  *SNP of interest but did not meet criteria of p-value<0.01; Bonferroni corrected P-value 5.68 x10-05; §P-value <0.05 accepted as significant for SNPs with a previously 
described association; NA= Not applicable 
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Table 4. Genetic associations with detectable log10-transformed CSF-to-plasma 8-OH-EFV concentrations in 16 South African adults. 
Chromo
-some 
Gene Polymorphism (minor allele) MAF 
Univariate analysis 516G→T adjusted 516G→T & 983T→C adjusted 516G→T & 983T→C &  
CYP2B6 15582C→T adjusted 
β(95%CI)  P-value β(95%CI)  P-value β(95%CI) P-value β(95%CI) P-value 
3 ABCC5 rs6762938 (T) 0.31 0.23 (0.14 to 0.32) 2.6 x 10-04 0.23 (0.14 to 0.33) 3.9 x 10-04 0.22 (0.12 to 0.32) 1.1 x 10-03 0.22 (0.11 to 0.33) 2.1 x 10-02 
13 ABCC4 rs11343244 (T) 0.10 0.41 (0.24 to 0.58) 3.8 x 10-04 0.41 (0.23 to 0.59) 6.2 x 10-04 0.39 (0.20 to 0.49) 1.1 x 10-03 0.41 (0.23 to 0.59) 8.5 x 10-04 
13 ABCC4 rs7997839 (G) 0.14 0.41 (0.24 to 0.58) 3.8 x 10-04 0.41 (0.23 to 0.59) 6.2 x 10-04 0.39 (0.20 to 0.49) 1.1 x 10-03 0.41 (0.23 to 0.59) 8.5 x 10-04 
3 ABCC5 rs10937161 (T) 0.20 0.34 (0.19 to 0.49) 4.7 x 10-04 0.36 (0.21 to 0.51) 4.1 x 10-04 0.36 (0.22 to 0.49) 2.3 x 10-04 0.35 (0.21 to 0.50) 5.0 x 10-04 
3 ABCC5 rs36092077 (A) 0.16 0.34 (0.17 to 0.51) 1.8 x 10-03 0.39 (0.21 to 0.56) 8.9 x 10-04 0.39 (0.23 to 0.54) 3.7 x 10-04 0.39 (0.21 to 0.56) 7.1 x 10-04 
3 ABCC5 rs6807271 (A) 0.31 0.21 (0.10 to 0.31) 1.8 x 10-03 0.21 (0.10 to 0.32) 2.6 x 10-03 0.21 (0.10 to 0.32) 2.6 x 10-03 0.20 (0.08 to 0.31) 5.8 x 10-03 
3 ABCC5 rs59309690 (A) 0.09 0.58 (0.26 to 0.90) 3.2 x 10-03 0.60 (0.27 to 0.93) 3.7 x 10-03 0.58 (0.26 to 0.90) 4.1 x 10-03 0.57 (0.24 to 0.90) 6.5 x 10-03 
4 ABCG2 rs2728108 (A) 0.08 0.58 (0.26 to 0.90) 3.2 x 10-03 0.60 (0.27 to 0.93) 3.7 x 10-03 0.58 (0.26 to 0.90) 4.1 x 10-03 0.57 (0.24 to 0.90) 6.5 x 10-03 
13 ABCC4 rs1678392 (A) 0.19 0.32 (0.14 to 0.50) 3.9 x 10-03 0.32 (0.14 to 0.51) 4.9 x 10-03 0.30 (0.11 to 0.50) 1.1 x 10-02 0.31 (0.11 to 0.51) 1.1 x 10-02 
13 ABCC4 rs116336902 (A) 0.07 0.32 (0.14 to 0.50) 4.1 x 10-03 0.32 (0.13 to 0.51) 5.1 x 10-03 0.30 (0.10 to 0.50) 1.1 x 10-02 0.31 (0.11 to 0.51) 1.1 x 10-02 
13 ABCC4 rs147385814 (C) 0.07 0.32 (0.14 to 0.50) 4.1 x 10-03 0.32 (0.13 to 0.51) 5.1 x 10-03 0.30 (0.10 to 0.50) 1.1 x 10-02 0.31 (0.11 to 0.51) 1.1 x 10-02 
13 ABCC4 rs4771904 (T) 0.27 -0.27 (-0.43 to -0.10) 6.4 x 10-03 -0.27 (-0.44 to -0.10) 7.8 x 10-03 -0.26 (-0.45 to -0.07) 2.2 x 10-02 -0.27 (-0.44 to -0.10) 3.3 x 10-02 
3 ABCC5 rs6794223 (G) 0.14 0.25 (0.10 to 0.41) 6.8 x 10-03 0.27 (0.10 to 0.43) 6.7 x 10-03 0.25 (0.09 to 0.41) 9.0 x 10-03 0.25 (0.08 to 0.42) 1.4 x 10-02 
11 SLCO2B1 rs57141326 (A) 0.08 0.34 (0.13 to 0.55) 7.2 x 10-03 0.34 (0.12 to 0.56) 9.6 x 10-03 0.31 (0.09 to 0.54) 1.8 x 10-02 0.33 (0.11 to 0.56) 1.5 x 10-02 
7 ABCB1 rs28401781 (T) 0.24 0.18 (0.07 to 0.30) 8.7 x 10-03 0.19 (0.07 to 0.32) 9.0 x 10-03 0.19 (0.06 to 0.31) 5.8 x 10-03 0.22 (0.11 to 0.33) 2.4 x 10-03 
3 ABCC5 rs56889675 (T) 0.26 0.21 (0.08 to 0.35) 8.8 x 10-03 0.24 (0.09 to 0.38) 7.6 x 10-03 0.27 (0.14 to 0.39) 1.1 x 10-03 0.26 (0.13 to 0.39) 2.1 x 10-03 
3 ABCC5 rs10470524 (T) 0.22 0.21 (0.08 to 0.35) 8.8 x 10-03 0.24 (0.09 to 0.38) 7.6 x 10-03 0.27 (0.14 to 0.39) 1.1 x 10-03 0.26 (0.13 to 0.39) 2.1 x 10-03 
13 ABBC4 rs4148551 (T) 0.36 -0.23 (-0.38 to -0.08) 8.9 x 10-03 -0.25 (-0.41 to -0.10) 7.4 x 10-03 -0.23 (-0.39 to -0.08) 1.1 x 10-02 -0.23 (-0.40 to -0.07) 1.8 x 10-03 
19 CYP2B6 Composite CYP2B6 516/983 0.41 -0.07 (-0.23 to 0.09) 0.42 NA NA NA NA NA NA 
19 CYP2B6 CYP2B6 516G→T§ 0.29 -0.00 (-0.17 to 0.17) 0.99 NA NA NA NA NA NA 
19 CYP2B6 CYP2B6 983T→C* 0.13 -0.17 (-0.42 to 0.08) 0.19 -0.18 (-0.45 to 0.08) 0.19 NA NA NA NA 
19 CYP2B6 CYP2B6 15582C→T* 0.10 0.02 (-0.22 to 0.25) 0.88 0.02 (-0.24 to 0.28) 0.88 -0.05 (-0.33 to 0.22) 0.70 NA NA 
19 CYP2A6 CYP2A6 -48A→C* 0.09 -0.03 (-0.30 to 0.23) 0.80 -0.04 (-0.32 to 0.25) 0.81 0.10 (-0.23 to 0.43) 0.55 0.09 (-0.26 to 0.52) 0.61 
CSF = cerebrospinal fluid; EFV = efavirenz; 8-OH-EFV = 8-hydroxy-efavirenz; MAF = minor alele frequency  *SNP of interest but did not meet criteria of p-value<0.01; Bonferroni corrected P-value 5.68 x10-05; §P-value 
<0.05 accepted as significant for SNPs with a previously described association; NA= Not applicable 
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Table 5. EFV metaboliser status and detectable EFV, 8-OH-EFV and 7-OH-EFV concentrations in CSF and plasma respectively. 
  Geometric mean concentration (95% CI) 

















9    
(19.1) 
6896.9 
(3984.1 - 11939.4)** 
1860.2  
(1421.3 - 2434.6) 
0.27  
(0.17 – 0.42)** 
810.7**  
(466.3 - 1409.6)** 
0.12  
(0.10 – 0.14) 
45.8  
(25.0 - 83.9)** 
1.8  
(1.4 - 2.4) 
0.04 







(1371.4 - 2572.0) 
1543.8  
(1091.4 - 2183.8) 
0.82  
(0.64 – 1.06) 
185.5 
(108.0 - 318.5) 
0.11  
(0.08 – 0.15) 
12.7  
(9.3 - 17.4) 
2.7  
(2.0 - 3.5) 
0.36  







(778.9 - 2017.2) 
1467.1 
(907.9 - 2370.6) 
1.17  
(1.03 – 1.33)  
89.6  
(45.4 – 176.7) 
0.07  
(0.05 – 0.11) 
9.0 
(5.0 - 15.9) 
2.2  
(1.6 - 3.0) 
 0.28  
(0.14 – 0.56) 
P value†  <0.01 NS <0.01 <0.01 NS <0.01 NS NS 




Figure 1. Pearson correlation plots for log10-transformed plasma and cerebrospinal 
fluid (CSF) concentrations for efavirenz and metabolites, emtricitabine and tenofovir 
in panels A-H.  The relationship between (A) log10 transformed plasma efavirenz 
concentrations and plasma 8-hydroxy-efavirenz concentrations (B) log10 transformed plasma 
efavirenz concentrations and plasma 7-hydroxy-efavirenz concentrations (C) log10 
transformed plasma efavirenz concentrations and log10 transformed cerebrospinal fluid 
(CSF) efavirenz concentrations (D) log10 transformed plasma emtricitabine and CSF 
emtricitabine (E) log10 transformed plasma tenofovir and CSF tenofovir (F) log10 transformed 
plasma efavirenz concentrations and detectable CSF 8-hydroxy-efavirenz concentrations (G) 
log10 transformed plasma 8-hydroxy-efavirenz and CSF 8-hydroxy-efavirenz (H) log10 





















Figure 2. Cerebrospinal fluid (CSF)-to-plasma concentration ratios of detectable pairs 
of plasma and CSF samples versus time after dosing. The lines are linear regression 
lines and were not statistically significant for any ratio, including 8-OH-EFV (p=0.09). EFV = 




Figure 3. Relationships between efavirenz CYP2B6 metabolizer status and log10-
transformed efavirenz and metabolites concentrations in plasma or cerebrospinal 
fluid (A) Relationship between CYP2B6/CYP2A6 polymorphisms and log10 transformed 
plasma efavirenz concentrations, (B) CYP2B6/CYP2A6 polymorphisms and cerebrospinal 
fluid efavirenz concentrations (C) CYP2B6/CYP2A6 polymorphisms and plasma 8-hydroxy-
efavirenz concentrations (D) CYP2B6/CYP2A6 polymorphisms and cerebrospinal fluid 8-
hydroxy-efavirenz and (E) CYP2B6/CYP2A6 polymorphisms and plasma 7-hydroxy-
efavirenz concentrations. The x-axes show CYP2B6/CYP2A6 haplotypes, number of 
participants with each haplotype and efavirenz metabolizer status (extensive, intermediate or 








Supplementary material: tables 
 
Table S1. Genetic associations with detectable log10-transformed plasma efavirenz, 8-hydroxy-efavirenz and 7-hydroxy-efavirenz concentrations in South African adults.† 
Plasma efavirenz  Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Gene Polymorphism β(95%CI)  P-value β(95%CI) P-value β(95%CI) P-value 
CYP2B6  Composite CYP2B6 516/983 0.34 (0.20 to 0.48) 1.7 x10-05 NA  NA  
CYP2B6 rs60618302 -0.43 (-0.62 to -0.25) 5.3 x10-05 -0.36 (-0.61 to -0.12) 5.6 x10-03 -0.26 (-0.51 to -0.03) 3.6 x10-02 
ABCB1 rs115780656 -0.45 (-0.70 to -0.20) 1.1 x10-03 -0.42 (-0.61 to -0.12) 5.8 x10-04 -0.37 (-0.58 to -0.17) 9.7 x10-04 
CYP2B6 rs73557157 -0.38 (-0.60 to -0.16) 1.6 x10-03 -0.24 (-0.52 to 0.04) 9.7 x10-02 -0.12 (-0.40 to 0.15) 0.38 
CYP2B6 CYP2B6 516G→T§ 0.30 (0.12 to 0.49) 2.0 x10-03 NA  NA  
CYP2B6 rs59243457 0.31 (0.12 to 0.49) 2.7 x10-03 0.13 (-0.34 to 0.61) 0.59 0.25 (-0.18 to 0.69) 0.26 
ABCC4 rs72643607 -0.60 (-0.98 to -0.22) 3.3 x10-03 -0.49 (-0.85 to -0.13) 1.1 x10-02 -0.46 (-0.78 to -0.14) 7.4 x10-03 
CYP2B6 rs56164728 -0.53 (-0.88 to -0.17) 5.7 x10-03 -0.40 (-0.74 to -0.06) 2.8 x10-02 -0.36 (-0.67 to -0.05) 3.0 x10-02 
ABCC5 rs56889675 -0.27 (-0.46 to -0.08) 7.3 x10-03 -0.20 (-0.38 to -0.02) 3.5 x10-02 -0.17 (-0.34 to -0.01) 5.0 x10-02 
CYP2B6 CYP2B6 983T→C§ 0.35 (0.08 to 0.62) 1.4 x10-02 0.38 (0.14 to 0.61) 2.7 x10-03 NA  
CYP2B6 CYP2B6 15582C→T* -0.23 (-0.54 to 0.08) 0.15 -0.14 (-0.43 to 0.15) 0.35 -0.00 (-0.29 to 0.28)  0.98 
CYP2A6 CYP2A6 -48A→C* 0.02 (-0.31 to 0.35) 0.91 -0.00 (-0.29 to -0.29) 1.00 -0.31 (-0.62 to -0.00) 0.05 
Plasma 8-hydroxy-efavirenz Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Gene Polymorphism β(95%CI)  P-value β(95%CI) P-value β(95%CI) P-value 
ABCB1 rs115780656 -0.36 (-0.55 to -0.18) 4.3 x10-04 -0.36 (-0.55 to -0.17) 5.2 x10-04 -0.35 (-0.55 to -0.16) 8.8 x10-04 
ABCG2 rs45621036 -0.30 (-0.46 to -0.14) 5.9 x10-04 -0.30 (-0.46 to -0.14) 6.3 x10-04 -0.30 (-0.46 to -0.13) 9.7 x10-04 
ABCG2 rs2231159 -0.28 (-0.44 to -0.13) 8.0 x10-04 -0.29 (-0.44 to -0.13) 8.9 x10-04 -0.28 (-0.44 to -0.13) 9.2 x10-04 
CYP2G1P rs142357867 -0.64 (-0.99 to -0.29) 9.1 x10-04 -0.64 (-1.00 to -0.29) 1.0 x10-03 -0.63 (-0.99 to -0.26) 1.6 x10-03 
ABCB1 rs57924923 -0.22 (-0.36 to -0.08) 2.4 x10-03 -0.23 (-0.36 to -0.09) 2.3 x10-03 -0.23 (-0.36 to -0.09) 2.5 x10-03 
ABCB1 rs2235023 -0.21 (-0.35 to -0.08) 3.5 x10-03 -0.22 (-0.36 to -0.09) 3.0 x10-03 -0.22 (-0.36 to -0.08) 3.1 x10-03 
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ABCG2 rs2622614 -0.22 (-0.36 to -0.08) 3.5 x10-03 -0.22 (-0.36 to -0.08) 3.5 x10-03 -0.23 (-0.37 to -0.09) 2.6 x10-03 
CYP2A6 rs16974537 -0.49 (-0.81 to -0.17) 4.6 x10-03 -0.50 (-0.82 to -0.17) 4.6 x10-03 -0.50 (-0.82 to -0.18) 4.2 x10-03 
ABCC4 rs72643607 -0.44 (-0.73 to -0.15) 4.6 x10-03 -0.46 (-0.76 to -0.16) 4.7 x10-03 -0.45 (-0.75 to -0.15) 5.4 x10-03 
CYP2A6 rs56164728 -0.38 (-0.65 to -0.11) 9.0 x10-03 -0.40 (-0.69 to -0.12) 8.6 x10-03 -0.39 (-0.68 to -0.10) 1.1 x10-02 
ABCC4 rs73557775 -0.27 (-0.47 to -0.08) 9.2 x10-03 -0.27 (-0.47 to -0.07) 1.0 x10-02 -0.28 (-0.48 to -0.08) 8.9 x10-02 
CYP2A7 rs149560129 -0.45 (-0.78 to -0.13) 9.2 x10-03 -0.46 (-0.79 to -0.13) 9.2 x10-03 -0.44 (-0.78 to -0.10) 1.4 x10-02 
CYP2B6 Composite CYP2B6 516/983* 0.05 (-0.08 to 0.18) 0.49 NA  NA  
CYP2B6 CYP2B6 516G→T* 0.03 (-0.13 to 0.19) 0.69 NA  NA  
CYP2B6 CYP2B6 983T→C* 0.07 (-0.15 to 0.29) 0.54 0.07 (-0.15 to -0.29) 0.53 NA  
CYP2B6 CYP2B6 15582C→T* -0.06 (-0.31 to 0.19) 0.64 -0.05 (-0.30 to -0.20) 0.70 -0.03 (-0.30 to 0.24) 0.85 
CYP2A6 CYP2A6 -48A→C* -0.15(-0.40 to 0.10) 0.26 -0.15 (-0.40 to 0.11) 0.26 -0.26 (-0.56 to -0.03) 0.09 
Plasma 7-hydroxy-efavirenz Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Gene Polymorphism β(95%CI)  P-value β(95%CI) P-value β(95%CI) P-value 
CYP2B6 Composite CYP2B6 516/983 0.45 (0.10 to 0.66) 5.9 x10-05 NA NA NA NA 
CYP2A6 rs56164728 -1.02 (-1.47 to -0.57) 6.4 x10-05 -0.89 (-1.33 to -0.44) 3.7 x10-04 -0.83 (-1.23 to -0.43) 2.4 x10-04 
ABCB1 rs115780656 -0.75 (-1.08 to -0.42) 6.8 x10-05 -0.71 (-1.01 to -0.42) 2.9 x10-05 -0.65 (-0.92 to -0.37) 4.1 x10-05 
CYP2B6 rs60618302 -0.56 (-0.84 to -0.28) 2.9 x10-04 -0.46 (-0.82 to -0.11) 1.5 x10-02 -0.33 (-0.68 to -0.03) 0.08 
CYP2B6 rs2279345 -0.54 (-0.82 to -0.27) 3.7 x10-04 -0.44 (-0.73 to -0.14) 6.0 x10-03 -0.35 (-0.63 to -0.06) 2.2 x10-02 
CYP2A6 rs10853742 -0.52 (-0.81 to -0.23) 1.2 x10-03 -0.45 (-0.72 to -0.17) 3.0 x10-03 -0.55 (-0.78 to -0.32) 3.5 x10-05 
CYP2A6 rs7248240 -0.67 (-1.07 to -0.27) 2.2 x10-03 -0.55 (-0.94 to -0.16) 9.0 x10-03 -0.51 (-0.87 to -0.16) 7.3 x10-03 
CYP2A6 rs7251418 -0.69 (-1.10 to -0.27) 2.5 x10-03 -0.58 (-0.98 to -0.18) 712 x10-03 -0.56 (-0.92 to -0.20) 3.9 x10-03 
ABCC4 rs72643607 -0.85 (-1.38 to -0.32) 3.3 x10-03 -0.71 (-1.22 to -0.19) 1.1 x10-02 -0.67 (-1.14 to -0.21) 7.4 x10-03 
CYP2B6 rs73557157 -0.50 (-0.81 to -0.19) 3.3 x10-03 -0.33 (-0.74 to 0.07) 0.11 -0.17 (-0.56 to 0.23) 0.41 
ABCB1 rs57924923 -0.38 (-0.64 to -0.13) 5.2 x10-03  -0.43 (-0.65 to -0.21) 4.7 x10-04 -0.42 (-0.62 to -0.23) 1.2 x10-04 
CYP2B6 rs59243457 0.40 (0.13 to 0.67) 5.4 x10-03 0.22 (-0.47 to 0.90) 0.54 0.38 (-0.24 to 1.01) 0.24 
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CYP2B6 CYP2B6 516G→T§ 0.39 (0.14 to 0.70) 5.5 x10-03 NA NA NA NA 
CYP2B6 CYP2B6 983T→C§ 0.50 (0.12 to 0.86) 1.5 x10-02 0.59 (0.22 to 0.96) 3.7 x10-03 NA NA 
CYP2B6 CYP2B6 15582C→T* -0.23 (-0.68 to 0.21) 0.31 -0.11 (-0.53 to -0.31) 0.61 0.09 (-0.35 to 0.53) 0.67 
CYP2A6 CYP2A6 -48A→C* -0.09 (-0.55 to 0.38) 0.71 -0.11 (-0.54 to -0.32) 0.62 -0.59 (-1.01 to -0.16) 1.0 x10-02 
†The targeted SNPs (CYP2B6 516G→T, CYP2A6 -48A→C, CYP2B6 983T→C, CYP2B6 15582C→T, SLCO1B1 521T→ C and SLCO1B1) included 47 patients and the rest 43 patients; *SNP of interest but did not meet 




Table S2. Genetic associations with detectable log10-transformed cerebrospinal fluid (CSF) efavirenz and 8-hydroxy efavirenz concentrations in South African adults.† 
CSF efavirenz Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Gene Polymorphism β(95%CI)  P-value β(95%CI) P-value β(95%CI) P-value 
CYP2B6 Composite CYP2B6 516/983 0.33 (0.17 to 0.48) 1.7 x10-04 NA NA NA NA 
ABCB1 rs115780656 -0.51 (-0.77 to -0.26) 3.4 x10-04 -0.50 (-0.72 to 0.26) 1.8 x10-04 -0.45 (-0.67 to 0.22) 3.3 x10-04 
CYP2B6 rs60618302 -0.40 (-0.61 to -0.19) 5.7 x10-04 -0.31 (-0.58 to -0.04) 3.0 x10-02 -0.22 (-0.49 to 0.06) 0.16 
ABCB1 rs57924923 -0.30 (0.49 to -0.12) 3.4 x10-03 -0.34 (0.50 to -0.18) 2.1 x10-04 -0.33 (0.50 to -0.18) 7.5 x10-05 
CYP2B6 rs59243457 0.31 (0.11 to 0.51) 4.0 x10-03 0.18 (-0.34 to 0.69) 0.50 0.29 (-0.19 to 0.77) 0.24 
ABCC4 rs72643607 -0.61 (-1.05 to -0.20) 5.5 x10-03 -0.49 (-0.88 to -0.10) 1.8 x10-02 -0.47 (-0.83 to -0.11) 1.5 x10-02 
CYP2B6 CYP2B6 516G→T 0.29 (0.09 to 0.49) 6.2 x10-03 NA NA NA NA 
ABCC5 rs56889675 -0.39 (-0.64 to -0.14) 7.3 x10-03 -0.21 (-0.41 to -0.02) 3.3 x10-02 -0.19 (-0.38 to -0.01) 4.8 x10-02 
CYP2B6 rs56164728 -0.55 (-0.92 to -0.16) 7.5 x10-03 -0.42 (-0.78 to -0.05) 3.3 x10-02 -0.38 (-0.73 to -0.03) 4.0 x10-02 
ABCB1 rs2235023 -0.27 (-0.47 to -0.08) 8.1 x10-03 -0.33 (-0.50 to -0.17) 3.2 x10-04 -0.33 (-0.50 to -0.17) 1.1 x10-04 
CYP2B6 CYP2B6 983T→C§ 0.33 (0.04 to 0.61) 3.0 x10-02 0.36 (0.10 to 0.62) 1.0 x10-02 NA NA 
CYP2B6 CYP2B6 15582C→T* -0.24 (-0.58 to 0.09) 0.15 -0.16 (-0.48 to 0.16) 0.33 -0.03 (-0.35 to 0.29) 0.85 
CYP2A6 CYP2A6 -48A→C* 0.02 (-0.33 to 0.37) 0.93 -0.00 (-0.33 to 0.32) 0.99 -0.30 (-0.64 to 0.05) 0.10 
CSF 8-hydroxy-efavirenz (n=16) Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Gene Polymorphism  β(95%CI) P-value β(95%CI)  P-value β(95%CI) P-value 
ABCC5 rs6762938 0.18 (0.11 to 0.24) 7.8 x10-05 0.18 (0.12 to 0.24) 9.8 x10-05 0.16 (0.10 to 0.23) 2.3 x10-04 
ABCC5 rs6807271 0.17 (0.10 to 0.24) 3.4 x10-04 0.17 (0.09 to 0.24) 6.2 x10-04 0.16 (0.10 to 0.22) 2.7 x10-04 
ABCC5 rs6807670 0.14 (0.06 to 0.21) 2.9 x10-03 0.14 (0.07 to 0.22) 2.9 x10-03 0.14 (0.09 to 0.20) 3.2 x10-03 
ABCC4 rs11343244 0.27 (0.12 to 0.41) 3.1 x10-03 0.27 (0.12 to 0.42) 4.2 x10-03 0.24 (0.09 to 0.38) 7.3 x10-03 
ABCC4 rs7997839 0.27 (0.12 to 0.41) 3.1 x10-03 0.27 (0.12 to 0.42) 4.2 x10-03 0.24 (0.09 to 0.38) 7.3 x10-03 
SLCO2B1 rs2851079 -0.14 (-0.23 to -0.05) 6.9 x10-03 -0.14 (-0.23 to -0.05) 9.5 x10-03 -0.12 (-0.23 to -0.01) 0.05 
ABCC4 rs9590177 0.20 (0.07 to 0.32) 8.2 x10-03 0.20 (0.07 to 0.33) 1.0 x10-02 0.17 (0.03 to 0.30) 3.4 x10-02 
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ABCC5 rs6794223 0.18 (0.06 to 0.30) 9.1 x10-03 0.19 (0.07 to 0.31) 7.4 x10-03 0.18 (0.07 to 0.28) 6.7 x10-03 
ABCB1 rs2235067 0.22 (0.08 to 0.36) 9.5 x10-03 0.24 (0.09 to 0.39) 8.8 x10-03 0.24 (0.12 to 0.37) 2.4 x10-03 
ABCB1 rs10274587 0.22 (0.08 to 0.36) 9.5 x10-03 0.24 (0.09 to 0.39) 8.8 x10-03 0.24 (0.12 to 0.37) 2.4 x10-03 
CYP2B6 Composite CYP2B6 516/983 -0.08 (-0.19 to 0.04) 0.20 NA NA NA NA 
CYP2B6 CYP2B6 516G→T§ -0.01 (-0.14 to 0.11) 0.83 NA NA NA NA 
CYP2B6 CYP2B6 983T→C§ -0.17 (-0.34 to 0.00) 0.08 -0.19 (-0.37 to -0.00) 0.07 NA NA 
CYP2B6 CYP2B6 15582C→T* 0.04 (-0.13 to 0.21) 0.64 0.04 (-0.15 to 0.23) 0.68 -0.03 (-0.22 to 0.16) 0.75 
CYP2A6 CYP2A6 -48A→C* -0.03 (-0.22 to 0.16) 0.76 -0.04 (-0.24 to 0.17) 0.71 0.10 (-0.12 to 0.32) 0.40 
CSF 8-hydroxy-efavirenz  Unadjusted analysis    
Gene Polymorphism OR (95%CI)  P-value     
ABCC5 rs35494670 0.13 (0.03 to 0.54) 4.8 x10-03 NA NA NA NA 
ABCC5 rs11404217 0.18 (0.05 to 0.64) 8.1 x10-03 NA NA NA NA 
ABCC4 rs1751046 0.21 (0.06 to 0.68) 9.7 x10-03 NA NA NA NA 
CYP2B6 Composite CYP2B6 516/983 0.98 (0.43 to 2.33) 0.96 NA NA NA NA 
CYP2B6 CYP2B6 516G→T§ 1.35 (0.51 to 3.58) 0.54 NA NA NA NA 
CYP2B6 CYP2B6 983T→C§ 1.48 (0.34 to 6.47) 0.61 NA NA NA NA 
CYP2B6 CYP2B6 15582C→T* 0.04 (-0.13 to 0.21) 0.64 NA NA NA NA 
CYP2A6 CYP2A6 -48A→C* 1.07 (0.80 to 5.17) 0.93 NA NA NA NA 
†The targeted SNPs (CYP2B6 516G→T, CYP2A6 -48A→C, CYP2B6 983T→C, CYP2B6 15582C→T, SLCO1B1 521T→ C and SLCO1B1) included 47 patients and the rest 43 patients; *SNP of interest but did not meet 




Table S3. Genetic associations with detectable log10-transformed plasma 8-OH-EFV/EFV, plasma 7-OH-EFV/EFV and CSF 8-OH-EFV/EFV concentrations in South African adults.† 
Plasma 8-OH-EFV/EFV Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Gene Polymorphism β(95%CI)  P-value β(95%CI) P-value β(95%CI) P-value 
CYP2B6 Composite CYP2B6 516/983 -0.29 (-0.38 to -0.21) 3.7 x10-08 NA NA NA NA 
CYP2B6 CYP2B6 516G→T -0.27 (-0.39 to -0.15) 6.5 x10-05 NA NA NA NA 
CYP2B6 rs73557157 0.31 (0.17 to 0.45) 7.9 x10-05 0.14 (-0.02 to 0.31) 0.09 0.06 (-0.09 to 0.21) 0.43 
CYP2B6 rs60618302 0.28 (0.15 to 0.41) 1.1 x10-04 0.13 (-0.02 to 0.28) 0.10 0.05 (-0.09 to 0.18) 0.51 
ABCC4 rs8001444 -0.27 (-0.39 to -0.14) 1.6 x10-04 -0.18 (-0.29 to -0.07) 2.2 x10-03 -0.12 (-0.23 to -0.01) 3.2 x10-02 
CYP2B6 rs59243457 -0.25 (-0.37 to -0.13) 1.8 x10-04 0.14 (-0.14 to 0.41) 0.33 0.06 (-0.18 to 0.30) 0.61 
PKD2 rs2728108 -0.36 (-0.54 to -0.18) 3.1 x10-04 -0.24 (-0.40 to -0.08) 5.6 x10-03 -0.18 (-0.32 to -0.04) 1.7 x10-02 
SLCO2B1 rs151119066 -0.48 (-0.76 to -0.21) 1.3 x10-03 -0.43 (-0.64 to -0.23) 1.7 x10-04 -0.31 (-0.51 to -0.11) 5.1 x10-03 
ABCC4 rs9524896 -0.23 (-0.37 to -0.10) 1.3 x10-03 -0.15 (-0.27 to -0.04) 1.3 x10-02 -0.10 (-0.20 to 0.01) 0.07 
SLCO2B1 rs114000664 -0.35 (-0.56 to -0.14) 1.9 x10-03 -0.25 (-0.42 to -0.08) 5.6 x10-03 -0.20 (-0.35 to -0.05) 1.2 x10-02 
ABCC4 rs1764417 -0.20 (-0.33 to -0.08) 3.1 x10-03 -0.13 (-0.24 to -0.03) 1.9 x10-02 -0.08 (-0.18 to 0.02) 0.13 
SLCO2B1 rs2712788 -0.21 (-0.34 to -0.08) 3.4 x10-03 -0.14 (-0.25 to -0.03) 1.9 x10-02 -0.08 (-0.18 to 0.02) 0.14 
ABCC4 rs114827818 -0.40 (-0.66 to -0.15) 3.4 x10-03 -0.26 (-0.49 to -0.06) 1.4 x10-02 -0.16 (-0.36 to 0.04) 0.13 
SLCO2B1 rs143837090 -0.40 (-0.66 to -0.15) 3.5 x10-03 -0.27 (-0.48 to -0.06) 1.5 x10-02 -0.16 (-0.36 to 0.04) 0.13 
ABCC4 rs58721524 -0.44 (-0.72 to -0.16) 4.1 x10-03 -0.31 (-0.54 to -0.08) 1.1 x10-02 -0.16 (-0.38 to 0.07) 0.19 
ABCC4 rs6076964 -0.44 (-0.72 to -0.16) 4.1 x10-03 -0.31 (-0.54 to -0.08) 1.1 x10-02 -0.16 (-0.38 to 0.07) 0.19 
CYP2B6 rs10401226 -0.19 (-0.32 to -0.07) 4.7 x10-03 0.31 (0.09 to 0.52) 7.4 x10-03 0.18 (-0.03 to 0.39) 0.10 
CYP2B6 CYP2B6 983T→C -0.28 (-0.46 to -0.09) 5.5 x10-03 -0.31 (-0.45 to -0.16) 1.8 x10-04 NA NA 
EGLN2 rs76268776 -0.38 (-0.64 to -0.13) 5.8 x10-03 -0.31 (-0.51 to -0.11) 3.9 x10-03 -0.26 (-0.43 to -0.09) 5.7 x10-03 
ABCC4 rs150301651 -0.30 (-0.50 to -0.09) 7.1 x10-03 -0.22 (-0.37 to -0.06) 9.4 x10-03 -0.15 (-0.30 to -0.004) 0.05 
ABCG2 rs2725256 -0.19 (-0.32 to -0.05) 8.1 x10-03 -0.12 (-0.23 to -0.01) 3.6 x10-02 -0.08 (-0.18 to 0.02) 0.11 
SLCO2B1 rs2510657 -0.18 (-0.32 to -0.05) 9.6 x10-03 -0.11 (-0.22 to 0.004) 0.06 -0.04 (-0.15 to 0.07) 0.46 
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CYP2B6 CYP2B6 15582C→T*§ 0.17 (-0.05 to 0.39) 0.14 0.04 (-0.14 to 0.23) 0.66 -0.06 (-0.22 to -0.11) 0.49 
CYP2A6 CYP2A6 -48A→C* -0.17 (-0.40 to 0.07) 0.17 -0.15 (-0.34 to 0.05) 0.14 0.04 (-0.15 to 0.25) 0.64 
Plasma 7-OH-EFV/EFV Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Gene Polymorphism β(95%CI)  P-value β(95%CI) P-value β(95%CI) P-value 
CYP2A6 rs56164728 -0.50 (-0.72 to -0.27) 1.1 x10-04 -0.49 (-0.73 to -0.25) 2.7 x10-04 -0.47 (-0.71 to -0.23) 3.6 x10-04 
CYP2B6 rs2279345 -0.28 (-0.42 to -0.15) 1.8 x10-04 -0.29 (-0.44 to -0.14) 4.5 x10-04 -0.28 (-0.43 to -0.12) 1.2 x10-03 
CYP2A6 rs10853742 -0.28 (-0.42 to -0.15) 2.5 x10-04 -0.28 (-0.42 to -0.13) 5.1 x10-04 -0.31 (-0.44 to -0.17) 6.7 x10-05 
ABCB1 rs115780656 -0.30 (-0.48 to -0.12) 2.1 x10-03 -0.29 (-0.47 to -0.11) 2.6 x10-03 -0.27 (-0.45 to -0.10) 4.6 x10-03 
ABCC4 rs2993590 -0.31 (-0.50 to -0.12) 2.7 x10-03 -0.29 (-0.49 to -0.10) 4.7 x10-03 -0.30 (-0.48 to -0.11) 3.7 x10-03 
ABCC4 rs7318327 -0.20 (-0.33 to -0.07) 4.5 x10-03 -0.19 (-0.32 to -0.05) 8.6 x10-03 -0.19 (-0.32 to -0.06) 7.8 x10-03 
CYP2A6 rs11878604 -0.17 (-0.28 to -0.06) 4.6 x10-03 -0.16 (-0.27 to -0.05) 7.8 x10-03 -0.19 (-0.30 to -0.08) 1.6 x10-03 
ABCC4 rs60338761 -0.27 (-0.46 to -0.09) 6.8 x10-03 -0.26 (-0.45 to -0.06) 1.4 x10-02 -0.25 (-0.45 to -0.06) 1.5 x10-02 
CYP2A6 rs7248240 -0.29 (-0.50 to -0.08) 8.8 x10-03 -0.27 (-0.49 to -0.06) 1.7 x10-02 -0.26 (-0.47 to -0.05) 2.0 x10-02 
CYP2B6 Composite CYP2B6 516/983 0.11 (-0.00 to 0.23) 0.06 NA NA NA NA 
CYP2B6 CYP2B6 516G→T*§ 0.09 (-0.06 to 0.23) 0.24 NA NA NA NA 
CYP2B6 CYP2B6 983T→C*§ 0.14 (-0.05 to 0.34) 0.16 0.17 (-0.05 to 0.38) 0.14 NA NA 
CYP2B6 CYP2B6 15582C→T*§ -0.00 (-0.23 to 0.22) 0.99 0.03 (-0.22 to 0.28) 0.83 0.09 (-0.17 to 0.35) 0.50 
CYP2A6 CYP2A6 -48A→C* -0.10 (-0.34 to 0.13) 0.38 -0.15 (-0.34 to 0.05) 0.14 0.04 (-0.15 to 0.25) 0.64 
CSF 8-OH-EFV/EFV (n=16) Unadjusted analysis 516G→T adjusted 516G→T & 983T→C adjusted 
Gene Polymorphism β(95%CI)  P-value β(95%CI) P-value β(95%CI) P-value 
ABCC5 rs6762938 0.36 (0.16 to 0.57) 3.5 x10-03 0.38 (0.09 to 0.20) 1.4 x10-03 0.34 (0.16 to 0.52) 3.3 x10-03 
ABCC5 rs6807271 0.35 (0.15 to 0.56) 4.8 x10-03 0.35 (0.16 to 0.55) 3.9 x10-03 0.33 (0.16 to 0.50) 2.5 x10-03 
EGLN2 rs76268776 -1.02 (-1.62 to -0.41) 5.6 x1003 -0.97 (-1.59 to -0.35) 9.1 x10-03 -0.83 (-1.62 to -0.03) 0.06 
CYP2B6 Composite CYP2B6 516/983 -0.29 (-0.56 to -0.02) 0.06 NA NA NA NA 
CYP2B6 CYP2B6 516G→T*§ -0.15 (-0.47 to 0.16) 0.36 NA NA NA NA 
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CYP2B6 CYP2B6 983T→C*§ -0.40 (-0.86 to 0.06) 0.11 -0.48 (-0.94 to -0.03) 0.05 NA NA 
CYP2B6 CYP2B6 15582C→T*§ 0.09 (-0.41 to 0.60) 0.73 -0.06 (-0.64 to 0.51) 0.83 -0.07 (-0.54 to 0.41) 0.79 
CYP2A6 CYP2A6 -48A→C* 0.14 (-0.35 to 0.64) 0.58 0.09 (-0.43 to 0.61) 0.73 0.54 (0.05 to 1.03) 4.8 x10-02 
†The targeted SNPs (CYP2B6 516G→T, CYP2A6 -48A→C, CYP2B6 983T→C, CYP2B6 15582C→T, SLCO1B1 521T→ C and SLCO1B1) included 47 patients and the rest 43 patients; CSF = cerebrospinal fluid; EFV 
= efavirenz; CSF = cerebrospinal fluid; 08-OH-EFV = 8-hydroxy-efavirenz; 7-OH-EFV = 7-hydroxy-efavirenz; *SNP of interest but did not meet criteria of p-value<0.01; Bonferroni corrected P-value 5.68 x10-05; §P-value 





Table S4. Genetic associations with detectable log10-transformed plasma, CSF and CSF-to-plasma tenofovir concentrations in 43 South African adults. 
Plasma tenofovir Unadjusted analysis 
Gene Polymorphism β(95%CI)  P-value 
ABCG2 rs2231159 -0.32 (-0.48 to -0.17) 2.2 x10-04 
ABCC4 rs7982526 -0.61 (-0.93 to -0.29) 5.3 x10-04 
ABCG2 rs45621036 -0.30 (-0.47 to -0.13) 1.1 x10-03 
SLCO1A2 rs12809856 -0.24 (-0.39 to -0.10) 2.4 x10-03 
ABCC5 rs35494670 -0.25 (-0.40 to -0.09) 3.2 x10-03 
ABCG2 rs28440048 -0.31 (-0.52 to -0.11) 4.4 x10-03 
ABCC5 rs6792482 -0.27 (-0.44 to -0.09) 5.8 x10-03 
SLCO1A2 rs7968842 -0.21 (-0.36 to -0.07) 6.1 x10-03 
ABCC5 rs56889675 -0.21 (-0.36 to -0.07) 7.4 x10-03 
SLCO1A2 rs12296154 -0.19 (-0.33 to -0.06) 7.5 x10-03 
CSF tenofovir Unadjusted analysis 
Gene Polymorphism β(95%CI)  P-value 
ABCC4 rs7982526 -0.58 (-0.85 to -0.30) 1.7 x10-04 
ABCC5 rs35494670 -0.24 (-0.37 to -0.10) 1.4 x10-03 
ABCG2 rs2231159 -0.23 (-0.38 to -0.08) 4.3 x10-03 
ABCB1 rs28401796 -0.25 (-0.41 to -0.08) 5.2 x10-03 
ABCB1 rs28381940 -0.25 (-0.41 to -0.08) 5.2 x10-03 
SLCO1A2 rs4762700 -0.17 (-0.29 to -0.05) 9.6 x10-03 
SLCO1A2 rs140377659 0.23 (0.06 to 0.40) 9.8 x10-03 
CSF-to-plasma tenofovir Unadjusted analysis 
Gene Polymorphism β(95%CI)  P-value 
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ABCB1 rs1989830 -0.12 (-0.19 to -0.05) 1.2 x10-03 
ABCB1 rs78551545 -0.28 (-0.43 to -0.12) 1.3 x10-03 
SLCO1A2 rs11535999 0.13 (0.05 to 0.21) 2.5 x10-03 
ABCG2 rs111917717 -0.28 (-0.46 to -0.11) 3.0 x10-03 
ABCG2 rs76462878 -0.22 (-0.36 to -0.08) 4.0 x10-03 
ABCB1 rs35572298 -0.18 (-0.30 to -0.06) 5.0 x10-03 
SLCO1A2 rs4149008 0.11 (0.03 to 0.18) 6.9 x10-03 
SLCO1A2 rs4149009 0.11 (0.03 to 0.19) 7.8 x10-03 
SLCO1A2 rs10841786 0.11 (0.03 to 0.19) 7.8 x10-03 
SLCO1A2 rs57472326 0.11 (0.03 to 0.19) 7.8 x10-03 
SLCO1A2 rs7968842 0.11 (0.03 to 0.19) 9.2 x10-03 




Table S5. Genetic associations with detectable log10-transformed plasma, CSF and CSF-to emtricitabine concentrations in 39 South African adults. 
Plasma emtricitabine Unadjusted analysis 
Gene Polymorphism β(95%CI)  P-value 
ABCC5 rs56889675 -0.26 (-0.40 to -0.12) 8.0 x10-04 
ABCC5 rs74763842 0.20 (0.07 to 0.33) 4.4 x10-03 
ABCC5 rs10470524 -0.25 (-0.42 to -0.08) 6.2 x10-03 
SLCO1A2 rs12296154 -0.20 (-0.34 to -0.07) 6.4 x10-03 
ABCC4 rs7982526 -0.54 (-0.91 to -0.16) 7.7 x10-03 
SLCO2B1 rs10793116 -0.42(-0.72 to -0.12) 8.8 x10-03 
CSF emtricitabine Unadjusted analysis 
Gene Polymorphism β(95%CI)  P-value 
ABCC5 rs56889675 -0.32 (-0.50 to -0.15) 7.2 x10-04 
ABCC4 rs7982526 -0.81 (-1.25 to -0.36) 9.9 x10-04 
SLCO1A2 rs4762700 -0.28 (-0.45 to -0.11) 2.3 x10-03 
ABCC5 rs11921035 -0.54 (-0.88 to -0.21) 3.2 x10-03 
SLCO1A2 rs12296154 -0.27 (-0.43 to -0.10)  3.8 x10-03 
ABCC4 rs2484983 -0.32 (-0.53 to -0.11) 4.5 x10-03 
ABCC4 rs60338761 -0.40 (-0.66 to -0.13) 5.7 x10-03 
ABCC4 rs4773884 -0.25 (-0.42 to -0.08) 6.6 x10-03 
ABCC5 rs11928606 -0.47 (-0.79 to -0.15) 6.9 x10-03 
ABCC5 rs10937161 -0.34 (-0.57 to -0.10) 7.5 x10-03 
ABCB1 rs28401796 -0.34 (-0.58 to -0.10) 8.1 x10-03 
ABCB1 rs28381940 -0.34 (-0.58 to -0.10) 8.1 x10-03 
CSF-to-plasma emtricitabine Unadjusted analysis 
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Gene Polymorphism β(95%CI)  P-value 
ABCC5 rs11921035 -0.32 (-0.50 to -0.14) 1.4 x10-03 
SLCO1A2 rs4762700 -0.16 (-0.25 to -0.06) 2.0 x10-03 
ABCC5 rs11928606 -0.27 (-0.44 to -0.10) 4.4 x10-03 
ABBC4 rs7322318 0.13 (0.05 to 0.22) 5.3 x10-03 
ABCC4 rs9590228 0.13 (0.04 to 0.22) 6.5 x10-03 
ABCC4 rs4148428 -0.18 (-0.30 to -0.06) 7.4 x10-03 
ABCC5 rs116312201 0.19 (0.06 to 0.33) 9.0 x10-03 
ABCG2 rs1448784 -0.32 (-0.54 to -0.09) 9.3 x10-03 




Supplementary material: linkage disequilibrium plots 
Figure S1. Linkage disequilibrium (LD) between polymorphisms in the ABCC5 locus from chromosome 3 created in Haploview. Data from 43 participants are 
included. Figure 1(a) includes all polymorphisms successfully genotyped that were not monomorphic in this cohort. Black denotes r2=1, shades of grey, 0 < r2 
< 1, white r2=0. Figure 1(b) includes only polymorphisms with P < 0.01 for association with at least one concentration value in at least one unadjusted 
analyses. r2 is shown to display LD. 
(a)                                         (b) 
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Figure S2. Linkage disequilibrium (LD) between polymorphisms in the ABCG5 locus from chromosome 4 created in Haploview. Data from 43 participants are 
included. Figure 2(a) includes all polymorphisms successfully genotyped that were not monomorphic in this cohort. Black denotes r2=1, shades of grey, 0 < r2 
< 1, white r2=0. Figure 2(b) includes only polymorphisms with P < 0.01 for association with at least one concentration value in at least one unadjusted 
analyses. r2 is shown to display LD. 
(a)                                                (b)  
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Figure S3. Linkage disequilibrium (LD) between polymorphisms in the ABCB1 locus from chromosome 7 created in Haploview. Data from 43 participants are 
included. Figure 3(a) includes all polymorphisms successfully genotyped that were not monomorphic in this cohort. Black denotes r2=1, shades of grey, 0 < r2 
< 1, white r2=0. Figure 3(b) includes only polymorphisms with P < 0.01 for association with at least one concentration value in at least one unadjusted 
analyses. r2 is shown to display LD. 
(a)                                                   (b)  




Figure S4. Linkage disequilibrium (LD) between polymorphisms in the SLCO2B1 locus from chromosome 11 created in Haploview. Data from 43 participants 
are included. Figure 4(a) includes all polymorphisms successfully genotyped that were not monomorphic in this cohort. Black denotes r2=1, shades of grey, 0 
< r2 < 1, white r2=0. Figure 4(b) includes only polymorphisms with P < 0.01 for association with at least one concentration value in at least one unadjusted 
analyses. r2 is shown to display LD.  
(a)                                        (b)  
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Figure S5. Linkage disequilibrium (LD) between polymorphisms in the SLCO1A2 locus from chromosome 12 created in Haploview. Data from 43 participants 
are included. Figure 5(a) includes all polymorphisms successfully genotyped that were not monomorphic in this cohort. Black denotes r2=1, shades of grey, 0 
< r2 < 1, white r2=0. Figure 5(b) includes only polymorphisms with P < 0.01 for association with at least one concentration value in at least one unadjusted 
analyses. r2 is shown to display LD. 
(a)                                                 (b)  
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Figure S6. Linkage disequilibrium (LD) between polymorphisms in the ABCC4 locus from chromosome 13 created in Haploview. Data from 43 participants are 
included. Figure 6(a) includes all polymorphisms successfully genotyped that were not monomorphic in this cohort. Black denotes r2=1, shades of grey, 0 < r2 
< 1, white r2=0. Figure 6(b) includes only polymorphisms with P < 0.01 for association with at least one concentration value in at least one unadjusted 
analyses. r2 is shown to display LD. 
(a)                                               (b)  
     
  
114
Figure S7. Linkage disequilibrium (LD) between polymorphisms in the CYP2B6/A6 locus from chromosome 19 created in Haploview. Data from 43 
participants are included. Figure 7(a) includes all polymorphisms successfully genotyped that were not monomorphic in this cohort. Black denotes r2=1, 
shades of grey, 0 < r2 < 1, white r2=0. Figure 7(b) includes only polymorphisms with P < 0.01 for association with at least one concentration value in at least 
one unadjusted analyses as well as CYP2B6 983 T→C (rs28399499) and CYP2B6 15582 C→T (rs4803419). r2 is shown to display LD. 
(a)                                            (b)  
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Abstract
Background: HIV-associated neurocognitive disorder (HAND) remains highly prevalent despite effective anti-retroviral therapy
(ART). A number of adjunctive pharmacotherapies for HAND have been studied with disappointing results, but preliminary data
suggest that lithium may provide clinical benefit. In addition, the low cost of lithium would facilitate access in low- and middle-income
countries which carry the greatest burden of HIV.
Methods:Our objective was to evaluate the 24-week efficacy and safety of lithium in patients with moderate to severe HAND. Our
primary efficacy endpoint was the change in Global Deficit Score (GDS) from baseline to 24 weeks, whereas our secondary endpoint
was the change in proton magnetic resonance spectroscopy (1H-MRS) brain metabolite concentrations. We conducted a 24-week
randomized placebo-controlled trial of lithium as adjunctive pharmacotherapy. We enrolled participants with moderate to severe
HAND, on ART for at least 6 months, with suppressed viral loads and attending public sector primary care clinics in Cape Town,
South Africa. We randomized 66 participants to lithium (n=32) or placebo (n=34). Lithium or placebo was dosed 12-hourly and
titrated to achieve the maintenance target plasma concentration of 0.6 to 1.0mmol/L. Sham lithium concentrations were generated
for participants receiving placebo.
Results:Totally 61 participants completed the study (lithium arm=30; placebo arm=31). Participants at enrolment had amean age
of 40 years and a median CD4+ T-cell count of 500cells/mL. The median change in GDS between baseline and week 24 for the
lithium and placebo arms were –0.57 (95% confidence interval [CI] –0.77, –0.32) and –0.56 (–0.69, –0.34) respectively, with a mean
difference of –0.054 (95%CI –0.26, 0.15); P=0.716. The improvement remained similar when analyzed according to age, severity of
impairment, CD4+ count, time on ART, and ART regimen. Standard 1H-MRS metabolite concentrations were similar between the
treatment arms. The study drug was well tolerated in both study arms. Six serious adverse events occurred, but none were
considered related to the study drug.Editor: Duane R. Hospenthal.
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Search terms: South Africa; Randomized controlled clinical trial; HIV neurocognitive impairment; HIV; Lithium; Placebo; Antiretroviral therapy
Authorship: ED—study concept and design, analysis and interpretation of data, drafting and revising the manuscript for content, acquisition of data, study supervision,
and obtaining funds; CF—revising the manuscript for content, interpretation of data, acquisition of data, study supervision and coordination; FH—analysis and
interpretation of data; MC-C—analysis and interpretation of data, revising the manuscript for content, acquisition of data and study coordination; ML—analysis and
interpretation of data, statistical analysis; EK—study concept and design, revising the manuscript for content, and obtaining funds; SL—study concept and design,
revising the manuscript for content and obtaining funds; GM—study concept and design, revising the manuscript for content, and obtaining funds; JJ—study concept
and design, revising the manuscript for content, study supervision, and obtaining funds.
Disclosure: Norgine Pty (Ltd) unconditionally donated lithium carbonate and identical placebo, and had no input in any aspect of the study.
Funding: This study was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP Grant number SP.2011.41304.065/BMBF 01KA1306).
The authors have no conflicts of interest to disclose.
Supplemental Digital Content is available for this article.
a Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, b Division of Neuropsychiatry,
Department of Psychiatry and Mental Health, Faculty of Health Sciences, c Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine,
d Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa, e Department of Psychiatry, University
of Oxford, United Kingdom, f Institute of Virology and Immunobiology, University of Würzburg, Germany, g Department of Medicine, Faculty of Health Sciences,
University of Cape Town, South Africa.
∗
Correspondence: Eric H. Decloedt, Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University,
Cape Town, South Africa (e-mail: ericdecloedt@sun.ac.za).
Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons Attribution-No Derivatives License 4.0, which allows for redistribution, commercial and non-
commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Medicine (2016) 95:46(e5401)
Received: 16 May 2016 / Received in final form: 14 September 2016 / Accepted: 22 October 2016
http://dx.doi.org/10.1097/MD.0000000000005401
1 117
Conclusion:Adjunctive lithium pharmacotherapy in patients on ART with HANDwas well tolerated but had no additional benefit on
Decloedt et al. Medicine (2016) 95:46 Medicineneurocognitive impairment.
Abbreviations: 1H-MRS = proton magnetic resonance spectroscopy, AIDS = acquired immune deficiency syndrome, ART =
anti-retroviral therapy, CES-D =Center for Epidemiologic Studies Depression, Cho = choline, CI = confidence interval, Cr = creatine,
DSMB = Data and safety monitoring board, eGFR = estimated glomerular filtration rate, FDR = false discovery rate, GDS = Global
Deficit Score, Glx= glutamate with glutamine, GSK-3-b= glycogen synthase kinase-3-beta, HAND=HIV-associated neurocognitive
disorder, mI =Myo-inositol, NAA = N-acetyl-aspartate, NAA+NAAG = N-acetyl-asparate with N-acetyl-aspartyl-glutamate, PACTR
= Pan African Clinical Trials Registry, TETRAS = TRG Essential Tremor Rating Assessment Scale.
Keywords: antiretroviral therapy, HIV, HIV neurocognitive impairment, lithium, Placebo, randomized controlled clinical trial, South
Africa
1. Introduction Test Non-Dominant Hand), psychomotor speed (Trail MakingHIV-associated neurocognitive disorder (HAND) remains highly
prevalent despite effective antiretroviral therapy (ART).[1,2] The
incidence of severe HAND has decreased, but with longer life
expectancy and associated risk factors for cerebrovascular
disease, the overall prevalence of HAND is projected to rise.[3,4]
HAND is associated with high rates of morbidity and
mortality.[1,5,6] Effective neuroprotective adjunctive pharmaco-
therapy for HAND has not yet been identified.
A number of adjunctive pharmacotherapies for HAND have
been studied with disappointing results thus far.[7] Preliminary
data suggest that lithium may provide clinical benefit as
adjunctive pharmacotherapy. In 2 pilot studies, adjunctive
lithium in HAND improved neurocognitive impairment in 1
study, whereas neuronal integrity on imaging improved in both
studies.[8,9] However, these pilot studies were limited by both the
lack of a comparator arm and the short duration of lithium
treatment. Lithium has also been associated with an increase in
gray matter volume on neuroimaging in other patient popula-
tions.[10] In addition, lithium has been associated with an
improvement in neurocognitive impairment in patients with
Alzheimer’s disease.[11] Lithium has complex pharmacological
effects but unequivocal is the inhibition of glycogen synthase
kinase-3-beta (GSK-3-b), a serine-threonine protein kinase, that
mediates neuronal function, cellular substrates for learning and
memory, as well as neuronal apoptosis and inflammation
signaling pathways.[12–14] In addition to the potential promise
of lithium as an adjuvant from preliminary work, its low cost
would facilitate access in low- and middle-income countries
which carries the greatest burden of HIV.
We conducted a 24-week randomized placebo-controlled trial
to study lithium as an adjunctive pharmacotherapy in patients
with moderate to severe HAND.2. Methods
Our primary efficacy endpoint was the change in the Global
Deficit Score (GDS) from baseline to 24 week in the placebo arm
compared to the lithium arm. Baseline was the screening period
up to 4 weeks prior to enrolment (–4–0 weeks). During the
screening period all investigations and assessments were
performed and week 1 started when the participant was enrolled
and study drug dispensed. GDS summarizes the neuropsycho-
logical test results of selected cognitive domains and adjusts for
age, education, gender, and ethnicity.[15] The following domains
and tests were included: attention (Mental Alternation Test, Digit
Span, Paced Auditory Serial Addition Test), learning andmemory
(the Hopkins Verbal Learning Test), motor speed (Finger
TappingDominant Hand, Finger TappingNon-Dominant Hand,
Grooved Pegboard Test Dominant Hand, Grooved Pegboard2
Test A, Color Trails Test 1, Digit Symbol-Coding), executive
function (Color Trails Test 2, Stroop Color-Word Test,
Wisconsin Card-Sorting Test), visual learning and memory
(Rey Complex Figure), and verbal fluency (Animals and Fruit and
Vegetables). We screened for symptoms of depression using the
Center for Epidemiologic Studies Depression (CES-D) scale.[16]
Our secondary endpoint was the change between baseline (–4–0
weeks) and week 23 in proton magnetic resonance spectroscopy
(1H-MRS, TE30, and TR2000 ms) brain metabolite concen-
trations of glutamate, glutamate with glutamine (Glx), myo-
inositol (mI), N-acetyl-aspartate (NAA), N-acetyl-asparate with
N-acetyl-aspartyl-glutamate (NAA+NAAG), choline (Cho) and
creatine (Cr) in 3 brain areas (cortical: anterior cingulate cortex,
white matter: left frontal white matter and deep brain structure:
left thalamus). The primary safety endpoint was the severity and
frequency of adverse events.
2.1. Study design and participants
Inclusion criteria were HIV-infected adults (≥18 and 70 years),
established on ART for at least 6 months with a suppressed viral
load (HIV PCR <400copies/mL), cognitive impairment as
defined by a GDS ≥ 0.5 attending public sector ART clinics in
Cape Town, South Africa. Enrolled participants were mainly
recruited from Nolungile Site C clinic in Khayelitsha and were
followed up at the University of Cape Town Clinical Research
Centre at Groote Schuur Hospital. Eligible participants gave
written informed consent; female participants were not pregnant
or breastfeeding and females of child-bearing potential commit-
ted to use of contraception. We required additional written
informed consent from each participant’s care giver as we
anticipated that participants may vary in their ability to provide
consent (participants may understand the need for ART and that
they have impaired memory, but may not be able to recall all
aspects of the study procedures and risks). Care givers had to
accompany participants to each study visit. We excluded
participants who received an investigational drug within 30
days, had evidence of an active acquired immune deficiency
syndrome (AIDS)-defining opportunistic infection, had a history
of drug or alcohol abuse within 3 months before screening, had a
positive urine drug screen for drugs of abuse (amphetamine,
benzodiazepine, cannabis, cocaine, opiate), had confirmed
neurosyphilis or vitamin B12 deficiency, had imaging structural
abnormalities, had a significant head injury or severe mental
illness. We minimized the risk of lithium exposure by excluding
participants with a QTc greater than 450ms for males and 470
ms for females, confirmed epilepsy on chronic treatment, use of
any medications that may predispose the participant to lithium
toxicity, clinically significant hypo- or hyperthyroidism or




–4 to 0 1 2 4 8 12 16 20 23 24
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12
Informed consent x
Medical history and physical exam x




Chemistry† x x x x x x x
HIV viral load x x
b-HCG x x
Drug screen‡ x
Electrocardiography x x x x x x x
CD4+ T-cell count x x
Neuropsychological battery x x
Tremor measurement x x x x x x x x x
Magnetic resonance spectroscopy x x
Investigational drug dispensing x x x x x x
Adverse event monitoring x x x x x x x x x x
b-HCG=beta-human chorionic gonadotropin.
∗
Full blood count including differential.
† Screening: Treponema palllidum antibodies, vitamin B12, calcium, magnesium, thyroid stimulating hormone (T3 and T4 if TSH is abnormal), sodium, potassium, calcium, urea, and creatinine; Visit 6–12:
sodium, potassium, calcium, urea, and creatinine; repeat thyroid-stimulating hormone (T3 and T4 if TSH is abnormal) at visit 12.
‡ Drug screen included cocaine, amphetamine, opioids, cannabis, and benzodiazepines.
Assessed for eligibility (n=147)
Excluded  (n=81)
♦ Not meeting inclusion criteria (n=79)
♦ Declined to participate (n=2)
♦ Other reasons (n=0)
Analysed  (n=30)
• Excluded from analysis (n=0)
Lost to follow-up (n=1)
• Relocated (n=1)
Discontinued intervention (n=1)
• Inaccurate scholastic information
provided at screening (n=1)
Allocated to lithium carbonate (n=32)
• Received allocated intervention (n=32)
Lost to follow-up (n=0)
Discontinued intervention (n=3)
• Developed major depressive disorder
with alcohol use disorder (n=2)
• Traumatic brain injury not diagnosed
at screening (n=1)
Allocated to placebo (n=34)
• Received allocated intervention (n=34)
Analysed  (n=31)






Figure 1. Diagram 1. Trial profile: eligibility, randomization, follow-up, and analysis.




Baseline characteristic Lithium (n=32) Placebo (n=34) P
Gender
Male n=6 (18%) n=2 (6%) 0.149jj
Female n=28 (82%) n=30 (94%)
Age
∗
39.34±8.07 y 40.59±8.54 y 0.545‡
CD4+ T-cell count† cells/mm3 502 (394–648) 498 (384–651) 0.788x
Months on ART† 51 (23–74.5) 40 (25–71) 0.640x
ART regimen
NNRTI-based n=26 (81%) n=30 (88%) 0.327jj
PI-based n=6 (19%) n=4 (12%)
Neurocognitive impairment
GDS overall† 1.08 (0.83–1.44) 1.11 (0.82–1.53) 0.793x
GDS ≥ 1 n=20 (62.5%) n=20 (58.8%) 0.479jj
Decloedt et al. Medicine (2016) 95:46 Medicinedefined as an estimated glomerular filtration rate (eGFR) < 60
mL/min using the Cockroft and Gault formula and current
diarrhea with dehydration.
2.2. Intervention
We dosed lithium carbonate 250mg tablets (Camcolit, Norgine)
and matching placebo (donated by Norgine). The investigational
drugs were donated by Norgine who had no input into the study
design, conduct, or analysis. Lithium was titrated to achieve the
maintenance target plasma concentration of lithium in patients
with bipolar mood disorder of between 0.6 and 1.0mmol/L.
Sham lithium concentrations were generated for participants
receiving placebo (details in Section 2.4.)GDS < 1 n=12 (37.5%) n=14 (41.2%)
Neuromedical assessment
No disease n=18 (56%) n=24 (71%) 0.170jj
Mild-moderate disease n=14 (44%) n=10 (29%)
Severe disease n=0 n=0
Years education
≥ 10 n=18 (56%) n=18 (53%) 0.491jj
< 10 n=14 (44%) n=16 (47%)
Employment status
Employed¶ n=8 (25%) n=13 (38%) 0.187jj
Unemployed n=24 (75%) n=21 (62%)
Depression score
CES-D 9 (4–17) 8 (3–14) 0.672x
ART = anti-retroviral therapy, CES-D=Center for Epidemiologic Studies Depression scale, GDS=
Global Deficit Score.
∗
Mean and standard deviation.
†Median and interquartile range.
‡ t-test (2 samples).
xWilcoxon sum rank.
jj Fisher’s exact test.
¶ Full-time or part-time work;2.3. Ethics and study oversight
The study was approved by the human research ethics
committees of the University of Cape Town (071/2013) and
Stellenbosch University (M13/07/027). The study was registered
on the Pan African Clinical Trials Registry (PACTR) with the
identifier number PACTR201310000635418. An independent
data and safety monitoring board (DSMB) oversaw trial safety,
whereas the trial steering committee mainly monitored progress
of the trial.
2.4. Randomization, treatment concealment, and blinding
Participants in each cohort were randomized to placebo or the
lithium carbonate prior to the start of the study using block
randomization of 4, 6, or 8 which were subject to the overall
constraint of adding to the total sample size. Once an enrolment
number was assigned by the investigators, the study pharmacist
dispensed treatment according to the randomization list. The
statistician compiled the randomization list prior to study start.
The randomization list was stored in a secure place with access
limited to the statistician and pharmacist ensuring that the
investigators and participants remained blinded throughout the
study. Plasma concentrations were measured in both the lithium
and placebo arms by the laboratory. The laboratory remained
blinded and reported placebo concentrations as lower than level
of detection. The laboratory forwarded the concentration results
only to the study statistician. The study statistician generated
sham lithium concentrations for the placebo patients and
forwarded blinded concentrations (measured for lithium arm
and simulated for placebo arm) to a coinvestigator who had no
direct participant contact. This coinvestigator also received the
adverse event logs, and in conjunction with the blinded
concentrations, made dose-adjustment recommendations which
were forwarded to the treating investigators. Only the study
statistician was unblinded to arm allocation throughout this
process. The sham lithium values were generated based on a
random sampling from a distribution that was parameterized
with the true measured lithium concentrations in the treatment
arm, and with some additional rejection sampling to ensure the
sham lithium values did not fall outside of feasible ranges.
2.5. Adverse events and safety investigations
We reviewed participants weekly for adverse events for the first
month followed by 4 weekly visits for adverse events and
adherence. Adherence was measured using pill counts and self-
report diary cards. Suspected poor adherence was flagged by the
study pharmacist when a >25% discrepancy in doses taken and4
the pill count was noted. Participants who were noted as
potentially being poorly adherent were intensively counseled by
the investigators and greater emphasis was placed on evaluating
adherence at subsequent visits. Participants with clinically
significant adverse events were reviewed more frequently as
needed. At screening (–4 to 0 weeks) and week 24 we measured
full blood count and differential, Treponema palllidum anti-
bodies (screening only), vitamin B12 levels (screening only),
chemistry (calcium, magnesium, thyroid function, sodium,
potassium, calcium, urea, and creatinine), viral load, CD4+
count, urine screen for amphetamines, benzodiazepine, cannabis,
cocaine, and opiate abuse (screening only) and b-HCG. At other
visits (week 4, 8, 12, 16, 20), we measured lithium concentrations
(actual and sham) and chemistry (sodium, potassium, calcium,
urea and creatinine). Other safety investigations included
electrocardiogram (screening, week 4, 8, 12, 16, 20, 24) and
TRG Essential Tremor Rating Assessment Scale (TETRAS)
(screening, week 1, 2, 4, 8, 12, 16, 20, 24). Neuroimaging was
performed at baseline and week 23 (Table 1).2.6. Statistical methods
We calculated our sample size to detect an absolute value change
in GDS of 0.25 and required 49 participants per arm for 90%
power at alpha 0.05. We aimed to enroll 54 participants in each
arm to account for a 10% loss to follow-up or withdrawal.
Previous research has shown that ART alone improved the GDS120
Table 3
Intent to treat analysis of neuropsychological changes.











Paced Auditory Serial Addition Test 15.0 (12.0–19.5)† 16.00 (13.0–22.0)† 0.908x 17.50 (11.5–23.0)† 17.0 (14.0–24.0)† 0.792x
Learning and memory
Hopkins Verbal Learning Test (recall) 5.0 (5.0–6.0)† 6.0 (4.0–7.0)† 0.319x 7.0 (7.0–8.0)† 8.0 (5.0–9.0)† 0.773x
Motor speed
Finger Tapping nondominant hand 7.58 (6.70–8.73)† 7.83 (6.84–8.64)† 0.868x 6.78 (6.30–7.88)† 7.31 (6.28–8.16)† 0.256x
Grooved Pegboard Test non dominant hand 96.60 (79.96–123.04)† 101.43 (84.13–118.29)† 0.635x 80.36 (75.16–96.79)† 89.03 (80.94–103.58)† 0.0704x
Psychomotor speed
Trail Making Test A 59.54 (46.46–88.58)† 66.62 (51.54–83.7)† 0.386x 47.05 (36.71–55.63)† 50.92 (37.7–65.67)† 0.218x















0.078‡ 143.33 (111.52–169.12)† 146.44 (122.49–163.12)† 0.793x









Wisconsin Card-Sorting Test 41.0 (31.0–87.5)† 42.0 (33.0–57.0)† 0.797x 41.0 (29.5–59.5)† 38.0 (32.0–45.0)† 0.542x
Visual learning and memory






































CES-D 9 (4–17)† 8 (3–14)† 0.672x 3 (0–8)† 4 (0–7)† 0.643x
Summary score
Global Deficit Score 1.08 (0.83–1.44)† 1.11 (0.82–1.53)† 0.793x 0.73 (0.35–0.92) 0.74 (0.44–1.12) 0.329x
CES-D=Center for Epidemiologic Studies Depression scale.
∗
Mean and standard deviation.
†Median and interquartile range.
‡ t-test (2 samples).
xWilcoxon sum rank.
Decloedt et al. Medicine (2016) 95:46 www.md-journal.comby a mean of 0.13 and 0.6 in patients with a GDS in the mild
to moderate (>0.25 to <0.75) and severe (>0.75) ranges,
respectively.[8,17] Twelve week adjunctive lithium therapy in
patients stable on ART improved the GDS by 0.3 and we opted to
detect a more conservative GDS difference of 0.25 with a
standard deviation of 0.375, which was calculated using the
range in the published studies divided by 4.[8,17] We conducted an
intention-to-treat and per protocol analysis for the primary
endpoint. For the intention-to-treat analysis, we carried over the
last data points when the week 24 endpoints were missing,
example for missing GDS at week 24 we used GDS at enrolment.
For the per protocol analysis, we included only participants who
completed the treatment originally allocated. We assessed the
normality of the data visually and using the Shapiro–Wilk test.
We compared baseline and week 24 values of continuous
variables with paired t-tests or Wilcoxon sum rank depending on
the distribution. Normally distributed data were described using
the mean and standard deviation, whereas non-normally
distributed data were described using median and interquartile
ranges. We applied correction for the false discovery rate (FDR)
by the method of Benjamin & Hochberg to comparisons. We
report raw P values throughout and note any P values that lose or
gain statistical significance after correction.3. Results
We enrolled our first participant in December 2013 and had our
last study visit in June 2015. Due to slow accrual we were unable
to enroll our original calculated sample size and randomized 665
participants to lithium (n=34) or placebo (n=32), whereas 61
participants completed the study (lithium arm=30; placebo
arm=31) (diagram 1). All participants were black Africans, first
language Xhosa. Baseline characteristics were similar between
the 2 groups with the majority of participants presenting with
severe neurocognitive impairment with GDS of ≥ 1 (Table 2).
Suspected poor adherence was similar in the placebo and
lithium arms. We recorded 47 poor adherence episodes of which
23 episodes occurred in 16 lithium arm participants and 24
episodes occurred in 17 placebo arm participants. In the 16
lithium arm participants: 10 participants had 1 poor adherence
episode, 5 participants had 2 poor adherence episodes, and 1
participant had 3 poor adherence episodes. In the 17 placebo arm
participants: 12 participants had 1 poor adherence episode, 3
participants had 2 poor adherence episodes, and 2 participants
had 3 poor adherence episodes. The majority of poor adherence
episodes occurred within the first 8 weeks of the study (57%).
Week 24 viral loads were not predictive of poor adherence as the
2 participants with slightly raised viral loads at the end of the
study (highest value 585 copies per mL) were not identified with
poor adherence. Both participants were allocated to the lithium
arms.
The improvement in GDS was not different between the
treatment arms in both the intent-to-treat and the per protocol
analysis (Table 3, supplemental file table 1, http://links.lww.com/
MD/B409, diagram 2 (A) (B)). The median change in GDS scores
between baseline and week 24 for the lithium and placebo arms
were –0.57 (95% CI –0.77, –0.32) and –0.56 (–0.69, –0.34)
respectively, with a mean difference of –0.054 (–0.26, 0.15);121
Figure 2. Diagram 2. Box-and-whisker plots of (GDS) at week 1 and week 24
analyzed (A) per protocol analysis and (B) intention to treat analysis. GDS =
Global Deficit Score.
Table 4







First degree heart block Mild 1 (2.9%) 1 (3.1%)
Bradycardia Mild 2 (5.9%) 1 (3.1%)
Tachycardia Mild 0 1 (3.1%)
QTc prolongation Mild 11 (32.4%) 14 (43.8%)
Moderate 1 (2.9%) 0
ST-elevation Mild 0 1 (3.1%)
T-wave changes Mild 2 (5.9%) 0
Endocrine disorders
Hypothyroidism Mild 2 (5.9%) 0
Weight gain Mild 1 (2.9%) 0
Symptoms of nephrogenic diabetes Mild 1 (2.9%) 0
Moderate 2 (5.9%) 0
Gastrointestinal disorders
Abdominal cramps Mild 2 (5.9%) 0
Constipation Mild 0 1 (3.1%)
Diarrhoea Mild 6 (17.6%) 7 (21.9%)
Moderate 2 (5.9%) 1 (3.1%)
Dyspepsia Mild 0 1 (3.1%)
Gastroenteritis Mild 0 1 (3.1%)
Increased stool frequency Mild 0 1 (3.1%)
Loose stool Mild 0 2 (6.3%)
Investigations
Hyperkalaemia Mild 1 (2.9%) 1 (3.1%)
Moderate 1 (2.9%) 0
Hypermagnesemia Mild 1 (2.9%) 0
Hypomagnesemia Mild 1 (2.9%) 0
Hypocalcaemia Mild 2 (5.9%) 3 (9.4%)
Low vitamin B12 Mild 1 (2.9%) 0
Raise in viral load Mild 2 (5.9%) 0
Nervous system disorders
Dizziness Mild 6 (17.6%) 4 (12.5%)
Headache Mild 4 (11.8%) 12 (37.5%)
Moderate 0 1 (3.1%)
Upper limb tremor Mild 26 (76.5%) 26 (81.3%)
Lower limb tremor Moderate 1 (2.9%) 0
Psychiatric disorders
Daytime somnolence Mild 2 (5.9%) 0
Insomnia Mild 1 (2.9%) 0
Major depressive disorder
with comorbid alcohol use




Mild 1 (2.9%) 2 (6.3%)
Total 81 (49.4%) 83 (50.6%)
Decloedt et al. Medicine (2016) 95:46 MedicineP=0.716. The improvement remained similar when analysed
according to age, severity of impairment, CD4+ count, time on
ART, and ART regimen. 1H-MRS metabolite concentrations
(supplemental file table 2, http://links.lww.com/MD/B409) were
also not different between the treatment arms. However, the 1H-
MRS metabolite concentrations could not be measured for all
participants due to intermittent periods of technical downtime of
the MRI scanner. The study drug was well tolerated with no
statistically significant difference (P=0.413) in total adverse
events between the 2 study arms (Table 4). Six serious adverse
events occurred but none were considered related to the study
drug (supplemental file table 3, http://links.lww.com/MD/B409).
4. Discussion
Our study is the first to test adjunctive lithium therapy in patients
with HAND in a randomized double blind controlled trial for a
period of 6 months. We found that adjunctive lithium in patients
with HAND was well tolerated but had no benefit on neuro-
cognitive impairment compared with placebo when assessing
neuropsychological test performance and 1H-MRS metabolite
concentrations. Neurocognitive impairment improved similarly
in both the lithium and placebo arm.
Lithium has demonstrated neuroprotection with an increase in
gray matter volume in various patient populations.[10,13]
However, controlled clinical data demonstrating neuroprotec-6
tion with clinical endpoints were lacking. The improvement in
GDS we observed in the lithium arm is similar to the
improvement noted by Letendre et al[8] (median improvement
0.29 while we found a median improvement of 0.47) in an open-
label 12-week lithium study in patients with HAND. The similar
improvement we observed in the placebo arm highlights the
importance of a comparator arm. There are a number of potential
explanations for our findings that lithium was no better than
placebo. First, the placebo effect is a well-described response
accompanied by psychobiological changes in the brain.[18]
Clinicians are held in high regard and could have biased our
participants’ expectations and response.[19] Second, participants
may have become more familiar with the neuropsychological
assessments leading to a practice effect. We deliberately
scheduled the neuropsychological assessments 6 months apart122
Decloedt et al. Medicine (2016) 95:46 www.md-journal.comto limit a potential practice effect, but cannot completely exclude
some practice effect. In addition, no participant underwent a
neuropsychological assessment prior to enrolment into this study.
Third, we assessed endpoints only twice 6 months apart which
prevents a longitudinal description of natural disease progres-
sion, placebo response, and lithium effect. The trajectory of
natural disease, placebo, and lithium would be best described in
longer term studies where quantitative modeling is applied.[20]
The possibility exists that the placebo response may be
temporary. Fourth, cognitive assessment is influenced by HIV
infection, physical -, psychiatric -, and social comorbidity.[21] We
monitored HIV -, physical- and psychiatric comorbidities and did
not detect an improvement, but it is plausible that we missed
social comorbidity improvement explained by trial participation.
Lastly, it is possible that only patients with certain covariates or
characteristics (such as depression comorbidity) may respond
significantly better to lithium compared with placebo. Recently a
genome-wide association between lithium response and common
genetic variants on chromosome 21 has been identified in patients
with bipolar disorder.[22]
Our study has a number of differences when compared with
the open-label pilot studies of adjunctive lithium in HAND:
longer study duration, randomized double-blind placebo-con-
trolled design, lithium, and placebo dose adjusted using
therapeutic drug monitoring with a target range used in the
treatment of bipolar mood disorder and mostly African female
participants.[8,9] The Letendre et al[8] study found that lithium
improved the GDS from impaired to normal after 12 weeks in 8
participants, whereas Schiffitto et al found no neurocognitive
improvement after 10 weeks in 13 participants, but found a
decrease in glutamate with glutamine (Glx) metabolites in the
frontal gray matter.[8,9] However, both studies were uncon-
trolled.
Our study has a number of limitations. First, our findings are
limited by the fact that we were unable to enroll our original
calculated sample due to slow accrual. However, an increase in
sample size is unlikely to change our findings as an interim review
by the DSMB determined that a sample size of 65 using the same
assumptions as the original calculation have a power of 70% to
90% for the standard deviation ranging from 0.3 to 0.5. Our
GDS standard deviation was 0.53 and 0.39 in the placebo and
lithium arms, respectively. To the contrary, the between-group
difference of GDS may be smaller than the assumed 0.25 and an
even larger sample size than originally calculated may have been
required to detect a significant difference. Second, 6 month trial
duration could not exclude a beneficial effect of lithium on long-
term functional worsening. Third, we cannot exclude selection
bias as the majority of our participants were unemployed females
with significant neurocognitive impairment. Fourth, all our
participants were black Xhosa speaking Africans which limits the
generalizability of our results.
In summary, we found no additional benefit of adjunctive
lithium to placebo in African patients with HAND after 6 months
of treatment. Future adjunctive lithium studies should follow-up
patients for a longer duration to determine whether lithium has a
beneficial effect on HAND progression.Acknowledgments
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Table 1. Per protocol analysis of neuropsychological changes  









Attention       
Digit Span 6.06 ± 1.27a 6.24 ± 1.23a 0.577c 6.33 ± 1.52a 6.68 ± 1.38a 0.357c 
Paced Auditory Serial Addition Test 15.0 (12.0 – 19.5)b 16.00 (13.0 – 22.0)b 0.908d 17.50 (11.0 – 23.0)b 16.0 (13.0 – 22.0)b 0.994d 
Learning and memory       
Hopkins Verbal Learning Test (recall) 5.0 (5.0 – 6.0)b 6.0 (4.0 – 7.0)b 0.319d 7.0 (7.0 – 8.0)b 8.0 (6.0 – 9.0)b 0.590d 
Motor speed       
Finger Tapping non-dominant hand 7.58 (6.70 – 8.73)b 7.83 (6.84 – 8.64)b 0.868d 6.76 (6.26 – 7.87)b 7.23 (6.28 – 8.15)b 0.228d 
Grooved Pegboard Test non- dominant hand 96.60 (79.96 – 123.04)b 101.43 (84.13 – 118.29)b 0.635d 79.79 (75.09 – 95.56)b 89.78 (80.94 – 103.86)b 0.025d,e 
Psychomotor speed       
Trail Making Test A  59.54 (46.46 – 88.58)b 66.62 (51.54 – 83.7)b 0.386d 47.05 (37.2 – 55.79)b 49.67 (37.51 – 59.99)b 0.471d 
Colour Trails Test 1 58.84 (50.58 – 82.15)b 78.07 (58.71 – 95.44)b 0.041d 64.23 (46.58 – 75.87)b 69.33 (57.78 – 81.19)b 0.141d 
Digit Symbol-Coding  28.84 ± 10.55a 27.79 ± 9.22a 0.668c 29.27 ± 9.72a 29.58 ± 11.50a 0.909c 
Executive function       
Colour Trails Test 2 154.82 ± 45.95a 173.98 ± 41.04a 0.078c 143.33 (114.24 – 167.67)b 132.95 (119.02 – 163.12)b 0.868d 
Stroop Colour-Word test  24.19 ± 8.25a 23.88 ± 8.53a 0.883c 26.80 ± 8.89a 27.06 ± 8.77a 0.907c 
Wisconsin Card-Sorting Test 41.0 (31.0 – 87.5)b 42.0 (33.0 – 57.0)b 0.797d 41.0 (30.0 – 61.0)b 37.0 (32.0 – 45.0)b 0.473d 
Visual learning and memory       
Rey Complex Figure (copy) 21.70 ± 7.87a 21.91 ± 8.0a 0.915c 23.0 ± 6.93a 20.52 ± 7.86a 0.196c 
Rey Complex Figure (3 minutes) 10.44 ± 4.59a 10.56 ± 3.89a 0.908c 12.27 ± 5.79a 10.37 ± 4.82a 0.169c 
Verbal Fluency       
Animals 13.72 ± 2.96a 13.71 ± 3.75a 0.988c 13.90 ± 2.51a 14.19 ± 2.68a 0.660c 
Fruit and Vegetables 14.06 ± 3.05a 12.88 ± 2.88a 0.111c 13.83 ± 2.95a 13.48 ± 3.34a 0.667c 
Depression score       
CES-D 9.0 (4.0 – 17.0)b 8.0 (3.0 – 14.0)b 0.672d 2.5 (0 – 7.0)b 3.0 (0 – 5.0)b  0.426d 
Summary score       
Global Deficit Score  1.08 (0.83 -  1.44)b 1.11 (0.82 - 1.53)b 0.793d 0.61 (0.33 - 0.89 0.68 (0.41 -  1.0) 0.462d 
aMean and standard deviation; bMedian and interquartile range; ct-test (2 samples); dWilcoxon sum rank; eNot significant p-value after False Discovery Rate (FDR) correction. CES-D = Center for 
Epidemiologic Studies Depression scale 
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Table 2. Changes in MRS metabolites  









Glutamate Cortical: anterior cingulate cortex 8.40 ±  0.95a 
(n=30) 
8.21 ± 0.95a 
(n=32) 
0.415c 8.33 ± 0.60a 
(n=28) 
8.01 ± 0.66a 
(n=27) 
0.068c 
 White matter: left frontal white matter 5.09 ± 0.84a  
(n=30) 
5.34 ± 0.97a 
(n=23) 
0.323c 5.07 ±  0.81a 
(n=18) 
5.04 ± 0.65a 
(n=17) 
0.911c 
 Deep brain structure: left thalamus 5.20 ± 0.81a 
(n=29) 
5.15 ± 0.86a  
(n=30) 
0.811c 5.09 ± 0.77a 
(n=26) 
4.91 ± 0.65a 
(n=23) 
0.395c 
Myo-inositol concentration (mI) Cortical: anterior cingulate cortex 5.20 ± 0.62a 
(n=30) 
5.19 ± 0.56a 
(n=32) 
0.921c 5.14  ± 0.76a 
(n=28) 
5.24  ± 0.70a 
(n=27) 
0.607c 
 White matter: left frontal white matter 4.64 (4.31 - 5.34)b 
(n=30) 
5.42 (4.28 - 7.41)b 
(n=23) 
0.037d,e 4.80 ± 0.67a 
(n=18) 
4.76 ± 0.88a 
(n=17) 
0.871c 
 Deep brain structure: left thalamus 4.12 ± 0.70a 
(n=29) 
4.16 ± 0.82a 
(n=30) 
0.843c 4.14 ± 0.67a 
(n=26) 
4.43 ± 0.60a 
(n=23) 
0.117c 
N-acetyl-aspartate (NAA) Cortical: anterior cingulate cortex 6.14 ± 0 .68a 
(n=30) 
6.29 ± 0.64a 
(n=32) 
0.366c 6.27 ± 0.64a 
(n=28) 
6.04 ± 0.71a 
(n=27) 
0.211c 
 White matter: left frontal white matter 5.46 ± 0.86a 
(n=30) 
5.51 ± 0.86a  
(n=23) 
0.855c 5.46 ± 0.61a 
(n=18) 
5.30 ± 1.01 
(n=17) 
0.565c 
 Deep brain structure: left thalamus 6.64 (5.99 - 6.95)b 
(n=29) 
6.64 (5.46 - 7.05)b 
(n=30) 
0.886d 6.58 (6.28 - 6.92)b 
(n=26) 
6.69 (5.98 -7.37)b 
(n=23) 
0.609d 
Choline (Cho) Cortical: anterior cingulate cortex 1.38 ± 0 .22a 
(n=30) 
1.40 ± 0.15a 
(n=32) 
0.749e    1.42 (1.30 - 1.57)b 
(n=28) 
1.33 (1.21 - 1.45)b  
(n=27) 
0.114d 
 White matter: left frontal white matter  1.34 ± 0.24a 
(n=30) 
1.37 ± 0.23a  
(n=23) 
0.695d 1.33 (1.21 - 1.47)b 
(n=30) 
1.39 (1.17 - 1.52)b 
(n=23) 
0.632d 
 Deep brain structure: left thalamus 1.38 ± 0.24a 
(n=29) 
1.37 ± 0.17a 
(n=30) 
0.777c   1.45 ± 0.18a  
(n=26) 






Cortical: anterior cingulate cortex 6.51 ± 0.73a 
(n=30) 
6.47 ± 0.60a 
(n=32) 
0.818c 6.64 ± 0.55a 
(n=28) 
6.36 ± 0.52a 
(n=27) 
0.058c 
White matter: left frontal white matter 6.08 ± 0.58a  
(n=30)   
  6.00 ± 0.51a 
(n=23) 
0.602c 5.81 ± 0.50a 
(n=18) 
5.88 ± 0.67a 
(n=17) 
0.728c 
Deep brain structure: left thalamus 6.91 (6.82 - 7.15)b 
(n=29) 
7.08 (6.41 - 7.42) 
(n=30) 
0.549d 6.94 ± 0.50a 
(n=26) 
7.07 ± 0.73a 
(n=23) 
0.819c 
Creatine (Cr) Cortical: anterior cingulate cortex 1.38 ± 0.22a 
(n=30) 
1.40 ± 0.15a 
(n=32) 
0.749e 1.49 ± 0.34a 
(n=28) 
1.35 ± 0.21a 
(n=27) 
0.086e 
 White matter: left frontal white matter 4.53 ± 0.52a 
(n=30) 
4.54 ± 0.66a 
(n=23) 
0.932c 4.36 ± 0.37a 
(n=18) 
4.43 ± 0.56a 
(n=17) 
0.634c 
 Deep brain structure: left thalamus 4.97 ± 0.52a 
(n=29) 
4.92 ± 0.57a 
(n=30) 
0.736c  5.02 ( 4.72 - 5.31)b 
(n=26) 
 4.78 (4.55 - 5.25)b 
(n=23) 
0.357d 
Glutamate with glutamine (Glx) Cortical: anterior cingulate cortex 10.35 ± 1.95a 
(n=30) 
10.31 ± 1.76a 
(n=32) 
0.928c   10.91 (9.92 - 11.96)b 
(n=28) 
9.50 (8.31 - 11.51)b 
(n=27) 
0.916d 
 White matter: left frontal white matter 6.52 ± 1.63a 
(n=30) 
6.75 ± 1.29a  
(n=23) 
0.589c 6.30 ± 1.42a 
(n=18) 
6.64 ± 1.21a 
(n=17) 
0.451c 
 Deep brain structure: left thalamus 6.68 ± 1.68a  
(n=29) 
6.31 ± 1.60a  
(n=30) 
0.382c 6.23 ± 1.00a 
(n=26) 
6.17 ± 1.53a 
(n=23) 
0.884e 
aMean and standard deviation; bMedian and interquartile range; ct-test (2 samples); dWilcoxon sum rank; et-test (2 samples for unequal variances); eNot significant p-value after False Discovery Rate (FDR) 
correction; mI = Myo-inositol concentration; NAA = N-acetyl-aspartate; Cho = Choline; NAA+NAAG = N-acetyl-asparate with N-acetyl-aspartyl-glutamate; Cr = Creatine; Glx = Glutamate with glutamine 
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Table 3. Serious adverse events 
Serious adverse event Relationship to study drug Lithium (n=32) Placebo (n=34) 
Orbital cellulitis secondary to bacterial sinusitis. 
Description: The complicated bacterial sinusitis was diagnosed after enrolment, but prior to study medication dosing. The 
infection resolved with appropriate intravenous antibiotic therapy.      
 
Not related  1 (3.1%) 0 
Severe major depressive disorder (MDD) episode without psychotic features, complicated by  an alcohol use disorder. 
Description: Both participants were not considered to have an alcohol use disorder upon screening, using the Alcohol Use 
Disorders Identification Test.(23) However, the clinical presentation of the MDD episode during the trial was considered 
severe enough in both participants to warrant withdrawal from the study and referral for further psychiatric care.  
 
Not related  0 2 (5.9%) 
Pelvic inflammatory disease (PID) requiring hospital admission. 
Description: The participant presented to a medical facility with lower abdominal pain and PID symptoms severe enough to 
require intravenous antibiotic therapy. The infection resolved after appropriate inpatient treatment. 
 
Not related  1 (3.1%) 0 
Post-lumbar puncture headache requiring hospital admission. 
Description: Consenting participants underwent cerebrospinal fluid collection for research purposes (not reported in this 
paper). The participant presented 5 days later with symptoms suggestive of meningitis. Meningitis was excluded and the 
participant was successfully treated with analgesics. 
 
Not related  1 (3.1%) 0 
Medically significant but asymptomatic hypochromic microcytic anaemia. 
Description: The participant presented at the last visit with an asymptomatic hypochromic microcytic anaemia of 5.9 g/dL. 
Vitamin B12 deficiency, hypothyroidism and alcohol abuse were excluded. Further workup was not possible as the 
participant relocated and care was handed over to her local practitioner. At enrolment, the participant was noted to have 
been previously treated for a mild iron deficiency anaemia secondary to menorrhagia.  
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Abstract 
Background: The prevalence of bipolar disorder in HIV-infected patients is higher than the general population. 
Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of 
combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could 
be additive, or a pharmacokinetic interaction may occur at renal transporters with a decrease in TDF elimination.
Objective: We report on the change in estimated glomerular filtration rate (eGFR) using the modification of diet in 
renal disease formula in participants who received ART including TDF and were enrolled in a 24 week randomised trial 
of lithium versus placebo in patients with HIV-associated neurocognitive impairment.
Methods: We included HIV-infected adults with cognitive impairment established on ART for at least 6 months with 
a suppressed viral load attending public sector ART clinics in Cape Town, South Africa. We excluded participants with 
an eGFR <60 mL/min and treated with medications predisposing to lithium toxicity. We reviewed participants weekly 
for the first month for adverse events followed by 4 weekly visits for renal function assessment, adverse event moni-
toring and adherence. Lithium dose was titrated to achieve the maintenance target plasma concentration of between 
0.6 and 1.0 mmol/L. Sham lithium concentrations were generated for participants receiving placebo.
Results: We included 23 participants allocated to the lithium arm and 30 participants allocated to the placebo arm. 
Baseline characteristics were not statistically different with a mean age of 37.7 and 40.8 years, a median time on ART of 
33 and 40 months and an eGFR of 139.3 and 131.0 mL/min in the lithium and placebo arms respectively. There was no 
statistical significant difference in the reduction in eGFR or increase in potassium between the two arms during the 
24 weeks.
Conclusions: We found that 24-week treatment of HIV-infected patients with lithium and TDF did not result in 
increased nephrotoxicity.
Trial registration The study was registered on the Pan African Clinical Trials Registry (PACTR) with the identifier number 
PACTR201310000635418. Registered 11 October 2013 before the first participant was enrolled
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Background
The prevalence of bipolar disorder in human immuno-
deficiency virus (HIV)-infected patients is 4–5 times 
higher than the general population [1, 2]. The most 
effective mood stabiliser is lithium while the nucleotide 
reverse transcriptase inhibitor tenofovir disoproxil fuma-
rate (TDF) is frequently used as part of combination 
antiretroviral therapy (ART) [3]. Both TDF and lithium 
are associated with renal tubular toxicity, which could 
be additive [4, 5]. Furthermore, a TDF-lithium pharma-
cokinetic interaction may occur at renal transporters. 
TDF is eliminated via proximal tubular secretion and 
renal toxicity is thought to be related to accumulation 
of intracellular tenofovir in the proximal tubular cell [6]. 
Intracellular TDF inhibits mitochondrial deoxyribonu-
cleic acid (DNA) polymerase gamma with DNA deple-
tion and oxidative respiratory chain dysfunction [7]. 
Mitochondrial dysfunction impairs tubular reabsorption 
of ions and molecules causing a Fanconi-like syndrome, 
or may lead to cell apoptosis and acute tubular necrosis 
[7]. TDF is a substrate of a number of transporters at the 
proximal renal tubule. The organic anion transporter-1 
(OATP-1) transports TDF intracellularly while the multi-
drug resistance protein 4 (MRP-4) mediates active secre-
tion from the tubular cell [8]. In rats lithium impairs 
OATP-1 function, which may protect against TDF renal 
toxicity [9]. Twenty to eighty seven percent of lithium 
treated patients develop a reduction in urinary concen-
trating ability within weeks after starting treatment [10]. 
Lithium-induced nephrogenic diabetes insipidus (NDI) is 
thought to be caused by downregulation of intracellular 
calcium signalling with inhibition of glycogen synthase 
kinase-3-beta (GSK-3-ß), resulting in a number of down-
stream effects including decreased aquaporin-2 expres-
sion [11]. Recently it was shown that MRP-1 expression 
is regulated by GSK-3-β, suggesting that lithium may 
decrease MRP expression and predispose to TDF renal 
toxicity [12]. The proximal tubule as a common site for 
TDF and lithium renal toxicity may further contribute 
to renal toxicity. Lithium-induced renal toxicity may 
involve any segment of the nephron or kidney although 
the distal tubule seems to be involved in NDI [13]. There 
is currently no published data on the renal safety of con-
comitant TDF and lithium.
We previously published the results of a 24 week ran-
domised placebo-controlled trial to study lithium as an 
adjunctive pharmacotherapy in patients with moderate 
to severe HIV-associated neurocognitive impairment 
[14]. In this study we report changes in the estimated glo-
merular filtration rate (eGFR) using the modification of 
diet in renal disease (MDRD) formula as well as changes 
in potassium in participants who received ART including 
TDF who were randomised to lithium or placebo.
Methods
Our methodology has been previously published, 
but in brief we included HIV-infected adults (≥18
and ≤70 years), established on ART for at least 6 months
with a suppressed viral load (HIV RNA  <400 copies/
mL) with cognitive impairment attending public sector 
ART clinics in Cape Town, South Africa [14]. We dosed 
lithium carbonate 250  mg tablets (Camcolit®, manufac-
tured by Norgine) and matching placebo (manufactured 
by Norgine). We excluded participants who used medi-
cations that may predispose to lithium toxicity (diuretics, 
angiotensin converting enzyme inhibitors or angioten-
sin receptor blockers and non-steroidal anti-inflamma-
tory medicines), participants with an eGFR of less than 
60 mL/min and dehydrated participants with diarrhoea. 
We reviewed participants weekly for first month followed 
by 4 weekly visits for adverse events and adherence. After 
screening and study drug initiation, we repeated renal 
function (sodium, potassium, urea and creatinine) at 
weeks 4, 8, 12, 16, 20 and 24. Some participants switched 
treatment to TDF during the study period, and for this 
analysis we only included patients who received TDF 
for the full 24  weeks. Lithium dose was titrated assum-
ing linear pharmacokinetics to achieve the maintenance 
target plasma concentration of lithium in patients with 
bipolar mood disorder of between 0.6 and 1.0  mmol/L. 
Sham lithium concentrations were generated for par-
ticipants receiving placebo by the study statistician who 
was unblinded to treatment allocation. After each visit 
an investigator not directly responsible for participant 
follow-ups received a log with the participant number, 
blinded lithium concentration from the study statistician 
(real or sham), current study drug dose and any adverse 
events noted by other investigators. Based on the infor-
mation the investigator recommended lithium and sham 
dose adjustments for implementation.
Results
We included 53 participants in this analysis with 23 par-
ticipants allocated to the lithium arm and 30 participants 
allocated to the placebo arm. Baseline characteristics 
between the 2 arms were similar and are described in 
Table 1. Adherence in both treatment arms were similar 
and reported previously [14]. The proportion of patients 
with lithium concentrations in the therapeutic range 
are presented in Fig.  1. Three participants allocated to 
the lithium arm developed symptoms of NDI (polyuria) 
which resolved on dose reduction (p = 0.042 compared
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to placebo arm). No participant allocated to the placebo 
arm developed symptoms of NDI. Change in eGFR, cre-
atinine and potassium were similar between the 2 arms 
(see Figs. 2, 3, 4). There was no statistical significant dif-
ference between the two arms in the proportion of par-
ticipants who had a reduction in eGFR (see Table  2). 
There was no statistically significant difference in the 
eGFR slope between the 2 treatment arms (see Fig. 2a) (p 
value = 0.06) when using linear regression.
Table 1 Baseline characteristics
eGFR estimated glomerular filtration rate, MDRD modification of diet in renal 
disease formula
a Mean and standard deviation
b Median and interquartile range
c t-test (2 samples)
d Wilcoxon sum rank









 Male n = 1 (4%) n = 4 (13%) 0.374e
 Female n = 22 (96%) n = 26 (87%)
Age 37.7 ± 8.1a years 40.8 ± 8.54a years 0.186c
Weight 68.5 ± 16.2a kg 71.2 ± 12.7a kg 0.493c
Months on ART 33 (12–56)b months 40 (26–68)b months 0.262d
Renal function
 Creatinine 58 (49–62)b µmol/L 58.5 (50–68)b 
µmol/L
0.404d


































Placebo (sham lithium concentraons generated)
Lithium
Target therapeuc range
Fig. 1 The graph shows the mean change in lithium concentrations. 
The bars indicate median and interquartile range change in lithium 
concentrations over the 24 weeks in the lithium and placebo arms 
respectively. Sham lithium concentrations were generated for the 



















































Fig. 2 a The graph shows the mean estimated glomerular filtration 
rate (eGFR) as calculated using the modification of diet in renal 
disease (MDRD). The bars indicate median and interquartile range 
change in eGFR over the 24 weeks in the lithium and placebo arms 
respectively. b Scatter plot of estimated glomerular filtration rate 
(eGFR) as calculated using the modification of diet in renal disease 
(MDRD) over the 24 weeks in the lithium and placebo arms respec-
tively. The solid lines indicate the linear regression lines for the lithium 
and placebo arms respectively. Treatment allocation did not have a 
























Fig. 3 The graph shows the mean change in creatinine (µmol/L). The 
bars indicate median and interquartile range of creatinine over the 
24 weeks in the lithium and placebo arms respectively
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Discussion
We reported the renal safety of lithium co-administered 
with TDF as part of a 24 week randomised placebo-con-
trolled trial. To the best of our knowledge we described 
the first safety data of co-administered lithium with TDF. 
We found that lithium and TDF co-administration did 
not increase the risk of renal impairment in HIV-infected 
patients with neurocognitive impairment and preserved 
renal function over a 24-week period.
NDI is a well-recognised early side effect of lithium 
administration. Lithium causes dysregulation of the 
aquaporin-2 water channels in the collecting ducts 
with impaired pro-urine concentration ability [13, 15]. 
Three patients in the lithium arm developed NDI which 
resolved with a lithium dose reduction. Lithium-induced 
nephrotoxicity has been long recognised, but the extent 
and risk factors required to frame a risk-benefit profile 
for patients has been much debated [16]. A recent pop-
ulation-based study in psychiatric patients with lithium 
exposure found that monthly eGFR decline was similar 
in the lithium and reference group after adjusting for co-
morbidities, concomitant medication and episodes of 
lithium toxicity [17]. Our findings in a young cohort with 
no lithium toxicity episodes and limited treatment dura-
tion echo these findings.
Our study has several limitations. First, we reported 
on the safety of lithium dosed with TDF in a randomised 
placebo-controlled trial that was not powered for this 
endpoint. Second, we followed patients for 24 weeks and 
we can only make inferences about the short-term safety 

















Fig. 4 The graph shows the mean change in potassium. The bars 
indicate median and interquartile range change in potassium over 
the 24 weeks in the lithium and placebo arms respectively
Table 2 Estimated glomerular filtration rate change
eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease formula
a Chi-squared test
b One-sided Fisher’s exact test
c Participants did not attend the specific study visit
d Grading according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (Version 2.0 November 2014)
eGFR MDRD changed Treatment arm Week 4 % (n) Week 8 % (n) Week 12 % (n) Week 16 % (n) Week 20 % (n) Week 24 % (n)
Increased Lithium 30.4% (7/23) 39.1% (9/23) 39.1% (9/23) 34.8% (8/23) 39.1% (9/23) 56.5% (13/23)
Placebo 40% (12/30) 50% (15/30) 43.3% (13/30) 33.3% (10/30) 43.3% (13/30) 46.7% (14/30)
p = 0.518a p = 0.621a p = 0.095a p = 0.012a p = 0.095a p = 0.506a
Grade 1
Decreased 0.1% to <10% from 
baseline
Lithium 34.8% (8/23) 13% (3/23) 8.7% (2/23) 26.1% (6/23) 17.4% (4/23) 8.7% (2/23)
Placebo 23.3% (7/30) 16.7% (5/30) 20% (6/30) 23.3% (7/30) 30% (9/30) 20% (6/30)
p = 0.495a p = 0.264b p = 0.229b p = 0.817a p = 0.233b p = 0.229b
Grade 2
Decreased 10 to <30% from 
baseline
Lithium 26.0% (6/23) 26.1% (9/23) 43.5% (10/23) 21.7% (5/23) 34.8% (8/23) 23% (6/23)
Placebo 26.7% (8/30) 13.3% (5/30) 30% (9/30) 33.3% (10/30) 13.3% (4/30) 30% (9/30)
p = 0.971a p = 0.164a p = 0.765a p = 0.484a p = 0.145a p = 0.814b
Grade 3
Decreased ≥30 to <50% from 
baseline
Lithium 8.7% (2/23) 8.7% (2/23) 8.7% (2/23) 8.7% (2/23) 8.7% (2/23) 8.7% (2/23)
Placebo 0% 0% 3.3% (1/30) 0% 13.3% (4/30) 3.3% (1/30)
p = 0.202b p = 0.202b p = 0.418b p = 0.202b p = 0.493b p = 0.418b
Grade 4
Decreased ≥50% from baseline
Lithium 0% 0% 0% 0% 0% 0%
Placebo 0% 0% 0% 3.3% (1/30) 0% 0%
p = 574b
Creatinine not measuredc Lithium 0% 0% 0% 4.3% (1/23) 0% 0%
Placebo 0% 10% (3/30) 3.3% (1/30) 3.3% (1/30) 0% 0%
p = 0.197b p = 0.574b p = 0.687b
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we may have missed more subtle markers of tubulopa-
thy as we did not measure urine markers of tubulopa-
thy. Fourth, only approximately half of participants had 
therapeutic lithium trough concentrations. We collected 
lithium trough concentrations as soon as participants 
arrived at the study site and despite best efforts, sample 
collection time for some participants was beyond 12  h. 
Last, we excluded patients with renal impairment and 
concomitant medication which may potentiate lithium 
toxicity.
We could not rule out nephrotoxicity of long-term 
concomitant treatment of TDF and lithium and future 
research should focus on the long-term follow-up of 
TDF-treated HIV-infected patients with lithium-treated 
bipolar disorder.
Conclusions
We found that 24-week treatment of HIV-infected 
patients with lithium and TDF, preserved renal func-
tion and no episodes of lithium toxicity did not result in 
increased nephrotoxicity. To the best of our knowledge 
we described the first safety data of co-administered lith-
ium with TDF. Our finding supports the renal safety of 
TDF-based ART in HIV-infected patients with bipolar 
disorder requiring lithium therapy as a mood stabiliser.
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Summary and conclusions 
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HIV-associated neurocognitive disorders (HAND) persist, with the prevalence 
increasing, despite antiretroviral therapy (ART).1,2 Local data from Cape Town found 
that while patients with severe cognitive impairment prior to ART initiation show the 
most cognitive improvement, 23% - 45% of patients remain cognitively impaired after 
1 year on ART.3 The social and economic burden of HAND is enormous.  HAND is 
associated with a range of impairments of daily activities, including employment, 
driving and medication adherence related to a combination of neurocognitive and 
neurological impairment.1 HAND will continue to place an increasing burden on 
health resources, especially as those living with HIV age and require residential 
care.4 This thesis investigated the treatment of patients with moderate to severe 
HAND. First, we investigated pharmacogenetic and pharmacokinetic data on CNS 
penetration of efavirenz-tenofovir-emtricitabine. Second, we investigated 
pharmacokinetic-pharmacodynamic relationships between CSF efavirenz (EFV), 8-
hydroxy-efavirenz (8-OH-EFV), tenofovir (TFV) and emtricitabine (FTC) exposure 
and neurocognitive performance. Third, we evaluated the efficacy of lithium as 
adjunctive therapy for HAND in a randomised controlled trial (RCT). Final, we 
investigated whether lithium causes additive nephrotoxicity in combination with TFV. 
 
In Chapter 4 we reported on the genetic polymorphisms  associated with CSF 
transfer of EFV, 8-OH-EFV, TFV and FTC in Black South Africans. To our knowledge 
this is the largest published study examining pharmacogenetic, pharmacokinetic and 
pharmacodynamic associations with CSF EFV-TFV-FTC. This study included 47 
adult participants with and without HAND on ART for at least 6 months. We identified 
novel genetic associations. First, the individual polymorphisms CYP2B6 516G→T 
and 983T→C as well as the composite CYP2B6 15582/516/983 genotype in 
univariate analyses were most strongly associated with the log10-transformed 
concentrations of plasma EFV, plasma 7-OH-EFV, plasma 8-OH-EFV/EFV ratio and 
CSF EFV. To the best of our knowledge, we are the first to describe the association 
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of the composite CYP2B6 15582/516/983 genotype with plasma 7-OH-EFV, plasma 
8-OH-EFV/EFV ratio and CSF EFV exposure.5–7 Second, we found that CYP2A6 
polymorphisms (-48A→C and rs10853742) are associated with lower plasma 7-OH-
EFV concentrations after adjusting for CYP2B6 516G→T, 983T→C, 15582C→T 
while others have found no association with EFV metabolites.6,7 The CYP2A6 
metabolism pathway of 7-OH-EFV becomes more relevant in patients with impaired 
CYP2B6 metabolism.8 We found that the CYP2B6 rs2279345 polymorphism was 
independently associated with lower plasma 7-OH-EFV/EFV ratio, which suggests 
that in addition to the loss of function polymorphisms in CYP2B6 516G→T, 983T→C, 
15582C→T, this polymorphism also impairs 7-OH-EFV metabolism via CYP2B6.  
Third, we found that ABCB1 rs115780656 was independently associated with lower 
plasma 7-OH-EFV concentrations. Polymorphisms in ABCB1 have not been 
conclusively associated with EFV concentrations and its association with 7-OH-EFV 
and 8-OH-EFV have not been assessed previously.9–11 Finally, we found that the 
CYP2A6 -48A→C polymorphism was independently associated with higher CSF 8-
OH-EFV/EFV ratio. It may be possible that the CYP2A6 -48A→C polymorphism may 
predispose CYP2B6 slow metabolizers to higher CSF 8-OH-EFV concentrations and 
worsen neurocognitive performance.   
 
In Chapter 5 we investigated lithium as adjunctive therapy in patients with moderate 
to severe HAND and found that lithium was well tolerated but had no observable 
benefit on neurocognitive impairment compared with placebo. The 2 pilot studies by 
Letendre et al and Schifitto et al who enrolled n=8 and n=15 participants respectively, 
had no comparator arm, used a fixed lithium dose of 300mg 12 hourly or titrated the 
dose to 0.4 – 0.8 mmol/l and a had treatment duration of 10 – 12 weeks.12,13 Our 
study had a number of advances compared to the 2 pilot studies. Our study duration 
was 24 weeks, the design was an RCT and the study drugs were dose adjusted 
using therapeutic drug monitoring with a target range used in the treatment of bipolar 
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mood disorder (0.6 to 1.0 mmol/l). We considered a number of explanations for our 
findings. First, the placebo effect is a well described response accompanied by 
psychobiological changes in the brain.14 Clinicians are held in high regard and could 
have biased our participants’ expectations and response.15 Second, participants may 
have become more familiar with the neuropsychological assessments leading to a 
practice effect. We deliberately scheduled the neuropsychological assessments 6 
months apart to limit a potential practice effect, but cannot completely exclude some 
practice effect. In addition, no participant underwent a neuropsychological 
assessment prior to enrolment into this study. Third, we assessed endpoints only 
twice 6 months apart which prevents a longitudinal description of natural disease 
progression, placebo response and lithium effect. The trajectory of natural disease, 
placebo and lithium would be best described in longer term studies where 
quantitative modelling is applied.16  It is possible that the placebo response may be 
temporary. Fourth, cognitive assessment is influenced by HIV infection, physical -, 
psychiatric -, and social comorbidity.17 We monitored HIV -, physical- and psychiatric 
comorbidities, but it is plausible that we missed social comorbidity improvement 
explained by trial participation. Fifth, it is possible that only patients with certain 
characteristics (such as depression co-morbidity) may respond significantly better to 
lithium compared with placebo. Recently a genome-wide association between lithium 
response and common genetic variants on chromosome 21 has been identified in 
patients with bipolar disorder.18 Finally, Schifitto et al found no neurocognitive 
improvement after 10 weeks in 13 participants but a decrease in glutamate with 
glutamine (Glx) metabolites (an intracellular neurotransmitter marker) in the frontal 
grey matter and on neuroimaging.13 It is possible that lithium may have a limited 
effect on neuronal plasticity and rather decrease brain activation similar to patients 
with bipolar mania.19 Although there are compelling mechanistic hypothesis and 
clinical evidence suggesting the lithium may be protective or treat Alzheimer’s 
Disease (AD), this may not apply to HAND.20,21 There are similarities in the CSF 
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biomarker profile of AD and patients with HIV-associated dementia, but also distinct 
differences eluding to different pathogenic pathways in AD and HIV neuronal injury.22 
 
Lithium-induced nephrotoxicity has been long recognised, but the extent and risk 
factors required to frame a risk-benefit profile for patients have been much debated.23 
In Chapter 6 we assessed whether lithium causes additive nephrotoxicity in 
combination with TFV. Both TFV and lithium are associated with renal tubular 
toxicity, which could be additive.24,25 The proximal tubule is a common site for TFV 
and lithium renal toxicity. In addition, a TFV-lithium pharmacokinetic interaction may 
occur at renal transporters.  TFV is eliminated via proximal tubular secretion and 
renal toxicity is thought to be related to TFV proximal tubular cell accumulation which 
inhibits mitochondrial deoxyribonucleic acid (DNA) polymerase gamma with DNA 
depletion and oxidative respiratory chain dysfunction.26,27 The organic anion 
transporter-1 (OATP-1) transports TFV intracellularly while the multi-drug resistance 
protein 4 (MRP-4) mediates active secretion from the tubular cell.28 MRP-1 
expression is regulated by glycogen synthase kinase-3-beta, suggesting that lithium 
may decrease MRP expression and predispose to TFV renal toxicity.29 To the best of 
our knowledge we described the first safety data of co-administered lithium with TFV. 
We reviewed the renal function of participants weekly for the first month followed by 
monthly monitoring. We included 53 participants (23 lithium arm and 30 placebo arm) 
enrolled in the RCT who received TFV as part of their ART. We found no statistical 
significant difference in the reduction in estimated glomerular filtration rate (eGFR) or 
increase in potassium between the two arms during the 24 weeks. A population-
based study in psychiatric patients with lithium exposure found that monthly eGFR 
decline was similar in the lithium and reference group after adjusting for co-
morbidities, concomitant medication and episodes of lithium toxicity.30 Our findings in 
a young cohort with no lithium toxicity episodes and limited treatment duration echo 
these findings.  
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Limitations of the thesis studies 
The study in Chapter 4 only consisted of 47 participants and had limited power to 
detect genetic associations between infrequent genotypes with small effect sizes 
(increase in plasma or CSF concentrations). For example, the CYP2A6 -48A→C 
polymorphism has been associated with increased plasma EFV concentrations in 
CYP2B6 slow metabolizers, but we found no association as there only 3 participants 
with CYP2B6 slow metabolizer genotype that carried a single CYP2A6 -48A→C 
allele.31 This may have also limited our ability to detect associations between 
CYP2B6 15582C→T and plasma EFV concentrations, as 15582CT heterozygosity 
has been associated with small increases in plasma EFV exposure, and there were 
no 15582TT homozygotes in our study.32 We were not able to detect 
pharmacokinetic-pharmacodynamic associations, but this may also be due to limited 
power to detect smaller differences in cognitive impairment. Second, our study was 
cross-sectional. Neurocognitive changes would have been better assessed 
longitudinally. Third, we did not measure the unbound concentrations of EFV-TFV-
FTC. EFV is 99.8% protein bound, but protein-free EFV concentrations are 
equivalent in blood plasma and CSF.33 TFV and FTC is less than 7% and 4% protein 
bound, respectively.34 We assessed CSF-to-plasma ratios of total concentrations. 
Protein-free CSF-to-plasma concentrations of EFV in particular may have more 
accurately reflected the pharmacodynamically active concentrations. Fourth, we did 
not measure the phase II EFV metabolites in CSF, which exceed concentrations of 
CSF EFV and CSF 8-OH-EFV.7 The effect of the phase II EFV metabolites on 
neurocognition are unknown. Last, our study only included adults. Our 
pharmacokinetic and pharmacodynamic findings can therefore not be applied to a 
paediatric population. There are concerns about the limited safety data of EFV on the 
neurocognitive development of children and our lack of an neurocognitive association 
with EFV-TFV-FTC pharmacokinetics in adults cannot be applied to children.35 
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We were unable to enroll our original calculated sample in our RCT described in 
Chapter 5 due to slow accrual. A 6-month trial duration could not exclude a 
beneficial effect of lithium on long-term functional worsening. We further cannot 
exclude selection bias as the majority of our participants were unemployed females 
with significant neurocognitive impairment. Finally, all our participants were Black 
Xhosa speaking Africans, which limits the generalisability of our results. Our findings 
of no additive nephrotoxicity of lithium dosed with TFV need to be viewed in context 
of the study limitations.  
In Chapter 6 we reported on the safety of lithium dosed with TFV in a RCT that was 
not powered for this endpoint. We followed patients for 24 weeks and we can only 
make inferences about the short-term safety of concomitant lithium and TFV 
administration. We may have missed more subtle markers of tubulopathy as we did 
not measure urine markers of tubulopathy. Only approximately half of participants 
had therapeutic lithium trough concentrations. We collected lithium trough 
concentrations as soon as participants arrived at the study site and despite best 
efforts, sample collection time for some participants was beyond 12 hours.  Finally, 
we excluded patients with renal impairment and concomitant medication which may 
potentiate lithium toxicity. 
Impact of the studies on the field 
This thesis contributes to the field of HAND research in several ways. First, we 
identified novel genetic associations with plasma EFV, plasma 7-OH-EFV, plasma 7-
OH-EFV/EFV ratio, plasma 8-OH-EFV/EFV ratio, CSF efavirenz and CSF 8-OH-
EFV/EFV ratio. We did not find pharmacokinetic-pharmacodynamic relationships 
between CSF EFV, 8-OH-EFV, TFV and FTC exposure and neurocognitive 
performance.  However, we found that the CYP2A6 -48A→C polymorphism was 
140
independently associated with higher CSF 8-OH-EFV/EFV ratio. It is possible that 
EFV is metabolized into 8-OH-EFV in the CSF by the accessory pathway CYP2A6 in 
CYP2B6 slow metabolizers. Participants with detectable CSF 8-OH-EFV scored 
worse on the Colour Trails Test and had a higher Global Deficit Score (GDS) which 
was not statistically significant. It may be possible that the CYP2A6 -48A→C 
polymorphism may predispose CYP2B6 slow metabolizers to higher CSF 8-OH-EFV 
concentrations and worsen neurocognitive performance. Future studies should 
replicate our genetic associations in particular the CYP2A6 -48A→C association with 
8-OH-EFV with a larger sample size. Second, we found that lithium was not effective 
in the treatment of HAND in a 24-week RCT. Our study demonstrated the importance 
of confirmatory placebo controlled studies. Although we did not enroll our original 
calculated sample due to slow accrual, an increase in sample size is unlikely to 
change our findings as a sample size of 65 using the same assumptions as the 
original calculation have a power of 70% - 90%. The published GDS standard 
deviations on which we based our sample size were similar to the GDS standard 
deviation in our cohort. Future studies should study other adjunctive therapy. Third, 
we found that lithium can be prescribed with TFV without additive nephrotoxicity. 
While our data do not support the use of lithium in patients with HAND, the 
prevalence of bipolar disorder in HIV-infected patients is 4 to 5 times higher than the 
general population and the most effective mood stabiliser is lithium.36–38 Our finding 
supports the renal safety of TFV-based ART in HIV-infected patients with bipolar 
disorder requiring lithium therapy as a mood stabiliser.  
 
Implications for clinical practice 
Our findings may have public health implications. We improved our understanding of 
genetic determinants of EFV-TFV-FTC exposure in the CSF which, is the current 
World Health Organisation recommended first-line ART.39 EFV slow metabolizers are 
most prevalent in Sub-Saharan Africa and predispose to high EFV plasma and CSF 
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concentrations. High EFV concentrations are associated with significant morbidity 
and even mortality and should be monitored.40,41   
 
We found a trend towards an association between neurotoxicity and higher CSF 8-
OH-EFV concentrations.   We confirm that there is limited clinical data to support 
EFV or 8-OH-EFV as a contributor to ongoing HAND irrespective of EFV metabolizer 
status. 
 
Lithium does not appear to have benefit as adjunctive therapy in patients with HAND.  
Our findings support its use the renal safety of TFV-based ART in HIV-infected 
patients with bipolar disorder requiring lithium therapy as a mood stabiliser. 
 
Future research 
Further studies should follow this work. First, we may not have found a difference in 
GDS between lithium and placebo arms, but may detect a change in other endpoints.  
In our future research we will perform biomarker studies on our stored CSF and 
plasma samples as well as study the diffusion tremor imaging and resting-state 
functional magnetic resonance imaging data. Raised CSF neurofilament light chain 
(NFL) has been associated with ongoing axonal injury in patients with HAND and 
may be a marker for neuronal apoptosis, which lithium may protect against.42 On 
imaging lithium induces changes in brain microstructure that may be associated with 
improved strength in functional connectivity.43  
 
Second, adjunctive pharmacotherapy should be studied further. Paroxetine for 
example was associated with neuropsychological test improvement in patients with 
HAND in a proof-of-principle RCT and should be followed by a confirmatory trial.44 
The mechanism of the neuroprotective effect of paroxetine is unclear, but was 
independent of the serotonin reuptake transporter and may be via mitochondria 
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proteins adenine nucleotide translocase (ANT) and the voltage dependent anion 
channel (VDAC).45 
 
Third, the genetic association of CYP2A6 -48A→C association with 8-OH-EFV 
should be studied in a larger study. We should consider targeting patients who 
present with EFV-induced neurotoxicity.  
 
Finally, the integrase inhibitors such as dolutegravir (DTG) are likely to replace EFV 
and genetic polymorphisms may be associated with DTG transfer into the CNS and 
associated adverse effects.46–49 The impact of genetic polymorphisms on DTG CNS-
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